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Abstract 
 
Background: The Liver X receptors, LXRα and LXRβ, belong to the superfamily of 
nuclear receptor ligand activated transcription factors. LXRs have been well 
characterised in the context of metabolism through their ability to induce 
reverse cholesterol transport leading to the excretion of cholesterol from the 
body. More recently, LXRs have been shown to play a role in inflammation in 
which they are often ascribed an anti-inflammatory effect. Rheumatoid arthritis 
(RA) is a chronic auto-immune condition manifest as inflammation of the 
diarthrodial joints predominantly in the hands and feet. It is now well recognised 
that RA is not just a local but rather a systemic disease that is associated with 
several co-morbidities including atherosclerosis. A major focus in the field of 
rheumatology is now to understand how cardiovascular disease might contribute 
to the pathogenesis of RA and vice versa and thereby connect metabolism with 
inflammation. Hypothesis: Since LXRs are central to the maintenance of a 
cholesterol homeostasis and have been shown to regulate inflammation we 
hypothesised that LXR agonists would be beneficial for the treatment of RA. 
Methods & Results: Treatment of male DBA1 mice with GW3965 or T1317 in the 
murine model of collagen-induced arthritis dramatically increased the onset and 
severity of disease. Exacerbation of disease severity was characterised by 
increased concentrations of multiple serum pro-inflammatory cytokines and 
chemokines, increased numbers of lymph node derived Th1 and Th17 cells and 
elevated titres of anti-collagen auto-antibodies. The effect of LXR agonist 
administration was mediated specifically by LXRs as the severity of disease was 
not altered in LXR null mice treated with GW3965. Furthermore, activation of 
LXRs in primary human monocytes potentiated the secretion of multiple 
proinflammatory cytokines in response to stimulation with LPS. Similarly, the 
concentration of multiple pro-inflammatory cytokines was also increased in an in 
vitro model of synovitis. Conclusion: These studies demonstrate a novel pro-
inflammatory role of LXR activation in the context of arthritis. Furthermore, 
these results suggest that the development of LXR agonists as a therapy for 
metabolic disorders should be done so with caution.  
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6.1 Nuclear receptors 
6.1.1 Classification of nuclear receptors 
Nuclear receptors (NRs) are a super-family of ligand activated transcription 
factors that represents the largest family of transcription factors in metazoans 
(1). To date 49 NRs have been identified in mice but only 48 have emerged in 
humans which lack the Farnesoid X receptor β (FXRβ), the function and 
consequences of which remain unknown (2, 3). NRs were originally grouped into 
three broad categories dependent upon their ligands:  
• Class I - the steroid family  
• Class II - the non-steroid family  
• Orphan receptors for which ligands are not known  
Profiling the expression of NRs in various murine tissues coincidentally revealed 
that Class I NRs were expressed in tissues associated with reproduction and 
central nervous system (CNS) function whereas Class II NRs were expressed in 
tissues with functions associated with nutrient metabolism and immunity (4). 
This study also led to the reclassification of the orphan NRs based upon the 
function of the tissues in which they are expressed. These groups were 
subsequently further subdivided into Class I A, B and C and Class II A, B and C on 
the basis of tissue specific expression (Figure  6.1). Grouping of NRs on the basis 
of tissue specific expression has revealed potential functional characteristics for 
each NR. Furthermore, grouping of NRs on this basis dictates that LXRα is 
associated with lipid metabolism whilst LXRβ is suggested to predominantly play 
a role in regulation of the CNS and basal metabolism. Moreover this study has 
also revealed potential hierarchical networks of NR interactions. The implication 
of these findings has been supported by other studies. Thus, LXRβ is grouped 
with Rev-erbα and activation of LXRs induces the expression of Rev-erbα which 
in turn negatively regulates the expression of LXR activation and subsequent 
target gene expression forming a self regulating feedback loop (5). Similarly, 
LXRα is found to be co-expressed with the Glucocorticoid Receptor (GR) and the 
Peroxisome Proliferator Activated Receptor γ (PPARγ). Activation of LXRs has 
  19 
been shown to both inhibit the synthesis and activation GR ligands but also 
induce the expression of PPARγ (6-8). So far no interaction of NRs across 
different groups has yet been reported. These studies demonstrate how the 
interaction of NRs is defined by spatial separation. However, it is important to 
take into account another dimension; namely time. Similar studies have also 
analysed the temporal regulation of NRs and have shown that in adipose tissue 
and liver 25 NRs are expressed in a rhythmical cycle e.g. Rev-erbα/β, 
PPARα/δ/γ and Estrogen related receptor (ERRα/β/γ) (9). The temporal 
regulation of NRs in other tissues has not been studied; however, these data 
suggest that the activities and interactions of NRs may be regulated temporally 
as well as spatially within the cell. Together these studies support the 
hypothesis that NRs form hierarchical networks that may serve to regulate the 
expression, activation and the magnitude of adjacent / parallel NR induced 
responses. This provides a tightly regulated network of interactions and 
transcriptional consequences that are now implicated in many aspects of normal 
physiology and increasingly in pathology. 
  20 
 
 
Figure  6.1 Nuclear receptor classification 
Classification, grouping and function of nuclear receptors based upon their common 
anatomical gene expression in murine tissues. This diagram does not represent nuclear 
receptor phylogeny. Adapted from (4). 
6.1.2 Common Nuclear receptor structure 
NRs regulate transcription of a variety of genes when activated by the binding of 
specific lipophilic ligands; these include entities such as vitamins, steroids and 
lipid molecules. Activation of NRs by ligand binding causes NR localisation to the 
nucleus where they bind to specific DNA sequences and subsequently recruit 
transcriptional co-activators thereby inducing transcription of selected target 
genes. Given this common function all NRs share some common tertiary 
structural domains which are translated as part a single polypeptide chain (10) 
(Figure  6.2). Firstly, each NR has a DNA binding domain (DBD) which binds to 
direct repeats (DR) of a specific hexameric nucleotide sequence separated by 
between 1-7 non-specific nucleotides. The ligand binding domain (LBD) has 
multiple functions as well as binding specific ligands. The LBD also contains a 
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ligand-regulated activation function (AF-2) which is responsible for the binding 
of co-activators, chromatin remodelling proteins such as histone 
acetyltransferases (HATs), required to “open up” chromatin for the initiation of 
transcription. Secondly, the ligand binding domain (LBD) has been implicated in 
the dimerisation of NRs which is required for stringent binding to response 
elements within the promoters of target genes (11). Most NRs also have a ligand 
regulated transcription activation function domain (AF-1) towards the N 
terminus of the DBD. This has been shown to exhibit broad diversity across NRs 
and as such has been proposed to be responsible for distinct effects of similar 
NRs through the binding of different transcriptional co-activators. Additionally, 
the AF-1 domain can synergise with AF-2 to mediate the magnitude of a 
transcriptional response by some NRs (12). 
 
Figure  6.2 Common nuclear receptor structure 
All nuclear receptors share some common structural components; a DNA binding domain 
(DBD), a ligand binding domain (LBD), which contains a ligand regulated transcription 
activation function domain (AF-2) and most nuclear receptors and a transcription activation 
function domain (AF-1) which can synergise with AF-2 to bind transcriptional co-activators 
(Adapted from (10)).  
6.2  Liver X receptors: Structure & Function 
6.2.1 Identification of Liver X Receptors 
The Liver X Receptors (LXRs) were first identified as members of the nuclear 
receptor superfamily of transcription factors in 1994 (13). Since their initial 
discovery two members have been identified, LXRα and LXRβ: although they are 
often referred to as “isoforms” LXRα and LXRβ are encoded by distinct genes on 
separate chromosomes (14). At the time of their discovery the endogenous 
ligands for LXRα and LXRβ were unknown and were therefore described first as 
orphan receptors.  
N C DBD 
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6.2.1.1 LXRα 
LXRα was identified in 1995, one year after LXRβ, and because of its high level 
of expression and subsequent purification from the liver the name “Liver X 
Receptor” was coined with the “X” referring to the lack of an identified ligand 
(14). As well as having a high level of expression in the liver, northern blot 
analysis also revealed a high level of expression in kidney, spleen, intestine and 
the adrenals, subsequently the expression of LXRα has also been demonstrated 
in adipocytes, macrophages, T cells, B cells, neutrophils and dendritic cells in 
both mice and humans (15-19). The anatomical expression profile dictates that 
LXRα is a Class II C NR, grouped with PPARγ and GR, in tissues which 
predominantly regulate lipid and energy homeostasis (4) (Figure  6.1). LXRα is 
encoded by the gene NR1h3 which is located on chromosome 11 in humans and 
chromosome 2 in mice. The murine LXRα gene spans approximately 11 Kb of DNA 
and consists of 10 exons which encode a transcript of approximately 1137 bp in 
length (20).  
6.2.1.2 LXRβ 
LXRβ was firstly described as “Ubiquitous Receptor” (UR) due to its ubiquitous 
expression in a widespread number of analysed rat tissues detected by Northern 
blot analysis; other synonyms included OR-1, Rip-15 and NER (13, 21-23). Using a 
probe homologous to the DBD of other known rat NRs a 1.9 Kb cDNA sequence 
was identified which did not code for any previously recognised NRs but was 
subsequently later identified as human LXRβ. The purified rat cDNA was 
subsequently cloned, sequenced and used to identify a cDNA sequence from 
human prostate cancer cells which had 90% homology. UR was later renamed 
LXRβ based upon the high level of similarity with LXRα, which share 77% amino 
acid sequence similarity within both the LBD and DBD (14) and has been 
positioned in class I C, grouped with RXRβ (Figure  6.1). Murine LXRβ is encoded 
by the gene, Nr1H2, located on chromosome 19q13.3. Nr1H2 consists of 9 exons 
from which a cDNA sequence of 1652 bp has been identified (20). 
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6.2.1.3 The Liver X Receptors are evolutionary conserved 
Both LXRα and LXRβ have been conserved throughout evolution and as such 
human LXR orthologs have been identified in worms (caenorhabditis elegans), 
flies (drosophila melongaster), fish (fugu ruripes), frogs (xenopus laevis) and 
mice (mus musculus). Murine LXRs are evolutionary closely linked to humans (14, 
24-26). Indeed there is a high degree of amino acid sequence homology of the 
LBD (98% and 94%) and DBD (95% and 90%) for LXRα and LXRβ respectively 
between humans and rodents (13, 14). Furthermore, recent studies have 
demonstrated robust activation of LXRα and LXRβ by both synthetic and 
endogenous ligands in many species throughout evolutionary history (24). These 
studies would suggest that the LXRs have a long evolutionary history and that 
their ability to be activated and bind target sequences has been conserved. In 
addition these data provide support for the use of rodents as a good in vivo 
model system to elucidate the biology of LXRs. 
6.2.2 Liver X receptor ligands 
The activation of LXRs is therefore regulated post-translationally predominantly 
by the binding of endogenous ligands. In screening efforts to identify a potential 
ligand, retinoids were found to activate the expression of a luciferase reporter 
which was ligated in turn to a promoter bound by LXRα (14). However, retinoids 
had previously been shown to specifically activate the Retinoid X Receptors 
(RXRs) and further studies revealed that activation of LXR induced transcription 
was mediated through heterodimerisation with RXR (27). Cholesterol loading of 
macrophages has been shown to induce LXR activation thereby implicating LXRs 
as sensors of cholesterol homeostasis. However, the induction of LXR activation 
by cholesterol has since been shown to be mediated by oxidised cholesterol 
derivatives; oxysterols (28). Oxysterols can be formed by direct ‘attack’ from 
reactive oxygen species or may be absorbed pre-formed in the diet. However, 
the primary pathway of oxysterol formation is by the enzymatic oxidation of 
cholesterol during cholesterol degradation and synthesis by members of the 
cytochrome family of enzymes. Several species of oxysterols were first shown to 
induce LXRα activation in vitro; particularly 22(R) hydroxycholesterol, 24(S) 
hydroxycholesterol, 20(S) hydroxycholesterol and 24(S),25 epoxycholesterol 
(Figure  6.3) (28, 29). Furthermore, it is now known that LXRβ is also activated by 
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similar oxysterol ligands reflecting the high degree of amino acid sequence 
conservation of the LBD between LXRα and LXRβ (14, 30). However, not all 
oxysterols function as LXR agonists as 22(S) hydroxycholesterol has recently been 
shown to have inhibitory effects upon LXR activation and subsequent 
downstream signalling both in vitro and in vivo (31, 32).  
Subsequently, several synthetic LXR agonists have been designed which are 
widely used for the investigation of LXR biology (Figure  6.3). Similar to the 
oxysterol ligands these synthetic agonists are active in many species including 
mice and humans (24). Firstly, Tularik (Amgen) developed T0901317 (T1317) and 
demonstrated that treatment of HEK293 cells with this agent potently induced 
the activation of both LXRα and LXRβ, although the magnitude of LXRα 
activation was greater than that of LXRβ; 35 fold relative to 15 fold respectively 
(33). GlaxoSmithKline later developed a non-steroidal agonist (GW3965) which 
exerted similar levels of potency with respect to the activation of LXRα 
compared to LXRβ and was shown to successfully induce the expression of the 
LXR target gene ABCA1 in vivo (34). More recently several other companies have 
developed LXRα/β dual agonists and demonstrated similar effects upon the 
induction of LXR target genes however their effects remain to be confirmed by 
other investigators (35, 36). Furthermore, elucidation of the individual role of 
either LXRα or LXRβ has until recently been restricted to the use of knockout 
animals as agonists that distinguish between the two did not exist. However, 
there are now reports of agonists that specifically activate LXRα or LXRβ and will 
undoubtedly prove useful in separating the individual roles of LXR activation 
(37). In addition a synthetic LXRα/β dual antagonist has been described although 
its specificity with respect to its effect upon other NRs remains unknown (38).  
In addition to sensing alterations in cholesterol concentrations LXRs have also 
been implicated in the regulation of carbohydrate metabolism. Recently glucose 
has been shown to activate both LXRα and LXRβ in vitro where it was shown to 
induce the expression of a luciferase reporter at levels comparable to synthetic 
LXR agonists (39). Moreover, this was shown to be a direct effect as glucose was 
shown to displace the high affinity LXR ligand T1317 from an LXRE containing 
promoter, recruit transcriptional co-activators and induce transcription of 
multiple LXR target genes.  
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Figure  6.3 Endogenous and synthetic LXR ligands 
The structure of the oxysterols which have been identified as endogenous LXR ligands and 
the most commonly used synthetic LXR agonists GW3965 and T1317. Glucose has recently 
been identified as a direct activator of LXRs.  
It is therefore evident that there are a multitude of potential LXR ligands all of 
which are intermediates of metabolic processes; in particular they subserve 
either lipid or carbohydrate metabolism. How these different endogenous 
ligands interact and impact the activation of LXRs and down stream target genes 
in physiology is of great interest but remains poorly understood reflecting the 
lack of specificity noted above. However, many studies utilising the synthetic 
LXR agonists have identified a large number LXR target genes and have therefore 
expanded our understanding of LXR biology.  
6.2.3 Regulation of LXR expression 
LXRα and LXRβ are both constitutively expressed across a broad distribution of 
tissues. However, it is possible to modulate the level of LXRα or LXRβ expression 
through tissue specific exogenous and endogenous signalling pathways which 
alters synthesis of LXR transcripts. Changes in LXR expression may ultimately 
Cholesterol 
25  hydroxycholesterol 
GW3965 T1317 
24 (S), 25 Epoxy cholesterol 
22 (R) hydroxycholesterol 
24S hydroxycholesterol 
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lead to altered LXR induced responses. However, only a few studies have 
focussed upon the factors that regulate the expression of LXRs. As such this is an 
area of considerable interest in terms of understanding their inducible biology.  
After the identification of the genes that encode the LXRs, promoter analysis 
revealed several potential transcription factor binding sites for SP1 (20). SP1 was 
known to bind and regulate the expression of multiple house keeping genes and 
it was proposed that SP1 may be responsible for regulating the basal expression 
of LXRα and LXRβ. However, binding of SP1 to an LXR promoter and regulation of 
LXR expression by SP1 has never been demonstrated, it therefore remains 
unknown how the basal level of the LXRs’ expression is maintained.  
At the same time potential NF-κB and AP-1 binding sites were also identified in 
the promoter of LXRβ which have since been confirmed by other studies. Since 
these signal transducers are implicated primarily in leukocyte activation, this is 
compatible with an additional role of LXRs in immunity. Treatment of human 
hepatic and kidney cell lines with TNFα in vitro inhibits the expression of both 
LXRα and LXRβ (40-42). However, contradictory results have been obtained in 
two further studies where the expression of LXRs has been shown to be 
increased in rabbit adipocytes treated with TNFα (43, 44). TNFα also clearly 
activated NF-κB in these latter studies which suggest that TNFα signalling, 
mediated by interactions of NF-κB with the LXR promoter, may lead to different 
outcomes upon LXR expression in distinct cell types. Microarray analysis has also 
demonstrated that the expression of LXRα was increased upon the 
differentiation of human monocytes with granulocyte/ macrophage-colony 
stimulating factor (GM-CSF) to macrophages (45).  
Activation of LXRs in human macrophages by cholesterol loading and treatment 
with synthetic or endogenous ligands has been shown to up-regulate the 
expression of LXRα (46-48). This capacity was lost upon mutation of LXR binding 
sites within the LXRα promoter suggesting that the expression of LXRα is 
positively auto-regulated. However, this auto-regulatory loop is (i) specific to 
the induction of LXRα expression and not LXRβ, and (ii) is likely to be cell type 
specific since it was not observed in human adipocyte and hepatic cell lines. 
Furthermore, the induction of the LXR target gene ABCA1 expression was greater 
in human macrophages compared to adipocytes or hepatocytes suggesting that 
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this auto-regulatory loop serves to further enhance the induction of LXRα target 
genes specifically in macrophages. In contrast to macrophages, adipocytes and 
hepatocytes apparently lack LXR associated signalling pathways responsible for 
the increased expression of LXRs in human macrophages. Moreover, all studies 
concur in showing that the ability of LXRα to auto-regulate its expression is 
specific to macrophages of a human origin as induction of LXRα expression in 
mouse macrophages was not observed upon treatment with LXR agonists. Further 
analysis revealed that the murine LXRα promoter was found to lack the 5’ region 
containing the LXRE explaining the lack of LXRα auto-regulation in mouse 
macrophages. This is indicative of a species difference in the mechanism 
regulating the expression of LXRα. These studies have important implications for 
LXR biology and add another level of complexity to the regulation of LXR 
transcription. However, caution should be applied when comparing the 
regulation of LXRs and consequent transcription of designated target genes 
between mice and humans. This is also relevant in considering interpretation of 
murine in vivo model studies and human analyses as will become important later 
in my studies. 
Previous investigations studying the regulation of LXR expression have shown 
that PPARγ ligands were able to upregulate the expression of LXRα in human and 
mouse macrophages and consequently LXRα target genes (47, 49). Furthermore, 
sequence analysis identified PPAR response elements (PPRE) within both the 
human and mouse LXRα promoters’. Additionally, treatment with LXR and PPARγ 
ligands drive the expression of LXRα and the effect is synergistic when the 
ligands are added in combination (47). This demonstrates once again how 
multiple signalling pathways may interact to regulate the transcription of LXRs. 
6.2.4 LXR splice variants 
Ongoing attempts to decipher the mechanisms by which LXR expression is 
regulated have identified two additional novel transcripts encoded by the human 
LXRα gene, NR1H3 (50). Similarly, alternative transcript start sites have also 
been identified in the NR1H3 gene in mice (20). LXRα sequence analyses have 
identified these transcripts as alternative splice variants of LXRα and have been 
named LXRα2 and LXRα3; where LXRα1 (referred to throughout as LXRα) is the 
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originally described full length transcript. LXRα3 is transcribed from the same 
promoter as LXRα1, however exclusion of exon 6 caused an in frame deletion of 
50 amino acids from the LBD. The transcription of LXRα2 is regulated by an 
alternative promoter, 5’ of the originally identified promoter sequence, and is 
lacking 45 amino acids in the N terminus AF-1 domain in LXRα1. These structural 
differences are illustrated in Figure  6.4. The sub-cellular localisation of the 
three LXRα isoforms was identical; i.e. predominantly nuclear. However, HEK-
293 cells transfected with LXRα2 or LXRα3 expression vectors and treated with 
the LXR agonist T1317 revealed that the induction of ABCA1 transcripts was 
diminished. These data are suggestive of a decreased capacity of LXRα2 and 
LXRα3 to be activated by known LXR ligands which may be mediated through an 
altered ability to recruit transcriptional co-activators or bind agonist 
respectively. Importantly the transcription of alternative LXRα splice forms may 
provide a regulatory mechanism for the induction of LXR target genes.  
LXRα1 is known to be expressed in a wide variety of tissues; however in 
comparison LXRα2 and LXRα3 are expressed at very low levels except in the 
testes where LXRα2 is highly expressed. Additionally, LXRα2 and LXRα3 were 
expressed at a level comparable to that of LXRα1 in several tumour cell lines 
including Thp-1 cells; notably the expression in primary human monocytes/ 
macrophages was not assessed. Since, the isoforms are expressed at a higher 
level in tumour cell lines this may suggest that LXRα2 and LXRα3 might have 
pathophysiological roles in disease; although this remains to be explored. 
However, the identification of similar LXRα transcripts in the mouse has not 
been reported to date. Additionally, a pseudogene for murine LXRβ (ΨLXRβ) has 
been identified which contains multiple point mutations and deletions in 
comparison to LXRβ cDNA (20). The implications for the (potential) physiological 
role of these LXRα isoforms is not clear however, it is possible that their 
expression may be induced by specific metabolic or inflammatory stimuli. 
Further studies are required to elucidate their endogenous roles.  
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Figure  6.4 Alternative splice forms of LXRα. 
A schematic of the protein polypeptides of the three human LXRα splice variants.  LXRα1 is 
encoded by the full length transcript to form the AF-1 domain, DNA binding domain (DBD) 
and the ligand binding domain (LBD). LXRα2 is truncated at the N terminus and is formed by 
use of an alternative promoter and removal of an exon encoding the AF-1 domain. LXRα3 is 
truncated at the C terminus resulting in partial deletion of the LBD.  
6.2.5 Regulation of Liver X Receptors activation & transcriptional 
activity 
The expression and activation of LXRs is tightly regulated - within the nucleus 
LXRs are in complex with the nuclear receptor Retinoid X Receptor (RXR) 
forming LXRα/RXR or LXRβ/RXR heterodimers (14). In the absence of ligand the 
LXR/ RXR heterodimer complex is present in an inert conformation and is bound 
by transcriptional co-repressors rendering it transcriptionally inactive. Recently 
the corepressors nuclear receptor corepressor (NCoR) and silencing mediator of 
retinoic acid and thryroid receptor (SMRT) have been implicated in the 
regulation of LXR target genes (51). They function by recruiting additional 
transcriptional repressor molecules such as histone deacetylases (HDACs) forming 
large corepressor complexes that promote a ‘closed’ chromatin conformation. 
However, binding of an agonistic ligand to the LXR LBD induces a conformational 
change of the LXR/RXR heterodimer releasing the corepressor complex and 
allowing binding of coactivator complexes and transcription of LXR target genes 
(52). It has been suggested that the extent of LXR activation may be mediated 
by differential cofactor recruitment; indeed partial agonism of LXR has been 
shown to be due to the recruitment of the corepressor NCoR (53).  
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LXRs are predominantly localised within the nucleus regardless whether or not 
they are bound by ligand (54). However, there is a growing body of evidence 
demonstrating that LXRα, but not LXRβ, can translocate between the cytoplasm 
and the nucleus even when bound by agonist. This may impose additional levels 
of regulation upon the transcriptional activity of LXRα (55). Retention of LXRα 
within the nucleus has been shown to be in part regulated by TNFα induced 
phosphorylation within the AF2 region of LXRα (56-58). Additionally, a nuclear 
localisation sequence has been identified on both LXRα and RXR which are 
essential for nuclear import, although RXR mediated translocation of LXR can not 
induce transcription of LXR target genes (59). The activation of LXRs is 
summarised in Figure  6.5.  
 
Figure  6.5 Regulation of LXR transcriptional activation 
Oxygenated forms of cholesterol (oxysterols) or synthetic LXR agonists bind to the ligand 
binding domain in LXRα or LXRβ which are in partnership with RXR. Ligand binding 
induces the conformational change of the LXR/RXR complex inducing the release of 
transcriptional co-repressors and allowing the binding of transcriptional co-activators 
thereby switching on target gene transcription. LXRα, but not LXRβ, can be translocated 
between the cytoplasm and the nucleus and vice versa even in the presence of agonist.  
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Upon activation of LXRs within the nucleus they can induce transcription by 
binding to LXR response elements (LXRE) within the promoter region of 
designated target genes. LXREs are formed from two hexameric direct repeats 
(DR) separated by 4 nucleotides as such they are designated DR4 type response 
elements (60). Many genes have now been identified as being directly regulated 
by LXRS by the presence of LXRE within their promoters and in the context of 
reporter based assays. However, although LXRs have been implicated as having 
an immuno-modulatory role most of the LXR target genes that have been 
identified have been ascribed functions regulating lipid metabolism and 
transport e.g. ABCA1, NPC-1 and PLTP. To date the only LXR target genes that 
have been identified with a direct role in inflammation are those encoding 
CCL24, human TLR4 and human MPO (61, 62). A full list of known LXR target 
genes along with a brief description of their assigned functions is shown in Table 
 6.1. 
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Physiological role Target gene Assigned function Ref 
aP2 ↑ Specifically expressed in adipocytes. Activated by binding of fatty acids and regulates 
adipocyte differentiation. 
(63) 
GLUT4 ↑ Widely expressed glucose transporter of which the expression in epididymal white 
adipose tissue is regulated by LXRα.  
(64) 
LGK ↑ Predominantly expressed in the liver, pancreatic β cells and the brain where it 
phosphorylates glucose to glucose-6-phosphate for entry into glycolysis or to be stored 
as glycogen. LGK expression is also regulated by the LXR target gene SREBP-1c thereby 
amplifying the level of expression. 
(65) 
Adiposity and 
glucose metabolism 
PPARγ ↑ Predominantly expressed in adipocytes and is the master regulator of adipocyte 
differentiation. PPARγ activation ameliorates type II diabetes, cardiovascular disease 
and has been shown to exert anti-inflammatory effects.  
(6, 66) 
 PPARα ↑ PPARα is associated with anti-inflammatory effects and regulates uptake of 
triglycerides and glucose in cardio myocytes.  
(67, 68) 
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 UCP-1 ↓ Inhibition mediated by LXRα. UCP-1 regulates thermogenesis in brown adipose tissue   (69) 
ABCA1 ↑ 
ABCG1 ↑ 
Promote efflux of cholesterol from macrophage foam cells onto apoA-I and HDL 
particles and therefore promotes reverse cholesterol transport. Mutations in ABCA1 are 
associated with Tangier disease. 
(49, 70, 
71) 
AIM ↑ Member of the scavenger receptor cysteine-rich superfamily which secreted by and 
protects macrophages from apoptosis. Induction of AIM is regulated by LXRα, but 
deletion of AIM protects against atherosclerosis. (Alias SPα). 
(72) 
Arg II ↑ Catalyses the conversion of L-Arginine to ornithine and urea. Arginine is required for 
nitric oxide synthesis. Arginase II inhibits the production of nitric oxide by 
inflammatory cells.  
(73, 74) 
ApoD ↑ Apolipoprotein which transports cholesterol as part of HDL particles from the periphery 
to the liver for excretion from the body. 
(75) 
Lipid transport and 
metabolism 
 
 
 
 
 
 
 
 
ApoE ↑ Transports cholesterol as part of LDL and VLDL particles from the periphery for 
degradation and excretion as bile through binding to LDL receptors in the liver. ApoE4 
alleles are associated with Alzheimer’s disease.  
(70, 76) 
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ApoA-V ↑ Synthesised in the liver and secreted into the plasma where it is associated with VLDL 
and HDL and regulates the concentration of triglycerides. SNPs in the human 
population correlate with increase triglyceride levels. 
(77, 78) 
CD36 ↑ Scavenger receptor mediated in the cellular uptake of free fatty acids in the liver and 
oxLDL on macrophages. Direct induction of CD36 by LXRs is unique to the liver, 
although CD36 is expressed on a variety of cell types. 
(79) 
CYP7A1 ↑ Regulates the rate limiting step of bile acid synthesis which can in turn repress CYP7A1 
through activation of FXR. 
(80) 
FAS ↑ Synthesis of fatty acids (conversion of melanyl CoA to palmitate) and subsequent 
synthesis and elevation of serum and hepatic triglycerides. 
(33, 81, 
82) 
LDLR ↑ Mediates the endocytic uptake of LDL cholesterol in the liver which has been 
transported by lipoproteins (predominantly HDL) from the periphery. Induction of LDLR 
can be induced by LXRα. 
(83) 
 
NPC-1 ↑ Regulates trafficking of cholesterol from the cholesterol endocytic pathway to the 
plasma membrane and endoplasmic reticulum. Activation of NPC-1 has been 
implicated in the amelioration of atherosclerotic plaques in ApoE-/- mice through 
(84-86) 
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activation of LXRs. Mutation in NPC-1 is causes Niemann-Pick C disease resulting in 
early death.  
 
PLTP ↑ Transfer of phospholipids from VLDL particles to HDL particles during reverse 
cholesterol transport. Also has been implicated in the neutralisation and clearance of 
lipopolysaccharide by transfer from HDL to LDL.  
(87-89) 
 RENIN ↑ A protease expressed in the kidney which converts angiotensinogen to angiotensin I 
which induces the secretion of aldosterone from the adrenal gland to promote salt 
absorption. 
(90) 
 SREBP-1C ↑ Transcription factor that regulates the expression of glycolytic and lipogenic genes e.g. 
FAS, LDL receptor and glucokinase.  
(6, 91, 
92) 
Steroidogenesis 11β-HSD-1 ↓ Is expressed in liver, adipose and macrophages and regulates the activation of inert 
cortisone into biologically active cortisol. Modulation of 11β-HSD1 expression therefore 
impacts upon GC signalling through the GR.   
(7) 
 GR ↓ A nuclear receptor activated by the binding of corticosteroids or synthetic steroids. (93) 
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 StAR ↓ Rate limiting enzyme involved in the synthesis of de novo glucocorticoids in the 
adrenal glands from cholesterol.  
(94) 
Inflammation CCL24 ↑ Chemokine secreted by monocytes and T cells that interact with the chemokine 
receptor CCR3 to induce chemotaxis of eosinophils and basophils. Expression of CCL24 
can be induced phosphorylation of LXRα.  
(56) 
 TLR4 ↑ Binds LPS and activates NF-κB inducing the transcription, translation and secretion of a 
variety of pro-inflammatory cytokines and chemokines. LXR only regulates TLR4 
expression in humans.  
(5, 61) 
 MPO ↓ LXR down-regulates the expression of myeloperoxidase only in human but not mouse 
macrophages and neutrophils.  
(62) 
Table  6.1 LXR target genes 
A description of genes that have been shown to be directly transcriptionally regulated by the activation of LXRs in mice and humans and a brief description 
the assigned function in the context of LXR activation. ↑ or ↓ represents increased or decreased expression of target gene respectively. Adipocyte fatty 
acid binding protein 2 (aP2), glucose transporter (GLUT4), liver glucokinase (LGK), peroxisome proliferator activated receptor (PPAR), Uncoupling Protein 
1 (UCP-1), ATP binding cassette A1/G1 (ABC A1/G1), apoptosis inhibitor factor expressed by macrophages (AIM/ SPα), arginase II (Arg II), apolipoprotein D 
(ApoD), apolipoprotein E (ApoE), cholesterol 7 alpha-hydroxylase A1(CYP7A1), fatty acid synthase (FAS), low density lipoprotein Receptor (LDLR), 
Niemann-Pick C1 (NPC-1), phospholipid transfer protein (PLTP), sterol regulatory element binding protein 1c (SREBP-1c), 11β hydroxysteroid 
dehydrogenase type 1 (11β HSD-1), glucocorticoid receptor (GR), steroidogenic acute regulatory protein (StAR), CCL24 (Eotaxin), toll like receptor 4 (TLR4) 
and myeloperoxidase (MPO). 
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In addition to the well recognised role as a transcription factor LXRβ has more 
recently been shown to exert regulatory effects upon LXR target gene products 
post translationally (95). In a low cholesterol environment LXRβ was shown to 
associate with ABCA1 at the plasma membrane thereby rendering ABCA1 
inactive. However, upon cholesterol accumulation LXRβ dissociated from ABCA1 
promoting ABCA1 mediated reverse cholesterol transport. This is the first 
example where LXRs have been shown to regulate both the transcription and 
activity of a target gene product and highlights a novel way in which the 
regulatory aspects of LXRs might be considered in complex inflammatory 
systems. 
6.2.6 Liver X Receptors in physiology & disease 
6.2.6.1 Atherosclerosis 
Several studies using synthetic LXR agonists have demonstrated beneficial 
effects of LXR activation upon atherosclerosis in apolipoprotein E knockout 
(ApoE- -/-) and Low Density Lipoprotein Receptor null (LDLR-/-) mice fed a high 
fat diet. Systemic administration of either of two LXR agonists, T1317 and 
GW3965, can inhibit the development of, and promote the regression of 
established atherosclerotic lesions (96, 97). These observations were associated 
with a beneficial lipid profile; reduced total and VLDL cholesterol but increased 
HDL. Amelioration of atherosclerotic plaques by LXR agonists has been shown to 
be mediated primarily through the efflux of cholesterol from macrophage foam 
cells through the increased expression of the cholesterol transporters ABCA1 and 
ABCG1. More recently many more effects of LXR activation have now been 
identified and implicated in the reversal of atherosclerotic plaque development. 
LXRs have been shown to up-regulate the expression of the Niemann- Pick 
protein C-1 (NPC-1) (85). NPC-1 regulates intra-cellular cholesterol trafficking 
and deletion of NPC1 promotes atherosclerotic lesion formation (98). NPC-1 is 
also involved in the generation of oxysterols which may activate LXRs; increased 
expression of NPC-1 may therefore provide a positive feedback loop upon the 
activation of LXRs and subsequently up-regulate the expression LXR target genes 
involved in reverse cholesterol transport e.g. ABCA1 and NPC-1. Activation of 
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LXRs has also been shown to inhibit the uptake of cholesterol loaded LDL by 
macrophages thereby preventing foam cell formation (99). More recent studies 
in primates have demonstrated that administration of an LXR agonist reduced 
the concentration of total and LDL cholesterol in a dose dependent manner 
whilst increasing the expression of ABCA1 (100).  
Such studies in rodents and primates have provided support that administration 
of LXR agonists may be beneficial for the treatment of atherosclerosis. However, 
it is evident that the dual activation of LXRα and LXRβ in rodents, as with T1317 
or GW3965, causes the undesirable effects of hepatic steatosis and 
hypertriglyceridaemia which may lead to liver cirrhosis. These lipogenic effects 
are mediated through the increased induction of fatty acid synthase (FAS), CD36 
and sterol regulatory element binding protein 1c (SREBP-1c) expression. These 
genes have been shown to be predominantly regulated by LXRα. As such the 
activation of LXRβ in LXRα-/-, ApoE-/- double KO mice has been shown to reduce 
the size of atherosclerotic plaques but did not induce hepatic steatosis or 
hypertriglyceridaemia (101, 102). These studies therefore suggest that the 
development of agonists that specifically activate LXRβ may be more beneficial 
for the treatment of atherosclerosis in humans. Given the high level of homology 
in the LBD between LXRα and LXRβ this may prove to be problematic although 
there are now reports emerging demonstrating the development of compounds 
with a degree of LXRβ selectivity (103). The specificity of such compounds 
remains to be confirmed by additional groups and there efficacy is yet to be 
assessed in models of atherosclerosis.  
Atherosclerotic plaques are associated with chronic low grade inflammation and 
as LXRs have been ascribed a recent novel role in inflammation LXR agonists 
have also been suggested to inhibit inflammation associated with CVD. Indeed, 
serum analysis by ELISA and hepatic microarray gene analysis demonstrated a 
decrease in the pro-inflammatory cytokines IL-1 and IL-6 in ApoE-/- mice treated 
with T1317 (104). However, although the investigators reported a predominantly 
anti-inflammatory effect the administration of T1317 was associated with an 
increase in TNFα and MMP9. Additionally, oxysterols, which activate LXRs, have 
been shown to enhance the expression of the adhesion molecules, inter-cellular 
adhesion molecule 1 (ICAM 1) and vascular cell adhesion molecule 1 (VCAM1) 
(105). ICAM1 and VCAM1 are expressed on the surface of endothelial cells and 
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direct leukocyte migration into tissue and blood vessels during atherosclerotic 
lesion development. The effect of LXR activation upon the inflammatory 
component of atherosclerosis is therefore not clear. Furthermore, the 
development of LXRβ agonists for the treatment of atherosclerosis should be 
done so with caution as the effect of LXRβ agonism upon inflammation has not 
been studied and the effects unknown. 
6.2.6.2 Obesity 
Obesity was originally regarded as simply storage of excess fats within white 
adipose tissue (WAT); however, it is now evident that obesity is associated with 
low grade chronic inflammation. Adipocytes in WAT are situated in close 
proximity to macrophages, dendritic cells and lymphocytes (106-110) in which 
both LXRα and LXRβ are highly expressed. Similarly, the nuclear receptor PPARγ 
is highly expressed in adipocytes where it acts as the master regulator of 
adipocyte differentiation and regulates the expression of LXRs during adipocyte 
development (111). The role of LXRs in adipogenesis and adipocyte lipid 
accumulation has been investigated. Lipid accumulation in LXRα/β double 
knockout mice is reduced when fed a high fat diet over a prolonged period of 12 
months in which the size of adipocytes and WAT is reduced (112). Similarly, LXR 
agonism during adipocyte differentiation has been shown to promote a greater 
accumulation of lipids (111). This effect was shown to be LXRβ specific as LXRα-/- 
mice do not exhibit the same phenotypic changes in the reduction of adipocyte 
and WAT size. It has now been determined that LXRs do not affect adipogenesis, 
but do regulate lipid metabolism within adipocytes (112-115). Reduced lipid 
accumulation in adipocytes deficient in LXRβ has been proposed to be regulated 
through the Uncoupling Protein 1 (UCP-1). UCP-1 regulates mitochondrial 
respiration and increased expression of UCP-1, as seen in LXRβ-/- adipocytes, 
leads to the oxidation of lipids without the production of ATP. Similar to 
observations seen in rodent models the expression of LXRα was found to be 
significantly increased in WAT from obese women. A role of LXRs in obesity has 
further been confirmed through human genetic analysis. Recently several single 
nucleotide polymorphisms (SNPs) were found in Nr1h3 and Nr1h2 which were 
shown to associate with increased and decreased Body Mass Index (BMI) (116). 
This is suggestive of a genetic predisposition to either a protective or predictive 
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phenotype for the onset of obesity which might be regulated by an altered 
functional activity of LXRs. 
Obesity is often associated with type II diabetes. As well as reduced adiposity 
LXRβ-/- mice are also glucose intolerant and exhibit impaired glucose induced 
insulin secretion from pancreatic islet cells (112). Furthermore, activation of 
LXRs has been shown to improve glucose tolerance through the increased 
expression of an insulin sensitive glucose transporter (GLUT4) and suppression of 
gluconeogenesis (114). Since macrophages are involved in both inflammation and 
metabolism a role for them in LXR driven glucose tolerance was investigated. 
However, transfer of LXRα/β double knockout bone marrow into wild-type 
recipients was shown to have no effect upon net body weight gain and glucose 
tolerance (113), although the effect specifically upon adipose associated 
inflammation was not assessed.  
6.2.6.3 Autoimmunity and inflammation 
LXRs have a well defined role in tissues which exhibit metabolic functions and as 
regulators of cholesterol homeostasis. More recently LXRs have been implicated 
as having a modulatory effect upon inflammation in which they have generally 
been ascribed an anti-inflammatory function. However, the role of LXRs in 
inflammation is controversial and the mechanism by which they modulate 
inflammatory processes remains largely unknown. 
LXR agonism was first suggested to exert potent anti-inflammatory effects 
exemplified in the suppression of pro-inflammatory cytokine secretion from 
lipopolysaccharide (LPS) stimulated murine macrophages treated by GW3965, 
T1317 or endogenous agonistic LXR ligands (117). Inhibition of the pro-
inflammatory mediator Cox-2 by this route was shown to be NF-kB dependent. 
LXR activation effectively inhibited the expression of a Cox-2 luciferase reporter 
which was lost upon mutation of the NF-kB binding sites with the promoter 
region. These results suggest that the anti-inflammatory effects attributable to 
LXR activation were mediated through inhibition of NF-kB signalling. However, 
similar studies analysing the role of LXR activation in human macrophages 
demonstrated a bi-modal effect of LXR activation. Pre-incubation of primary LPS 
stimulated monocyte derived macrophages with LXR agonists for less than 24 
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hours inhibited the secretion of TNFα and MCP-1. In contrast cytokine and 
chemokine release was exacerbated when pre-incubation of macrophages with 
T1317 was greater than 24 hours (61). Similar results have also been obtained in 
primary human pulmonary derived macrophages (118). Further studies 
demonstrated an LXRE within the human TLR4 promoter and that the increased 
cytokine secretion in response to TLR4/ LXR ligation was mediated by the 
increased induction of TLR4 expression. These observations therefore 
demonstrate a species difference in the response to endotoxin in the context of 
LXR activation between mouse and humans. To date no other studies have 
analysed the effect of LXR activation upon other pattern recognition receptors 
(PRRs) in mice or humans and whether the regulation of human TLR4 by LXRs is 
unique or is a characteristic of other human TLRs is unknown. 
The potential for LXR activation to modulate an immune response has been 
assessed in pulmonary inflammation. Two studies have independently 
demonstrated that induction of pulmonary inflammation with an LPS aerosol was 
significantly attenuated by systemic administration of T1317 or GW3965. This 
was associated by a reduction of iNOS and IL-1β expression and reduced 
neutrophil infiltration into the trachea (19, 118). However, the inhibition of 
cytokine expression and neutrophil recruitment by LXR activation was shown to 
have detrimental consequences upon intra-tracheal infection of mice with the 
gram negative bacterium K. pneumoniae where the number of lung and spleen 
colony forming units was increased leading to an increased level of mortality. 
However, in an endotoxin free antigen driven model of asthma administration of 
GW3965 significantly increased airway smooth muscle proliferation, reactivity 
and eosinophilia (119). Together these studies suggest that the inflammatory 
context in which LXRs are activated will dictate whether a beneficial or 
detrimental outcome is achieved. Furthermore, LXR activation should therefore 
be described as having an immune modulatory potential as opposed to the 
current anti-inflammatory role which LXRs are generally ascribed.  
LXR agonism has also been shown to inhibit cytokine release and proliferation of 
antigen stimulated murine CD4+ T cells in vitro demonstrating a potential role 
for LXRs in the adaptive immune response (17, 120, 121). Accordingly, the effect 
of LXR activation has been investigated in rodent models of human autoimmune 
disease. Treatment of mice with T1317 ameliorated the severity of an in vivo 
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model of human multiple sclerosis (experimental autoimmune encephalomyelitis 
- EAE) (121, 122). However, ex vivo analysis demonstrated that this was not 
associated with a decrease in antigen driven T cell proliferation contradictory to 
preliminary in vitro observations (121). Furthermore, gene expression analysis of 
human peripheral blood mononuclear cells (PBMCs) from patients with MS 
showed altered levels of LXR expression supporting a role for LXRs in human 
disease pathology. Interestingly, the changes in LXR expression were shown to 
differ between different ethnic and geographical groups (123, 124). It is 
therefore clear that the expression of LXRs and potentially their activity is 
influenced through genetic and/ or environmental differences although the 
specific factors and their magnitude of effect are currently unknown. 
More recently the effects of LXR activation have also been assessed in the 
murine collagen-induced arthritis (CIA) model. Administration of T1317 at high 
dose after antigen challenge was shown to significantly inhibit disease 
progression and was therefore suggestive of a beneficial effect of LXR agonists 
for the treatment of rheumatoid arthritis (RA) (125). However, my work 
presented within this thesis shows a clear contradictory outcome; I have 
demonstrated that administration of either T1317 or GW3965 dramatically 
increase the severity and onset of disease progression in multiple CIA models. 
The results of my studies and an in depth comparison of these studies will be 
presented and discussed in the respective chapters contained herein. 
6.2.7 Liver X Receptor agonists as therapeutics for disease 
It is evident from studies in rodents that synthetic LXR agonists may exert 
potential beneficial effects upon metabolic related pathologies. Several 
pharmaceutical companies are competing to develop LXRβ agonists that will 
mediate these potentially beneficial effects without inducing LXRα activation 
which is implicated in fatty acid and triglyceride synthesis in turn promoting the 
development of hepatic steatosis. Recently, a novel LXRα/ LXRβ dual agonist, 
WAY-252623, was tested in a human recipient and was shown to up-regulate 
ABCA1 expression in PBMCs. These results suggest that the ability of LXR 
activation to induce reverse cholesterol transport in mice, the primary 
mechanism of atherosclerotic lesion size reduction by LXRs, is conserved 
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between rodents and humans in vivo (36). Furthermore, this study provided the 
first evidence that LXRs agonists may indeed be an appropriate therapeutic 
approach for the treatment of human metabolic disorders. The safety of WAY-
252623 has since been tested in a phase I dose ascending study in a total of forty 
volunteers (126). The agonist was shown to be readily absorbed and to induce 
the expression of ABCA1 and ABCG1 in PBMCs; suggestive of sufficient exposure 
of LXRs to agonist at all concentrations by oral administration. However, whilst 
no deaths or serious adverse effects were reported, 55% of the participants 
experienced mild adverse effects of a psychiatric or neurological nature during 
and post termination of their assigned treatment regime. Some of the symptoms 
included forgetfulness, drowsiness and confusion. From this single study it is not 
clear if these adverse effects were a result of agonist toxicity, lack of specificity 
or alteration of LXR function and downstream pathways within the brain. It is 
however clear that further studies are required to elucidate the mechanism of 
these effects if LXR agonists are to go forward to the clinic. 
The role of LXRs in inflammation remains unclear and at this stage it is not clear 
whether development of LXR agonists would be useful in human inflammatory 
diseases. This is particularly relevant since unexpected events could occur 
through the modulation of inflammatory pathways associated with metabolic 
disease.  
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6.3 Rheumatoid arthritis 
6.3.1 Diagnosis 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that 
affects 1% of the population of which approximately 70% of patients are female. 
RA presents as polyarthritis that predominantly affects the hands, feet and 
wrists but can affect any diarthrodial synovial joint. Diagnosis of RA requires the 
presence of four or more of the 1987 American College of Rheumatology (ACR) 
criteria for the classification of RA (Table  6.2) (127). These symptoms must 
persist for at least six weeks to exclude confounding conditions, such as viral 
infection, for a clinician to be confident of the correct diagnosis. Unfortunately 
this also presents a period of time in which symptoms may progress untreated. 
Novel criteria for the classification and diagnosis of RA that recognise these 
deficiencies are in the process of being prepared and will be available in early 
2010 under the direction of EULAR and the ACR. RA is extremely debilitating - 
approximately 80% of patients have reduced functional capacity to varying 
degrees and RA is therefore associated with a high social burden and economic 
cost due to unemployment (128). Therefore, identifying the underlying cause of 
RA and developing remission inducing treatment strategies is essential.   
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Criteria Definition 
Early morning stiffness Stiffness of the joints lasting at least one hour 
Arthritis of > 3 joints Three joint areas that exhibit joint swelling 
Hand joint arthritis Arthritis of at least one area of the hand/ wrist 
Symmetrical arthritis Arthritis of the same joint areas on either side 
of the body 
Rheumatoid nodules Subcutaneous non tender nodules generally 
found at pressure points near joints 
Rheumatoid factor (RF) Presence of an autoantibody against self IgG 
Bone erosions Radiographic changes typical of rheumatoid 
arthritis on hand and wrist including erosions or 
bone decalcification 
Table  6.2 American College of Rheumatology (ACR) criteria for classification of rheumatoid 
arthritis. 
Diagnosis of rheumatoid arthritis requires the presence of at least four of the ACR criteria to 
be diagnosed by a clinician (127). 
6.3.2 Etiology of rheumatoid arthritis 
Although how RA is initiated remains unknown there are a number of factors, 
both genetic and environmental, which are known to contribute to the 
susceptibility of developing RA. These risk factors may confer an increased risk 
of developing RA whilst others may offer protection. Similarly, others factors 
may exert modulatory effects upon the disease once onset. Whether protective 
or causative identifying these risk factors and understanding how they impact 
upon pathogenesis is vital to identifying the cause of RA. 
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6.3.2.1 Genetic associations 
Twin studies suggest that the genetical heritability of RA is approximately 50% in 
the UK (129). The most striking genetic association is with the various HLA-DRB1 
and HLA-DR4 alleles within the MHC class II region on human chromosome 6 
(130). Several HLA-DRB1 genotypes have been shown to confer a higher risk of 
early disease onset whilst others were associated with delayed onset and were 
therefore suggested to be protective (131). Association of MHC class II 
haplotypes with RA has given rise to the shared epitope hypothesis (132). The 
shared epitope hypothesis suggests that mutations in the β chain of the MHC 
class II molecules may alter T cell receptor (TCR) selection in the thymus, the 
recognition of self or modified self peptide by antigen presenting cells or the 
way in which antigen/ MHC class II interacts with the TCR to drive an immune 
response. However, it is evident that not all individuals with these 
polymorphisms develop RA and therefore there must be other contributing 
factors. Genome wide association studies have been utilised to identify further 
genetic risk factors of RA in which genomic markers adjacent to candidate genes 
such as STAT4, TNFα receptor and PTPN22 were identified as being disease 
associated (130). These observations imply that there are multiple pathways 
that may contribute to potentiate the development of RA. Theoretically, by 
understanding the genetics of RA, treatment regimes may be tailored towards 
individuals with a particular genetic predisposition. For example it is proposed in 
one study that mutations within the gene encoding TNFα may predict a poor 
response to antibody mediated anti-TNFα therapies (Infliximab) but not soluble 
TNFα receptor mediated therapy (Etanercept) (133). Many other studies are 
ongoing to clarify such an approach particularly in predicting response to 
biologic therapeutics. However, as susceptibility to RA is also largely influenced 
by environmental variation it is unlikely at present that genetic screening alone 
will be useful for the pre-clinical diagnosis of RA. 
6.3.2.2 Environmental impact 
As the genetic heritability of RA has been estimated to be approximately 30-50% 
it is evident that environmental risk factors confer a large influence upon the 
susceptibility to RA. In particular cigarette smoking, which is of a higher 
incidence in RA populations, has been one of the most widely studied 
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environment risk factors (134). Epidemiological studies have demonstrated that 
smoking is associated with a thirteen fold increase in the incidence of RA and an 
increased severity of disease (134-136). Furthermore, smoking induces long term 
susceptibility as individuals who have stopped smoking for more than ten years 
remain twice as likely to develop RA than the general population (137). 
Cigarette smoking promotes the process of citrullination; the post-translational 
modification of the amino acid arginine by de-imination to citrulline is catalysed 
by the enzyme peptidylarginine deaminase 4 (PAD 4). Citrullinated proteins 
including type II collagen, α-enolase, fibronectin, vimentin and fibrin have been 
identified in RA synovium and have been shown to be targets of an autoantibody 
response (138-140). Indeed, anti-citrullinated protein antibodies (ACPAs) have 
been identified in up to 90% of patients with RA and although they are not 
absolutely specific to RA they do correlate with disease severity (141-143). 
Citrullinated proteins are more immunogenic and have been suggested to 
contribute via the shared epitope hypothesis by modifying self peptide which 
may drive an immune-response (143). In support of this there is a strong 
association of smoking with “pathogenic” HLA-DRB1 alleles and the production of 
ACPAs in RA, thereby providing an example of how genetic and environmental 
factors may interact to drive pathology in RA (144).  
6.3.3 RA synovium 
The primary site of inflammation in RA is the synovial membrane (synovium). In 
a non-inflamed joint a protective smooth layer of cartilage acts as a “shock 
absorber” and provides a low friction surface to allow the bones to slide over 
each other. This is lubricated by synovial fluid which in addition is also a source 
of nutrients to chondrocytes as cartilage lacks blood vessels. A fibrous and 
ligamentous capsule around the joint is lined by the synovial membrane that is 
normally one to three cell layers thick comprising a thin lining layer of 
predominantly synovial fibroblasts and some macrophages with underlying 
adipose cells and a few blood vessels. RA is characterised by articular 
destruction and inflammation mediated by inflammatory infiltration of the 
synovial membrane (synovitis). This in turn drives joint pain and stiffness 
representing typical symptoms. Radiographic examination reveals decreased 
joint space and loss of cortical bone integrity i.e. cartilage and bone erosion, 
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limiting articulation and promoting further bone erosion potentially via 
biomechanical pathways. Articular destruction is accompanied with synovial 
membrane hyperplasia, pannus formation (intrusion by proliferation of the 
synovial membrane into the cartilage and bone interface) and inflammatory cell 
infiltration into the synovium. Infiltrating leukocytes promote synovitis by 
secreting cytokines, chemokines and proteases which mediate cartilage and 
bone erosion and promote a state of hypoxia. Hypoxia in turn induces 
angiogenesis of the synovial membrane and may actually enhance the survival of 
some inflammatory cells e.g. neutrophils (145). The comparison between a 
normal healthy and an inflamed RA synovium is illustrated in Figure  6.6.  
 
Figure  6.6 Rheumatoid Synovium 
Comparison of a normal synovial joint compared to an inflamed rheumatoid arthritis 
synovial joint. The illustration demonstrates the presence of inflammatory cell infiltrates 
synovial membrane hyperplasia, cartilage and bone erosion and angiogenesis. The 
histology photograph is a representative Haematoxylin & Eosin stained rheumatoid synovial 
membrane. The white arrow indicates a blood vessel (photo kindly supplied by Dr Axel 
Hueber). 
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6.3.4 Inflammatory cell types of the synovium 
It is evident that synovitis is accompanied by an inflammatory cell response 
which drives tissue destruction and inflammation. In order to develop an 
understanding of the processes which drive synovitis it is important to firstly 
identify which cells are present within the synovium and elucidate how they 
might contribute to the ongoing inflammatory response. The interactions 
between inflammatory cells is summarised in Figure  6.7.  
6.3.4.1 The monocyte/ macrophage lineage 
Monocytes are derived from common myeloid progenitor cells within the bone 
marrow. Myeloid progenitors firstly differentiate into monoblasts and 
subsequently pro-monocytes which upon migration into the blood give rise to 
monocytes. However, the monocyte population is not homogenous and in mice 
they have been separated into two general categories; inflammatory monocytes 
(GR1+, CCR2+ and CX3CR1
-) and blood resident monocytes (GR1-, CCR2- and 
CX3CR1
+) (146). Similarly, human monocytes can be categorised as classical 
monocytes (CD14+CD16-) which are analogous to the murine inflammatory 
monocytes and account for approximately 90% of monocytes in the blood (146, 
147). Additionally, approximately 10% of human monocytes are described as non-
classical monocytes (CD14+CD16+) akin to the murine blood resident monocytes. 
These two monocyte populations give rise to two broad classes of macrophage 
populations, termed M1 and M2, which exert different effects during an 
inflammatory response (discussed below).   
Classically activated/ effector macrophages (M1) differentiate from classical/ 
inflammatory monocytes and are found within the inflamed synovial membrane 
in RA. They are characterised by the expression of inducible nitric oxide 
synthase (iNOS) and are generally associated with bacterial clearance and exert 
pro-inflammatory effects (148). Differentiation of M1 macrophages is induced 
upon exposure to the Th1 cytokine IFNγ in combination with TNFα, both of which 
are elevated in patients with RA. M1 macrophages can also be differentiated in 
an autocrine dependent manner through the secretion of TNFα and IFNβ upon 
stimulation with Toll Like Receptor (TLR) ligands e.g. LPS in response to 
bacterial infection. Furthermore, TLR ligands such as bacterial cell wall 
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fragments, peptidoglycan and double stranded DNA have been identified within 
the synovium of RA patients which may drive polarisation of M1 cells (149). The 
expression of TLR3 and TLR4 are enhanced in synovial tissue from a proportion of 
patients with RA relative to osteoarthritis (OA) (150). Administration of LPS in 
the murine model of CIA also dramatically increases the severity of disease and 
re-initiates disease in mice during remission (151). Additionally, inhibitors of 
TLR7/8 have been shown to reduce TNFα secretion from RA synoviocytes (152). 
This has lead to suggestions that RA may be initiated by bacterial and or viral 
infection although to date no microorganism has been specifically linked to 
pathogenesis. However, it is now recognised that TLRs can be activated by 
endogenous ligands such as heat-shock proteins and double stranded RNA 
released from necrotic synovial cells (153). Therefore, it is possible that the 
local environment within the synovium may potentiate the inflammatory 
response through a TLR mediated pathway by the secretion of pro-inflammatory 
cytokines, e.g. IL-12, IL-23 and TNFα, and activation of other immune cells e.g. 
T cells and fibroblasts. Future studies will almost certainly implicate further 
pattern recognition receptors e.g. NOD family members.  
The effector pathways mediated by classical synovial macrophages are well 
defined and include the secretion of cytokines and chemokines (e.g. TNFα, IL-1, 
IL-6, MIP-1α and MCP-1) and matrix metalloproteinases (e.g. MMP9 and MMP12). 
Additionally, macrophages can induce the activation of other adjacent cells by 
cell contact such as fibroblasts to induce the secretion of GM-CSF, IL-6 and IL-8. 
Although macrophages are not considered as professional antigen presenting 
cells such as dendritic cells and B cells, are it is clear that they can process and 
present peptides through MHC class II to induce the activation of CD4+ T cells. 
Such cellular interactions between macrophages and T cells enforces the 
inflammatory response within the RA synovium. Macrophages can also interact 
with and subsequently induce the activation of endothelial cells. This has been 
suggested to be in part responsible for the sustained influx of inflammatory cells 
into the synovium. Additionally, activated macrophages in RA may also drive 
atherosclerotic plaque development through the interactions with vascular 
endothelial cells. However, as professional phagocytes macrophages also serve 
to resolve inflammation through the phagocytosis of neutrophils and the 
secretion of anti-inflammatory cytokines such as IL-10 and TGF-β. 
  51 
Although the function of the non-classical/ resident monocytes is poorly 
understood they have recently been described as patrolling monocytes since 
they migrate along the luminal surface of blood vessel walls (154). These cells 
are ideally situated for immuno-surveillance and rapidly extravasate upon 
surrounding tissue damage and bacterial infection to provide a rapid and early 
but short lived (< 8hrs) inflammatory response. These monocytes were also 
characterised by the induction of arginase 1 and mannose receptor (CD206) 
expression which is typical of alternatively activated (M2) macrophages. M2 
macrophages can be differentiated in vitro upon exposure to the Th2 cytokines 
IL-4 and IL-13 and are generally associated with a wound healing response and 
an anti-inflammatory function (148). Although M2 macrophages do not appear to 
have a dominant role in bacterial clearance they have been implicated in the 
clearance of nematode parasite infections (155). To date the presence of 
alternatively activated macrophages within the synovium, either in a healthy or 
pro-inflammatory environment, has not been demonstrated and their potential 
role is unknown. However, providing they are present in the first instance, it is 
likely that during propagating stages of synovial inflammation that they are 
differentiated towards or replaced by macrophages exerting a pro-inflammatory 
phenotype.  
The role of M1 and M2 macrophages has been studied in the pathogenesis of 
many inflammatory disorders. However, it is now evident that these M1 and M2 
phenotypes represent two extremes of the macrophage activation spectrum that 
is in fact rather plastic (148). Furthermore, the monocyte lineage is highly 
heterogeneous and upon migration into tissues they will differentiate according 
to the external signals they receive. This is of importance in RA since ligation of 
receptor activator of NF-kB ligand (RANKL) expressed on synovial fibroblasts and 
T cells with its cognate receptor on monocytes, RANK in the presence of M-CSF 
induces the differentiation of osteoclasts. These are multi-nucleated cells that 
promote bone resorption and are responsible for the degradation of bone 
commonly seen in RA. Thus monocyte lineages can not only promote 
inflammation by virtue of cytokine and enzyme release but can also contribute 
directly to the resorption of bone by alternate differentiation.  
It is evident that monocytes and macrophages are central to the cellular 
responses involved in the pathogenesis of RA. Understanding the signals that 
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induce monocyte/ macrophage differentiation and the subsequent implications 
upon their activities is therefore crucial to understanding the development of RA 
pathology. 
6.3.4.2 Dendritic cells 
As well as giving rise to monocytes myeloid progenitor cells can also 
differentiate into dendritic cells (DCs) - classical/ inflammatory monocytes may 
also be able to replenish specific dendritic cell populations e.g. Langerhans cell 
in the skin. DCs are highly phagocytic and endocytotic cells that are able to both 
recognise and respond to microbial infection and thereafter present antigen and 
are therefore central to the cross-talk between the innate and adaptive immune 
response. DCs are found in tissues in an inactive state however upon immune-
activation, either by TLR ligands or antigen uptake they down-regulate their 
phagocytic capacity but up-regulate antigen processing and presentation and are 
directed to lymph nodes via CCR7 dependent pathways to induce T cell 
activation (156). Two major subsets of dendritic cells have been identified; 
plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs). mDC 
have a dominant role in antigen uptake and subsequent presentation. They 
express a large variety of TLR and NOD receptors and rapidly sense tissue 
damage or ‘danger’.  They predominantly produce cytokines such as IL-12, IL-23, 
IL-15, IL-18 and by this means mediate significant effects on subsequent T cell 
differentiation. pDC in contrast have equivocal antigen presenting function but 
particularly upon viral infection are a major source of type I interferon synthesis 
and release. In RA circulating numbers of mDC and pDC are both reduced and 
both correlate with disease activity inversely as assessed by correlation with CRP 
(157). Depletion of murine pDCs in vivo has recently been shown to enhance an 
anti-collagen response suggesting that they mediate mainly anti-inflammatory or 
regulatory effects (158, 159). mDCs in contrast when transferred into recipient 
mice and pulsed with collagen induce erosive arthritis and as such they seem 
likely to exert pro-inflammatory effects in arthritis (159).  
6.3.4.3 Synovial T cells 
CD4+ effector T cells can be divided into distinct lineage subsets depending upon 
their cytokine secretion profile. Th1 cells are categorised by the secretion of the 
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pro-inflammatory cytokine IFNγ and IL-2 which is required for T cell proliferation 
whereas Th2 cells are typified by the secretion of the cytokines IL-4, IL-5 and IL-
13. In addition a new subset of CD4+ T cells has recently been described termed 
Th17 due to their secretion of the pro-inflammatory cytokine IL-17A, together 
with IL-17F, IL-22 and CCL20.  
Cytokines secreted by activated macrophages regulate T cell activation and 
survival; thus IL-12 secretion from M1 macrophages or mDCs induces the 
polarisation of naïve CD4+ T cells towards a Th1 IFN-γ secreting phenotype. 
Th1,CD4+ IFNγ+, cells are detectable in synovial membrane at an elevated ratio 
to Th2 cells (160). In addition to IFNγ and IL-2, ligation of the T cell receptor 
(TCR) induces the secretion of TNFα and potentially a variety of other cytokines. 
However, whilst synovial T cells secrete TNFα a proportion also secrete IL-10 and 
only a very small number are found to express IFNγ in situ in the tissue (161).  
Therefore only a proportion of synovial T cells fit the classical Th1 cytokine 
secretion profile. 
Synovial T cells were shown to have a similar phenotype to cytokine activated T 
cells (TcKs). These can be generated in vitro by treatment with IL-6, TNFα and 
IL-2 which when co-cultured with M-CSF matured macrophages induce the 
secretion of multiple macrophage derived pro-inflammatory cytokines including 
TNFα (162). IL-2, IL-6 and TNFα are all detectable at elevated levels within the 
synovium and histological analysis of synovial membrane has revealed that 
macrophages and T cells are within close proximity to each other. In accordance 
co-culture of synovial membrane derived T cells with macrophages was shown to 
induce the secretion of macrophage derived TNFα in a cell-contact dependent 
manner independent of TCR ligation. In comparison treatment with IL-15 alone 
has also been shown to induce proliferation and activation of T cells akin to the 
cytokine cocktail IL-2, IL-6 and TNFα. Furthermore, co-culture of IL-15 activated 
T cells induced macrophage derived secretion of TNFα (163). IL-15 is expressed 
primarily by macrophages, fibroblast like synoviocytes and endothelial cells and 
is found at elevated levels in the serum and synovial fluid of RA patients relative 
to osteoarthritis (OA) patients (164). Serum and synovial fluid concentrations 
correlate strongly to disease severity, CRP and DAS28, in established disease 
thus suggesting a central role in disease pathogenesis (165). 
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IL-15 has also been shown to induce the secretion of IL-17 from PBMCs and RA 
synoviocytes (166). IL-17 is found at elevated levels in RA synovial fluid and was 
first shown to be produced by CD4+ T cells termed Th17 cells (167). Deletion of 
IL-17 or administration of an anti IL-17 antibody markedly reduced the severity 
of CIA whereas overexpression of IL-17 exacerbated disease severity (168, 169). 
As noted above however, Th17 cells are present in low numbers in inflamed RA 
synovium (170). Differentiation of CD4+ T cells towards a Th17 phenotype can be 
induced in vitro by IL-21, IL-6 and TGF-β whilst the expansion of Th17 cells is 
mediated by IL-23. However, the frequency of Th17 cells is low and Th1 cells 
may even predominate within the synovium (171). It is not clear whether this 
represents plasticity of the Th17 lineage or differentiation of a proportion of 
naïve T cells present within the heterologous Th17 population. However, Th17 
cells also secrete IL-22 and CCL20 and in humans a proportion of Th17 cells are 
IFNγ+ (172). Additionally, it is now evident that IL-17 is also secreted by non 
CD4+ T cells; specifically NK cells, γδ T cells, CD8 T cells, macrophages and more 
recently mast cells (unpublished data Hueber et al) (173-175). It is therefore 
unlikely that the observed phenotype upon deletion of IL-17 or IL-17 blockade is 
completely attributable to Th17 cells, contrary to initial suggestions, but rather 
a combination of cellular sources. Secretion of IL-17 drives activation of 
monocytes/ macrophages and synovial fibroblasts to secrete a milieu of pro-
inflammatory cytokines and chemokines e.g. IL-1, IL-6, IL-8, TNFα and GM-CSF 
(176). Blockade of IL-17 is therefore expected to be beneficial and is an 
attractive therapeutic target for the treatment of RA. 
In addition to the Th1, Th2 and Th17 subsets is the CD4+, CD25+ regulatory T cell 
lineage(s) (Tregs) that express forkhead box p3 (Foxp3). Unlike CD4+ effector T 
cells which promote an inflammatory reaction the role of Tregs is to regulate 
effector T cell activation and are therefore generally ascribed an anti-
inflammatory property. Tregs have been shown to suppress inflammation 
through direct cell-cell contact and by the secretion of the anti-inflammatory 
cytokines IL-10 and TGF-β. However, the precise mechanisms by which Tregs 
mediate inflammatory suppression are not fully understood. Although Tregs are 
detectable in peripheral blood and synovial fluid of patients with RA they have a 
decreased capacity to suppress IFNγ production from CD4+ T cells (177). 
Intriguingly the ability of Tregs to inhibit effector T cell IFNγ secretion was 
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shown to be mediated through TNFα; as treatment of RA patients with anti-TNFα 
antibodies (Infliximab) restored the capacity of Tregs to suppress pro-
inflammatory cytokine secretion. Thus the synovial inflammatory environment 
may inhibit the action of Tregs and thereby potentiate effector T cell 
proliferation and subsequent monocyte/macrophage activation through 
enhanced cytokine secretion.  
CD8+ T cells are typically described as cytotoxic T cells due to their ability to 
recognise virus infected cells and induce programmed cell death (apoptosis). 
This is mediated by the release of lytic granules which form pores in plasma 
membranes and digest proteins and nucleic acids. Additionally CD8+ T cells also 
secrete IFNγ which inhibits virus replication and increases the expression of MHC 
class I.  CD8+ T cells are found diffusively spread within the RA synovium (178).  
Interestingly whilst the number of CD4+ T cells was shown to positively correlate 
with leukocyte infiltration the frequency of CD8+ T cells was inversely associated 
with synovial membrane leukocyte numbers. This therefore suggests that CD8+ T 
cells could promote or regulate an inflammatory response within the RA 
synovium. However, the role of CD8+ T cells in RA is unclear and reports are 
conflicting as CD8+ T cells have also been suggested to modulate formation of 
germinal centres (179, 180).  
6.3.4.4 B cells 
RA is associated with autoantibody production against self citrullinated proteins 
(ACPA) and IgG (rheumatoid factor - RF) which are detectable in serum up to 10 
years prior to the clinical onset of RA (181). Additionally, B cell depletion by the 
anti-CD20 targeting monoclonal antibody, rituximab, has been successful in 
ameliorating disease in a large number of patients with RA (discussed below). It 
is therefore evident that B cells are central to driving the pathology of RA. B 
cells drive the inflammatory response in part through antigen presentation 
thereby inducing T cell activation and proliferation. Upon activation by antigen 
B cells will migrate to the lymph nodes or spleen where they will differentiate 
into antibody secreting plasma cells. Auto-antibody production can then induce 
the activation of inflammatory cells through binding of the Fc portion of 
antibodies to Fc receptors expressed on leukocytes. The importance of antibody 
mediated immune cell activation has been confirmed by the induction of 
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arthritis through the transfer of serum from an immunized mouse into a non-
immunized recipient in which type II collagen is thought to be the dominant 
epitope (182). Furthermore, anti-collagen antibody cocktails have been shown to 
induce the development of collagen-antibody induced arthritis (CAIA) which is 
characterized by macrophage and polymorphonuclear inflammatory cell 
infiltrate (183). Finally B cells may act as a source of inflammatory cytokines in 
RA synovial membrane and promote inflammation by that route. 
Analysis of synovial membrane has revealed the presence of lymphoid like 
structures in a proportion of patients with RA (184, 185). These structures, 
which resemble lymph node germinal centres, range from loose T and B cell 
aggregates to highly organised lymphoid like structures. These ectopic germinal 
centres are in an environment surrounded by self antigen and pro-inflammatory 
cytokines; they therefore provide an ideal setting for antigen presentation, 
plasma cell differentiation, survival and auto-antibody production without the 
requirement for trafficking to peripheral lymph nodes (186). However, it is 
difficult to assess the role that ectopic germinal centres play in the pathology of 
RA. Most samples obtained are small biopsies which consist of only a small 
proportion of the total potentially involved synovial membrane and therefore 
determining even a correlation between the presence of ectopic germinal 
centres relative to disease severity has proven problematic. Further, studies are 
therefore required to define the role of such lymphoid structures upon B cell 
activation and how this may affect the pathology of RA. 
6.3.4.5 Other inflammatory cells 
Mast cells & Neutrophils 
 
In addition to lymphocytes, DCs and macrophages, mast cells are also thought to 
play a role in RA and are present within the RA synovium at sites of cartilage 
damage (187). However, arthritic protocols in mice to study the role of mast 
cells upon the initiation of inflammation have yielded conflicting results (188, 
189). Whereas it is uncertain if mast cells are crucial for the initiation of 
arthritis it is evident they can mediate disease severity (190). However, unlike 
mast cells, depletion of neutrophils prevents the onset of adjuvant induced 
arthritis suggesting a role for neutrophils in the effector phase of RA (191). 
Neutrophils are concentrated within synovial fluid which in part is due to the 
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nature of the synovial environment as synovial fluid in conjunction with hypoxia 
enhance neutrophil survival (145). Stimulation of fibroblasts with TNFα and IL-
17, two cytokines central to RA pathology, induces the secretion of GM-CSF 
which can promote the survival of neutrophils (192).  
Fibroblasts 
 
Fibroblasts are the major cell type of the synovial membrane and it is well 
established that they contribute towards pathology in RA. Activation of 
fibroblasts either by cytokines e.g. GM-CSF or by TLR ligands induces the 
secretion of a variety of cytokines including IL-1, IL-6, TNFα and M-CSF which 
can in turn potentiate the survival and activation of leukocytes such as 
macrophages. The secretion of inflammatory cytokines by fibroblasts also serves 
as an auto-regulatory loop to upregulate the expression of adhesion molecules 
ICAM-1 and VCAM-1 promoting the interaction of fibroblasts with T cells (193). 
Such interactions enforce the inflammatory response through the increased 
expression and secretion of pro-inflammatory cytokines such as IL-1. The 
secretion of pro-inflammatory cytokines by fibroblasts and other immune cells 
also induces the secretion of chemokines, e.g. CXCL2 and CCL8, which can 
induce the chemotaxis of neutrophils and monocytes/macrophages respectively 
into the synovium. It is therefore evident that fibroblasts are central to the 
inflammatory response in the RA synovium. Additionally, fibroblasts are also able 
to contribute towards articular destruction directly through the secretion of 
proteinases e.g. collagenase (MMP-1). RA fibroblasts also express higher levels of 
RANKL and therefore drive articular destruction indirectly through the induction 
of osteoclastogenesis (194). 
Osteoclasts & Chondrocytes 
 
Articular structure in healthy individuals is maintained in a stable equilibrium by 
which the rate of bone deposition and resorption and collagen synthesis and 
degradation is in balance. However, in the RA synovium this balance is skewed 
towards bone resorption and collagen destruction leading to articular 
destruction. Osteoclasts are the cells which mediate bone resorption which is 
necessary for skeletal remodelling during development but are also the major 
cause of bone digestion in RA. Osteoclasts are multi-nucleated cells 
differentiated from monocyte precursors through the interaction of RANK/ 
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RANKL. Osteoclast activation and differentiation can be enhanced through the 
actions of cytokines such as TNFα or through cellular interactions where by T 
cells or fibroblasts can promote the differentiation of monocytes to osteoclasts 
(194). Osteoclasts degrade bone through the secretion of acid and MMPs which 
can cleave matrix proteins such as collagen. Similarly collagen turnover is also 
regulated in part by the actions of MMPs although this process is primarily 
mediated through the actions of chondrocytes. The secretion of MMPs, and other 
proinflammatory mediators e.g. IL-17 and IL-6, from chondrocytes can be 
induced by multiple pro-inflammatory cytokines such as IL-1 and TNFα (195). 
Therefore, it is evident that the inflammatory environment within the RA 
synovium can promote articular destruction through several mechanisms.  
 
Figure  6.7 Inflammatory cell types of the synovium 
Schematic demonstrating the interactions of immune cells within an inflamed joint, adapted 
from (196).  
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6.3.5 Cytokines & chemokines in rheumatoid arthritis  
Neutralisation of cytokines is now an established therapeutic regime exemplified 
by the use of anti TNF-α antibodies and soluble receptor fusion proteins in the 
clinic. Therefore, understanding the impact of cytokine networks upon 
inflammation and identifying how they are regulated is central to elucidating the 
mechanisms by which disease progresses (summarised in Table  6.3). 
6.3.5.1 TNFα 
TNFα is detectable in synovial fluid and membrane and is secreted by 
monocytes/ macrophages, T cells, B cells, synovial fibroblasts and neutrophils 
upon cytokine activation, TLR ligation or cell-cell interactions. Binding of TNFα 
to its cognate receptor TNF receptor 1 (TNFR1) induces activation of NF-κB and 
the secretion of multiple pro-inflammatory cytokines, e.g. IL-1 and IL-6, from 
synoviocytes which is blocked by addition of anti-TNFα antibodies in vitro (197, 
198). As such TNFα is now considered to be at the top of the cytokine hierarchy, 
or at least critical to the regulation of such a hierarchy. Several in vivo studies 
demonstrated a pathogenic role for TNFα in arthritis. Transgenic mice expressing 
human TNFα spontaneously develop arthritis and administration of anti-TNFα 
blocking antibodies ameliorated the severity of disease in a dose responsive 
manner (199, 200). Since these observations several TNFα blocking agents have 
been developed for the treatment of human RA (discussed below).  
6.3.5.2 Interleukin-12 superfamily 
Members of the IL-12 superfamily of cytokines are related by their common sub-
units p35, p40 and p19 and are secreted primarily by macrophages and dendritic 
cells upon stimulation by cytokines or TLR activation. IL-12(p35/p40) plays a 
pivotal role in the development of Th1 responses by promoting the polarisation 
of naïve CD4+ T cells towards an IFN-γ secreting phenotype. The role of IL-12 in 
RA is unclear however low levels of IL-12(p35/p40), i.e. biologically active IL-12, 
are detectable in RA synovial membrane and may therefore support the 
expansion of the predominant Th1/ TcK population within the RA synovium 
(201). IL-12 is considered to be a pro-inflammatory cytokine. However mice 
deficient in IL-12p35 display increased severity of CIA, associated with enhanced 
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levels of multiple pro-inflammatory cytokines and chemokines including IL-6, IL-
17 and TNF-α, suggesting IL-12 is protective in this model (202). In contrast, 
studies in other models, e.g. EAE, have demonstrated beneficial effects 
attributable to targeted deletion of the gene encoding the p40 sub-unit (203). 
However, it is now recognised that the p40 sub-unit is shared with IL-
23(p19/p40). Therefore such beneficial effects may be at least in part elicited 
by IL-23 blockade (203, 204). Mice deficient in p19 exhibit reduced severity of 
CIA (202). Interestingly IL-12 is overexpressed in mice deficient for IL-23 
suggesting a mechanism of IL-12/ IL-23 cross regulation. IL-23(p19) has been 
detected at high levels in the serum and synovial fluid and is overexpressed by 
synovial fibroblasts in RA (205). Similarly, we have demonstrated IL-23(p19) 
expression by immunohistochemistry in RA and PsA synovial membrane. 
However, functional IL-23p19/p35 heterodimer was only detectable by ELISA in 
PsA, but not RA, synovial fluid (unpublished data from our group) suggesting that 
at least in established disease and within the synovium IL-23 does not have a 
pathological role in RA. The role which IL-23 plays in early disease is unknown 
however, as well as promoting Th17 cell survival IL-23 has been shown to induce 
the secretion of pro-inflammatory cytokines e.g. IL-6, TNFα and IFNγ from T 
cells (206).  
6.3.5.3 Interleukin - 17 
The IL-17 family consists of six members, IL-17 A through to F, of which IL-17A 
(commonly referred to as IL-17) has been the most widely studied. IL-17 signals 
through the IL-17 receptor A (IL-17RA) which is ubiquitously expressed. The 
secretion of IL-17 has been shown to induce the expression of IL-6 and IL-8 in 
mouse fibroblasts and promote neutrophil survival (207). A pathological role for 
IL-17 in the development of arthritis has now been demonstrated in the murine 
CIA model as previously mentioned. Furthermore, mice deficient in IFNγ were 
more susceptible to the development of CIA which was suggested to be due an 
unrestricted expansion of the Th17 cell population mediated by loss of IFNγ 
(208). Given the highly pathological role of IL-17 there has been a concerted 
effort to elucidate the biology of IL-17 with particular emphasis upon Th17 cells; 
the first identified cellular source of IL-17; although as discussed above multiple 
sources have since been identified. Given the necessity of IL-6 for Th17 cell 
differentiation targeting of IL-6 may inhibit Th17 cell polarisation whilst 
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favouring the development of regulatory T cells mediated by TGFβ and thereby 
promote a protective immune response.  
6.3.5.4 Interleukin- 6 
IL-6 is expressed by monocytes, lymphocytes and fibroblasts and is detectable at 
elevated levels in the serum and synovial tissue of RA patients. Serum 
concentrations of IL-6 correlate with levels of CRP and disease severity (209). 
This strongly suggests a central role in disease pathogenesis and supports the 
suggestion that IL-6 blockade may yield beneficial effects in RA. IL-6 knockout 
mice are resistant to CIA and show reduced levels of serum TNF-α (210). IL-6 
signals through the IL-6R (IL-6Rα and gp130 sub-units) inducing the secretion of 
acute phase proteins (CRP and serum amyloid A), inflammatory chemokines (IL-8 
and MCP-1) and up-regulates the expression of adhesion proteins (211). IL-6 
signalling induces the accumulation of monocytes, promotes neutrophil apoptosis 
and macrophage phagocytosis akin to the resolution phase of many inflammatory 
reactions and which may reflect some of the pleiotropic effects attributable to 
IL-6 (211). To date blockade of IL-6 signalling has been successfully achieved in 
clinical trials using an antibody generated against the IL-6R to inhibit IL-6 
binding. Treatment with Tocilizumab, a humanised anti-human IL-6R monoclonal 
antibody, in RA patients with active disease revealed an improvement in all 
disease activity assessments in a dose responsive manner; normalisation of CRP 
levels and a significant improvement in RF titres relative to the placebo group 
(212). IL-6 blockade is therefore an attractive therapeutic target and the 
development of soluble IL-6 receptors, similar to anti-TNFα therapy, are being 
investigated (213, 214). 
6.3.5.5 Interleukin-1 superfamily 
The IL-1 family comprises eleven structurally related cytokines of which the 
biological activity of only five has been well characterised, namely IL-1α, IL-1β, 
IL-1 receptor antagonist (IL-1Ra), IL-18 and IL-33. Early in vivo studies 
demonstrated that injection of IL-1 into the knee joint of rats caused symptoms 
akin to chronic arthritis due to the secretion of matrix metalloproteinases 
(MMPs) and proteoglycans mediated via macrophage activation, causing cartilage 
and bone destruction. RA is associated with elevated levels of IL-1 in the 
  62 
synovium. Thus much effort has been directed towards finding appropriate 
methods of inhibiting IL-1 activity. Despite positive pre-clinical studies, IL-1 
blockade using Anakinra (IL-1 receptor antagonist) has failed to provide 
adequate therapeutic value in a large enough number of patients. It is not clear 
whether this reflects disease heterogeneity, suboptimal drug design (e.g. short 
half life) or an inadequate understanding of the role of IL-1 in the RA synovial 
cytokine hierarchy. Studies using anti-TNF in combination with IL-1Ra provide an 
additive functional effect upon cytokine inhibition from synovial tissue in vitro 
(215). 
IL-18 is synthesised as a 23kD pro-molecule that is cleaved by caspase 1, 
proteinase 3 or elastase to an 18kD ligand which is then able to bind IL-18R. The 
level of IL-18 within RA serum and synovial fluid correlates with DAS28 and CRP 
and suppression of disease by DMARD therapy (165, 216). IL-18 is able to induce 
expression of multiple cytokines and chemokines, particularly TNFα, in both in 
vitro and in vivo models whilst promote the differentiation of CD4+ T cells 
towards a Th1 phenotype in the presence of IL-12. IL-18 has been also shown to 
induce vascular endothelial growth factor (VEGF) expression in fibroblast like 
synoviocytes implicating IL-18 in angiogenesis. Multiple approaches have 
therefore been employed in an attempt to inhibit its pro-inflammatory effects  
(217). Administration of anti IL-18 antibody suppressed streptococcal cell wall 
arthritis (218). Similar to IL-1 it is unclear what proportion of RA pathology is 
attributable to the effects of IL-18 and the efficacy of IL-18 targeted therapy in 
RA remains to be identified. 
There is no doubt that cytokines represent valid therapeutic targets for the 
treatment of RA, exemplified by the success of anti-TNFα therapy. However, it 
remains unclear to what extent distinct patterns of synovial cytokine hierarchy 
exist within clinical subsets of RA. This is therefore a source of uncertainty in 
the ability to predict clinical effectiveness of specific cytokine blockade alone. 
However, the combination of cytokine blocking agents may prove more 
efficacious in the treatment of RA.  A summary of additional relevant cytokine 
activities is included in Table  6.3. 
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Cytokine Cellular source Role in rheumatoid arthritis 
IL-1 Monocytes, B cells & 
fibroblasts 
Induces cytokine secretion from fibroblasts 
and monocytes and activates osteoclasts. 
IL-6 Monocytes/ 
macrophages, 
fibroblasts, lymphocytes 
Induces proliferation of lymphocytes and 
differentiation of Th17 cells. Supports B 
cell antibody production. 
IL-12 Macrophages & 
dendritic cells 
Primarily secreted upon exposure to TLR 
ligands and induced maturation and 
proliferation of Th1 cells.  
IL-15 Monocytes, fibroblasts, 
mast cells, neutrophils 
& dendritic cells 
Promotes activation of T cells, fibroblasts, 
macrophages and neutrophils.  
IL-17 T cells, macrophages, 
dendritic cells & γδ T 
cells 
Induces the secretion of pro-inflammatory 
cytokines from macrophages, fibroblasts 
and endothelial cells.  
IL-18 Monocytes, neutrophils 
& dendritic cells 
Promotes differentiation of T cells to a Th1 
phenotype and induces activation of 
monocytes/ macrophages.  
IL-23 Macrophages & 
dendritic cells 
Secreted in response to TLR ligands and 
promotes survival and expansion of Th17 
cells. 
APRIL Monocytes/ 
macrophages & 
lymphocytes  
Member of the TNF superfamily and 
promotes B and T cell survival and 
proliferation. 
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BAFF T cells, monocytes/ 
macrophages & 
dendritic cells 
Member of the TNF superfamily and 
promotes B cell survival and maturation.  
GM-CSF Monocytes, osteoclasts, 
fibroblasts & T cells 
Stimulates the differentiation and survival 
of neutrophils and macrophages.  
MCP-1 Osteoclasts and 
macrophages  
Exert chemotactic effects upon 
macrophages, dendritic cells, neutrophils 
and lymphocytes. 
M-CSF Lymphocytes, 
monocytes, fibroblasts 
and osteoclasts 
Regulator of monocyte differentiation and 
proliferation and macrophage survival. 
MIP-1α/β Macrophages Exert chemotactic effects upon 
macrophages, dendritic cells, neutrophils 
and lymphocytes.  
TNFα Adipocytes, monocytes/ 
macrophages, 
fibroblasts, T cells and 
B cells 
Induces the activation of macrophages and 
endothelial cells whilst promoting 
apoptosis of neutrophils. Inhibits the 
regulatory function of regulatory T cells. 
Table  6.3 Cytokines and chemokines implicated in the pathology of rheumatoid arthritis 
A brief description of the cellular source and the role of the major cytokines and 
chemokines implicated in the development of rheumatoid arthritis. Interleukin (IL), a 
proliferating inducing ligand (APRIL), B cell activating factor belonging to the TNF family 
(BAFF), granulocyte/ macrophage colony-stimulating factor (GM-CSF), monocyte 
chemoattractant protein -1 (MCP-1), macrophage colony stimulating factor (M-CSF), 
macrophage inflammatory protein (MIP) and tumour necrosis factor α (TNFα). 
6.3.6 Animal models of rheumatoid arthritis 
The complex cellular and cytokine mediated interactions requires sophisticated 
modelling capabilities. Whereas these may be achieved in vitro it is not always 
possible to recapitulate the in vivo inflammatory environment. Furthermore, 
clinical studies analysing the potential pathological components of RA are often 
limited by a restricted time window of observation and, along with genetic and / 
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or environmental diversity, means that interpretation of results can often be 
difficult. It is therefore not uncommon to find contradictory observations 
generated from different clinical studies; e.g. it is still not clear whether lipids, 
particularly total cholesterol, is increased, decreased or stays the same and 
when these changes may occur in the development of human RA. Therefore, 
animal models have been used extensively in studies of RA pathogenesis to allow 
dissection of pathways involved in the disease and despite their limitations, have 
significantly contributed towards major advances in the development of novel 
therapeutics. This is exemplified in the development of anti-TNFα therapy in the 
murine (CIA) model (199). However it is important to realise the limitations and 
advantages of commonly used animal models of arthritis and their comparison to 
the human disease. There are many rodent models of arthritis although many of 
them are not as directly comparable to the pathology of human RA as CIA. The 
aspects of CIA are described below. However, whilst many other models have 
been used to study the arthritis e.g. collagen antibody induced arthritis, 
zymosan arthritis and the human TNFα transgenic mouse, these will not be 
discussed here but have recently been reviewed by Asquith et al (219) and are 
summarised in Table  6.4.  
6.3.6.1 Collagen-induced arthritis 
Collagen-induced arthritis shares many similarities with human RA. In particular, 
breach of tolerance and generation of auto-antibodies towards self collagen are 
generated, and as such CIA is considered the gold standard in vivo model to 
study RA. CIA was first described in rats and subsequently shown to be inducible 
in susceptible strains of mice, following inoculation with type II heterologous 
collagen in Complete Freund’s Adjuvant (CFA) (220, 221). Susceptibility is 
restricted to strains that have MHC Class II I-Aq and I-Ar haplotypes, e.g. DBA/1, 
similar to RA in humans (222). CIA can also be initiated in non-human primates, 
making it a useful model in which to better assess efficacy of novel therapeutic 
targets and aid their transition through the primary stages of pre-clinical 
development. Male mice are most widely used to exclude complications with sex 
hormones although CIA is not considered to be sex biased. Clinical signs of 
disease typically develop 21 to 25 days after the initial inoculation and presents 
as a polyarthritis which is most prominent in the limbs and characterized by 
synovial inflammatory infiltration, cartilage and bone erosion and synovial 
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hyperplasia similar to human RA. Disease severity is expected to peak at 
approximately day 35 after which DBA/1 mice enter remission, marked by 
increased concentrations of serum IL-10 and a subsequent decrease in pro-
inflammatory Th1 cytokines (223). In a development of the model, inoculation 
with homologous type II collagen has been reported to cause chronic relapsing 
arthritis more akin to human RA which has been suggested to be more useful for 
studying remission inducing therapies (224).  
The ability to study the effect of genetic modification or targeted gene deletion 
has been problematic in the DBA/1 model as most transgenic mice are on the 
C57BL/6 background which is generally considered resistant to CIA.  However, 
with the recent development of a refined protocol for the induction of CIA in 
C57BL/6 mice, the possibility to study arthritis in genetically modified mice is 
now more amenable (225, 226). There are differences in the onset and 
progression of disease between the DBA/1 and C57BL/6 which may cause 
discrepancies when comparing studies between these two strains. The C57BL/6 
strain develops arthritis approximately 4 to 7 days later eventually reaching 
severity at a level comparable to arthritis in DBA/1 mice but which is sustained 
as opposed to the remitting / relapsing arthritis observed in DBA/1 mice (224). 
This was associated with sustained levels of serum anti-collagen antibody titres, 
higher levels of T cell proliferation and IFNγ secretion in the late stage of 
disease. Therefore, whilst both strains of mice may be a useful to study the 
preclinical development or prophylactic treatment of arthritis, the C57BL/6 
mice may be more suited for analysis of late / established arthritis. 
As eluded to above the CIA model of arthritis is a widely used and is therefore a 
very well characterised model of arthritis. This is may be in part through the 
relative ease as to which arthritis can be induced with the CIA protocol unlike 
the antigen and zymosan induced arthritis which requires a high level of 
operator skill to be able to accurately perform intra-articular injections in mice. 
The CIA model has several more advantages over other in vivo models in which 
to study potential interventions in RA. CIA model is a polyarthritis affecting any 
and potentially all of the limbs and by analysis of serum cytokines it is evident 
that there is a systemic elevation of multiple pro-inflammatory cytokines and 
chemokines akin to human disease. This is in comparison to the zymosan model 
of arthritis which is monoarthritic and may therefore not reflect the systemic 
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nature of disease. Additionally, the CIA model involves both the innate and 
adaptive arms of the immune response whereas inflammation in the collagen 
antibody-induced arthritis relies upon complement activation and is therefore 
predominantly mediated through macrophage and polymorphonuclear cell 
activation. Although useful for dissecting out a role for particular arms of the 
immune response, once again this does not reflect the inflammation in RA. 
Finally, with all interventions in which the aim is to inhibit disease progression 
drugs are required to trialled in primates prior to clinical trials. With the ability 
to induce arthritis in primates as well as rodents the CIA model is ideal for the 
development of potential therapeutics. Therefore, the CIA model was selected 
for all future studies to test whether LXR agonists were potential therapeutics 
for the treatment of RA. 
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Model Species Characteristics Ref. 
Collagen-induced 
arthritis 
Mouse, Rat, 
Rabbit, non-
human primate 
Inducible in susceptible strains of rodents Polyarthritis associated with antibody 
and T cell responses. Low incidence and variability of disease severity in C57BL/6 
mice. Inoculation with homologous collagen induces relapsing/ remitting arthritis 
but otherwise is self limiting.  
(220, 221, 
225, 227, 
228) 
Collagen antibody-
induced arthritis 
Mouse, Self limiting polyarthritis in 100% animals but limited to macrophage and 
polymorphonuclear cell involvement. Can be induced in most strains of mice. 
(182, 183, 
229) 
Zymosan-induced 
arthritis 
Mouse, Rat Monoarthritis and requires a high degree of technical ability but can be induced in 
multiple strains of mice. TLR 2 dependent and therefore recapitulates infection 
driven pathology. 
(230, 231) 
Antigen induced 
arthritis 
Mouse, Rat Requires a high degree of technical ability and precludes analysis of the systemic 
component of disease. 
(232, 233) 
Spontaneous 
transgenic models 
of arthritis. 
Mouse Spontaneous chronic and progressive polyarthritis, onset of disease at 3-4 weeks of 
age. This includes the KBxN, SKG and DNase II-/-IFN-IR-/- and human TNFα 
transgenic mice. These mutations have so far only been identified in mice.  
(200, 234-
236) 
Table  6.4 Animal models of arthritis.  
The characteristics of the most commonly used animal models of arthritis with explanation of their advantages, limitations and the species they can be 
induced in. 
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6.3.7 Cardiovascular disease in rheumatoid arthritis 
RA is associated with multiple co-morbidities and reduced life expectancy. The 
increased mortality rate is largely attributable to cardiovascular disease (CVD) 
and many studies have now suggested that CVD contributes directly to disease 
pathology emphasising the systemic nature of RA.  I shall give detailed 
consideration to this co-morbidity since one attraction of the LXRs in RA as a 
regulatory molecular pathway resides in their capacity to modulate both 
inflammatory and metabolic events of relevance.  
6.3.7.1 Atherosclerosis 
Atherosclerosis is characterised by the formation of fatty lesions (plaques) in 
arterial vessel walls. The environment within an atherosclerotic plaque is highly 
pro-inflammatory and plaque progression is associated with immune cell 
infiltration, lipid accumulation and the secretion of multiple pro-inflammatory 
cytokines and chemokines. Formation of an atherosclerotic plaque is suggested 
to be initiated by vascular endothelial cell damage and subsequent activation, 
although the precise mechanisms that induce damage are not known. 
Hypercholesterolemia is a major risk factor for the development of 
atherosclerosis and predicts disease progression. Indeed, feeding mice an 
atherogenic diet correlates with plaque size development (237). Low density 
lipoprotein (LDL) cholesterol can penetrate the vascular endothelium into the 
intima where it can be oxidised forming oxidised LDL (oxLDL) causing endothelial 
cell activation in which the expression of the adhesion molecules, typically 
VCAM-1 and ICAM-1, are up-regulated (238). In addition, to an elevated plasma 
lipid profile, hypertension is another well recognised risk factor for the 
development of atherosclerosis. Atherosclerotic plaques generally form in 
arteries and are typically located at sites of hemodynamic strain; high blood 
flow and shear stress. Exposure of human umbilical vein endothelial cells 
(HUVECs) to dynamic flow in vitro induces cytoskeleton rearrangements, NF-κB 
activation and the expression of VCAM-1, ICAM-1 and IL-1β (239). Furthermore, 
hemodynamic stress may also enhance the “leakiness” of the vascular 
endothelium allowing LDL penetration into the intima and thereby present a 
mechanism by which hypercholesterolemia and hypertension may synergise to 
promote vascular inflammation.  
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Inflammatory cells, typically monocytes and T cells, roll and bind to the 
adhesion molecules expressed on the blood vessel wall and then migrate into the 
intima directed by the interactions of chemokines and chemokine receptors e.g. 
MCP-1/ CCR2 and Rantes/ CCR1. Differentiation of monocytes into macrophages 
is necessary for the progression of atherosclerosis demonstrated by the 
amelioration of plaques in M-CSF-/- mice (240, 241). Macrophage differentiation 
is marked by the up-regulation of scavenger receptors which internalise a variety 
of lipoprotein molecules including oxLDL (242). In a state of 
hypercholesterolemia the rate of oxLDL uptake exceeds the rate of cholesterol 
clearance, excess cholesterol is therefore stored in cytoplasmic lipid droplets 
resulting in macrophage foam cell formation. Lipid loading of macrophages is 
also associated with the secretion of IL-1β, TNFα, MMPs and augmentation of 
oxidative stress (243, 244). Accumulation of foam cells and extracellular lipids 
forms a lipid core within a plaque which is surrounded by a cap of endothelial 
cells, smooth muscle cells and a collagen matrix. Atherosclerotic plaques are 
generally stable structures which can occlude the vessel lumen reducing blood 
flow and may cause angina or tissue ischemia but in a large proportion of 
patients the presence of atherosclerotic plaques are asymptomatic. However, 
plaque destabilisation can cause plaque rupture and thrombus formation leading 
to myocardial infarction and/ or stroke. Plaque destabilisation can occur through 
a variety of mechanisms including the actions of pro-inflammatory cytokines and 
proteases as found in RA (245-247). It is therefore evident that inflammation is 
central to plaque development. Understanding the inflammatory processes and 
how they interact with lipid metabolism is now subject to intense investigations 
for the development of future therapeutic targets for the treatment of 
atherosclerosis.  
6.3.7.2 Cardiovascular disease related mortality in rheumatoid arthritis 
The life expectancy of patients with RA is significantly reduced by up to 10 years 
and death is predominantly due to cardiovascular disease (CVD) related events. 
One study followed 603 RA patients relative to 603 sex and age matched healthy 
controls from the same geographical population for the development of coronary 
heart disease (CHD) related events (248). Data regarding CHD events was 
collected retrospectively from the subjects’ medical records over a mean period 
of approximately 15 years. This study revealed that the risk of myocardial 
  71 
infarctions in the RA population was more than five times more prevalent than 
that in the non-RA population. Similarly, the number of sudden deaths was twice 
that found in the non-RA population and in total nearly 50% of the RA subjects 
died of CVD related symptoms. These results were confirmed by an independent 
study which prospectively followed 114,342 women for the development of RA 
and CVD (134). The study revealed that of the 527 women that developed RA the 
prevalence of myocardial infarctions was approximately three fold higher than 
compared to subjects without RA. Although in both studies cigarette smoking 
was significantly more frequent in the RA cohorts the observations that CHD is 
increased in RA subjects could not be explained by other traditional CVD risk 
factors e.g. BMI, type II diabetes and hypertension. This therefore suggests that 
RA itself may be a risk factor for the initiation and progression CVD. Indeed a 
follow-up study revealed that Erythrocyte Sedimentation Rate (ESR), RF 
seropositivity, joint swelling and radiographic changes, as markers of systemic 
inflammation and RA disease severity, conferred a significant additional risk for 
CVD related deaths in subjects with RA (249). Interestingly the duration of RA 
disease had no impact upon CVD related outcomes. Subsequently many studies 
have tried to investigate the specific aspects of RA associated CVD with 
particular emphasis on potential changes in vascular function and alterations in 
serum lipids. 
6.3.7.3 The atherogenic profile in rheumatoid arthritis  
It is evident that prevalence of CVD and associated risk factors are elevated in 
RA. Indeed, carotid intima media thickness (IMT), as an indicator of 
atherosclerotic plaques, is increased in RA (250, 251). Many studies have since 
confirmed these observations and carotid IMT has been shown to predict the 
development of CVD in RA (252). Furthermore, it is evident that there are 
changes in the plasma lipid profile up to ten years prior to the clinical onset of 
RA (253). This was marked by an increase in plasma triglycerides and total 
cholesterol concentrations but a decrease in protective HDL-cholesterol. 
Although altered levels of serum lipids were suggested to be a potential 
mediator for the manifestation of clinical RA RF is also detectable many years 
prior to the clinical development of RA. This supports the consensus that sub-
clinical RA is present many years prior to its clinical manifestation. However 
whether cardiovascular disease drives the manifestation of clinical RA remains 
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unknown. Similarly, analyses of lipid profiles in patients with established RA 
have demonstrated increased concentrations of triglycerides and in some cases 
total cholesterol but a decrease in HDL-cholesterol which negatively correlated 
with CRP (254, 255). These studies suggest that the lipid profile in RA is pro-
atherogenic and may accelerate the formation of atherosclerotic plaques. 
Moreover, it is plausible that the inflammatory profile associated with RA may 
drive plaque destabilisation and may be in part responsible for the increased 
prevalence of myocardial infarctions and strokes in RA.  
It is now widely accepted that the inflammatory state associated with RA may 
promote atherogenesis however, how dyslipidemia and the inflammatory aspect 
of atherosclerosis impacts synovial inflammation is not known. However, oxLDL 
has been detected in RA synovial fluid and serum oxLDL concentrations correlate 
with CRP (256, 257). Elevated levels of oxLDL may promote macrophage 
activation directly within the synovium or indirectly by the secretion of pro-
inflammatory cytokines from atherosclerotic plaques.  
A better understanding of how inflammation and metabolism interact to drive 
the pathology of RA and associated CVD are therefore required for the 
development of therapeutics with higher degree of efficacy. Given the 
multifactorial nature of RA modern therapeutics may have to be more than just 
modulators of inflammation and treating RA associated co-morbidities may 
improve disease prognosis. Indeed it is already evident that a reduction of 
general inflammation in RA by some therapeutics is associated with an improved 
lipid profile as discussed below.  
6.3.8 Current therapeutics 
With an advancing knowledge of the mechanisms that drive RA pathogenesis the 
expectations of modern therapeutic regimes are now much greater. It is now no 
longer the aim to simply inhibit disease progression (although this reflects 
current clinical reality) but rather prevent the initial onset of disease through 
the identification of novel therapeutic targets and better biomarkers of disease 
activity.  
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6.3.8.1 DMARDs 
Disease modifying anti-rheumatic drug (DMARDs), in particular Methotrexate, 
have been widely used for the treatment of RA for nearly three decades. Several 
studies demonstrated that Methotrexate use is associated with improvement in 
disease activity e.g. measured as DAS28 in a proportion of patients (258-260). 
However, clinical improvements were often of short duration and in general a 
70% improvement of disease severity, ACR70 response, was only observed in less 
than 15% of patients (261). Even in the patients that enter clinical remission 
(DAS28 < 2.6) radiographic bone erosion is irreversible. Several studies suggest 
that radiographic damage progresses in some patients receiving DMARD therapies  
despite exhibiting ‘satisfactory’ clinical responses (262-264). Furthermore, up to 
60% of patients have reported adverse reactions to Methotrexate including 
nausea, diarrhoea, hepatitis and leukopenia which have only been resolved upon 
discontinuation of therapy (260). Methotrexate therefore does not exert 
therapeutic benefits in a large enough proportion of patients and simply delays 
the progression of disease onset and severity. Other DMARDs include 
sulphasalazine, hydroxychlorquine, leflunamide, and gold all of which mediate 
clinical benefit in a proportion of patients but often associated with significant 
toxicity and limited duration of benefit. Crucially none are used on the basis of 
sound pathological understanding of RA for which mechanism specific drug 
selections have been made.  Combinations of these agents have been shown to 
increase the benefits achieved and paradoxically to reduce adverse events.  
Despite this remission rates remain low and drug retention over the course of a 
chronic illness remains unacceptably low.  
Glucocorticoids have been widely used as an anti-inflammatory therapeutic in RA 
with some success. Glucocorticoids predominantly mediate their effects in RA 
via the suppression of T cell proliferation but also promote apoptosis of 
neutrophils whilst inducing macrophage phagocytosis and thereby promote 
inflammatory resolution (265-267). However, although glucocorticoids exert 
predominantly anti-inflammatory effects it is now well recognised that 
glucocorticoids are implicated in the progression of various metabolic disorders 
(268-270). Indeed, corticosteroid therapy was associated with a two fold 
increase of CVD related deaths in RA (248, 249, 271). The relationship between 
inflammation and cardiovascular disease in RA is complex. However, with an 
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increased understanding of the mechanisms that drive RA pathogenesis several 
novel biologics have been developed that target either the cellular source(s) or 
the components of molecular pathways that mediate inflammation. As such 
modern biologics have given promise of more efficacious therapies for the 
treatment of RA.   
6.3.8.2 Rituximab and B cell targeted therapies 
Rituximab is a humanised monoclonal antibody which targets the cell surface 
protein CD20 exclusively expressed on mature B cells, but not plasma cells. The 
use of rituximab as a potential immuno-therapy was first demonstrated in 
primates where it was shown to potently induce B cell depletion (272). 
Rituximab was first used as a treatment for non-Hodgkin’s lymphoma but was 
subsequently shown to be a highly effective therapy in RA (273, 274). Although 
several studies have suggested that CD20 may function as a calcium channel or 
as a cell surface signalling receptor the function of CD20 and the mechanism by 
which rituximab initiated B cell depletion in RA remains unknown (275). Several 
mechanisms have been suggested including antibody dependent cell mediated 
cytotoxicity, complement dependent cytotoxicity and inhibition of NF-κB. 
Effects in RA synovitis may result from reduced antibody production, altered 
antigen presentation or reduced secretion of B cell derived pro-inflammatory 
cytokines. Beneficial effects of single doses of rituximab have been reported 
from 3-12 months whilst repeated courses of therapy have lead to improvements 
lasting up to 5 years thus far (276). Interestingly, Rituximab was shown to 
transiently improve endothelial dysfunction (277). As such B cell depletion is 
now a favourable strategy for the treatment of RA. Therefore much effort has 
been expended in developing biologics against BLyS (B-lymphocyte stimulator) 
and APRIL (A Proliferation Induced Ligand) which are members of the TNF 
superfamily of cytokines and promote B cell survival, differentiation and 
activation. Belimumab an anti-BLyS human monoclonal antibody is now in 
clinical trials for the treatment of systemic lupus erythematosus (SLE) and 
similar studies are likely to be extended to RA (278).  
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6.3.8.3 Anti-TNFα 
TNFα blockade in the clinic is clearly associated with a reduction in articular 
inflammation and damage (279, 280). There are now three TNFα antagonists, 
Infliximab, Etanercept and Adulimumab, which are used for the treatment of RA 
with varying modes of TNFα inhibition. Two further agents will shortly be 
generally available namely golimumab and certolizumab. Infliximab and 
Adalimumab are humanised monoclonal antibodies specifically raised against 
TNFα whereas Etanercept is a TNF-receptor Fc fusion protein and acts as a 
soluble receptor. In all cases TNFα is prevented from interacting with the TNF 
receptor on the surface of immune cells. Although, TNFα blockade is more 
effective than methotrexate alone it is effective in approximately 70% of 
patients and is usually used in combination with MTX with which it has 
synergistic benefits (281). In addition to the anti-inflammatory effects treatment 
with anti-TNFα therapeutics has been shown to reduce carotid intima-media 
thickness and improve the atherogenic lipid profile in RA, although this remains 
controversial (282-284).   Once again therefore novel biologics suggest a 
relationship between inflammatory pathways and vascular events in the RA 
population.  
6.3.8.4 Anti IL- 6 Receptor 
The success of TNFα blockade has raised the expectations for novel therapeutics 
and provided proof of concept that cytokine blockade represents a valid therapy 
in RA. However, as anti-TNFα therapy is not effective in a proportion of patients 
other therapeutic options are required. In particular anti-IL-6R therapy with 
Tocilizumab, a humanised monoclonal antibody against the IL-6 receptor has 
provided encouraging results in patients who have previously failed anti-TNFα 
therapy (212, 285, 286). However, moderate increases in serum total cholesterol 
and triglyceride concentrations were observed (212). Similar studies are likely to 
be extended to other cytokines with clinical trials already proceeding for IL-17 
and IL-12/23 neutralising therapies and targeting GM-CSFR (168, 287, 288). 
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6.3.8.5 Abatacept 
Abatacept is a fusion protein of the extracellular domain of the cytotoxic T 
lymphocyte-associated antigen 4 (CTLA4) linked to the Fc portion of human 
IgG1. Abatacept functions to inhibit the activation of T cells by blocking co-
stimulation through the binding of CTLA4 to CD80/86 expressed on the plasma 
membrane of antigen presenting cells. During clinical trials treatment of RA 
patients with abatacept yielded a high ACR response and is now currently 
approved in Europe for the treatment of RA (289). 
6.3.8.6 Statins 
As cardiovascular risk is associated with increased morbidity and mortality 
statins were trialled to assess their therapeutic potential in RA. Statins inhibit 3-
hydroxy3methylglutarylcoenzyme A reductase (HMG-CoA) which is the rate 
limiting enzyme in the synthesis of cholesterol and are therefore widely used for 
the treatment of atherosclerosis. Treatment of patients with Atorvastatin was 
shown to modestly inhibit disease severity in RA associated with a decrease in 
ESR and CRP and improved measures of vascular function and atherogenic lipid 
profiles (290, 291). Whilst at first it was not clear if these beneficial effects 
were attributable to lipid lowering mechanisms or direct regulatory effects upon 
inflammation simvastatin has since been shown to inhibit cytokine secretion 
from synovial fibroblasts (292, 293). These studies demonstrate that statins may 
be able to both improve the atherogenic lipid profile and exert direct anti-
inflammatory effects providing support of statins as a therapy in RA which are 
predicted to improve morbidity whilst reducing CVD associated mortality. 
Certainly many studies indicate that statins mediate anti-inflammatory effects in 
vitro and therefore the foregoing is plausible. 
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7 Materials & Methods
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7.1 General reagents & buffers 
7.1.1 Materials and reagents 
General chemicals: All chemicals were purchased from Sigma (UK) unless 
otherwise indicated. 
Plastics: All plastics used for cell culture were purchased from Corning and 
Gibco unless otherwise indicated.  
Avertin®: 3g 1,1,1 tribromoethanol was mixed with 3ml amyl alcohol and placed 
on a rotator to fully dissolve. Avertin should be stored at 4oC in the dark. Stock 
Avertin was diluted 1:40 with PBS before use and given at a dose of 250 mg/kg 
(~500 µl). 
Lipopolysaccharide (LPS): Ultra pure LPS (Calbiochem) derived from Escherichia 
coli was dissolved in sterile water at a stock concentration of 1 mg/ml and used 
at a final concentration of 100 ng/ml. 
LXR agonists: GW3965 and T0901317 (T1317) were synthesised by Schering-
Plough Corporation (UK) and supplied in 2 g vials. Both T1317 and GW3965 were 
dissolved in 5% Mulgofen (GAF Co, UK)/ PBS or 5% Chremophore (Sigma)/ PBS at 
the indicated dose and administered daily in vivo by either intraperitoneal 
injection, sub-cutaneous injection or by oral gavage as indicated. The 
endogenous LXR agonists 24(S), 25-epoxycholesterol, 22(S) hydroxycholesterol 
and 22(R) hydroxycholesterol were purchased from Biomol or Sigma. For in vitro 
use all agonists were dissolved in DMSO (Riedel-de Haen). 
7.1.2  Buffers & culture media 
0.5M EDTA pH8 (1L): 186.1 g ethylenediaminetetraacetic acid (EDTA) and 20 g 
NaOH was mixed with 800 ml dH2O adjusted to pH8 and then made up to 1 L 
with dH20. 
0.1 M Bicarbonate buffer (50 ml): 0.42 g sodium bicarbonate (NaHCO3) was 
dissolved in a final volume of 50 ml dH2O and stored at 4
oC. 
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Complete media: RPMI1640, 10% heat inactivated foetal bovine calf serum, 
Penicillin (100 units/ml), Streptomycin (100 µg/ml) and L-Glutamine (2 mM) (all 
at final concentration from Invitrogen). 
Decalcificaiton buffer: 5.5 g of EDTA disodium salt was dissolved in 90 ml dH2O 
and made up to a final volume of 100 ml with formaldehyde. 
ELISA wash buffer: 1X PBS was mixed with 0.05% (final concentration) Tween 
20.  
PBS: Phosphate buffered saline was purchased from Invitrogen. 
PEA (PBS, EDTA, ALBA): 500 ml PBS, 1 ml 0.5 M filter sterilised EDTA pH8 and 
2.5 ml 4.5% ALBA (Bio Products Laboratory). 
Tris-acetate-EDTA (TAE) buffer: To make a 50x stock solution of TAE, 242 g of 
Tris base was dissolved in 750 ml dH2O. This was then mixed with 57.1 ml glacial 
acetic acid and 100 ml 0.5 M EDTA (Ph8). The final volume was then made up to 
1000 ml with dH2O. The buffer was then diluted 1:50 before use with dH2O. 
Trypan blue: 0.4 g Trypan blue was mixed with 80 ml PBS and brought to a slow 
boil, cooled to room temperature and made up to 100 ml with PBS. Stock Trypan 
blue was then diluted 1:2 with PBS before use. 
Tail tip lysis buffer: 1 ml 2 M Tris, 20 ml 0.5 M EDTA, 6.7 ml 3 M NaCl and 10 ml 
10% Sodium Dodecyl Sulphate (SDS) was dissolved in a final volume of 200 ml 
dH20. 500 µg/ml proteinase K (20 mg/ml stock concentration, Qiagen) was then 
added fresh before use. 
 
7.2 In vivo procedures 
7.2.1 Animal welfare 
All animals were housed in pathogen free conditions within the Biological 
Services Joint Research Facility (JRF) at the University of Glasgow. Animals had 
access to food and water ad libitum. All procedures were carried out in 
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accordance with project licences approved by the United Kingdom Home Office 
and in accordance with the Animals (Scientific Procedures) Act 1986.  
7.2.2 Mice 
C57BL/6 or DBA/1 mice: Male mice were purchased from Harlan at 
approximately eight weeks of age and allowed to acclimatise for one week 
before experimental procedures.  
LXR null mice: LXRα knockout (KO) or LXRβ KO mice and  
wild-type (WT) littermates on a C57BL/6 background were generated by Lexicon 
but supplied by Schering Plough Corporation (UK). These were bred in house and 
used to generate LXRα/β double KO mice (See results).  
All mice were culled by a recommended schedule 1 method or terminal 
anaesthesia by intraperitoneal injection of 700 µl of Avertin. 
7.2.3 Induction of Collagen-induced arthritis 
7.2.3.1 Induction of CIA in DBA1 mice. 
Induction of collagen-induced arthritis (CIA) was firstly described in rats (221) 
and subsequently in susceptible strains of mice (220). Male DBA/1 mice at 8 
weeks of age were used for induction of collagen-induced arthritis. 2 mg/ml 
type II bovine collagen (MD Biosciences) dissolved in 0.05 M glacial acetic acid 
was thawed overnight at 4oC. On the day of immunisation the collagen was 
mixed with an equal volume of 4 mg/ml Complete Freund’s Adjuvant (CFA – MD 
Biosciences) from M. Tuberculosis, to yield a final concentration of 1 mg/ml 
collagen. The collagen/ CFA mixture was emulsified on ice using a hand held 
homogeniser. To check the stability of the emulsification, 1 drop of the emulsion 
was dropped into a beaker of water. The emulsion was considered to be stable if 
it remained as a solid on the water surface. 
On the day of immunisation (day 0) the tail base of each mouse was shaved and 
the skin sterilised with 70% ethanol. Each mouse was intradermally injected with 
50 µl of the collagen/ CFA emulsion either side of the tail base so that each 
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mouse received a total of 100 µg of collagen (Figure  7.1). Mice were monitored 
daily for any signs of ulceration.   
 
Figure  7.1 Injeciton sites for induction of collagen induced arthritis. 
The collagen/ CFA is injected intradermally; the needle is inserted either side of the tail base 
(indicated by the arrows) and then pushed in approximately 1 cm further in where the 
emulsification was injected (E). 
Three weeks post immunisation (day 21) 2 mg/ml bovine type II collagen was 
mixed with an equal volume of PBS. Each mouse was injected intraperitoneally 
with 200 µl (200 µg) collagen/ PBS. Mice were monitored daily for signs of 
disease. 
7.2.3.2 Induction of CIA in C57BL/6 mice 
C57BL/6 mice are generally considered resistant to the induction of arthritis as 
they have the H-2b haplotype. Induction of CIA in wild-type or transgenic mice 
on C57BL/6 background (8 – 12 weeks old) was carried out following the protocol 
described by Inglis JJ et al (225). Type II chicken collagen dissolved in 0.05 M 
glacial acetic acid (2 mg/ml - MD Biosciences) was mixed with an equal volume 
of 4 mg/ml CFA and emulsified using a hand held homogeniser and the stability 
of the emulsification checked as above. 
On the day of immunisation (day 0) the tail base of each mouse was shaved and 
the skin sterilised with 70% ethanol. Each mouse was injected intradermally with 
50 µl of the collagen/ CFA emulsification at two sites either side of the tail base 
( total of four injections) so that each mouse received a total of 200 µg of 
collagen. Mice were monitored daily for any signs of ulceration.   
Three weeks post immunisation (day 21) 2 mg/ml chicken type II collagen was 
mixed with an equal volume of PBS. Each mouse was injected intraperitoneally 
EE 
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with 200 µl (200 µg) collagen/ PBS. Mice were monitored daily for signs of 
disease. 
7.2.4 Clinical assessment of arthritis 
Mice were monitored for clinical signs of disease from day 21 onwards. Clinical 
signs were assessed by micro-calliper measurements which measured any 
swelling of the wrist joint. Secondly, a clinical score was assigned to each paw 
based upon disease severity where 1 = swollen digit(s), 2 = erythema, 3 = 
swollen paw/ ankle and 4 = loss of function, visualised and described in Table 
 7.1, allowing a maximum score of 16 per animal. 
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Score Description 
Clinical 
appearance 
Comments 
0 No disease 
 
No swelling or redness of any digits or 
any part of the lower leg. 
1 
Swollen 
digits 
 
Swelling of individual or multiple 
digits, sausage like in appearance, but 
not extending into the upper region of 
the paw. 
2 Erythema 
 
Redness of the paw. This was usually 
transient and lead to swelling of the 
paw. 
3 
Swollen 
paw/ ankle 
 
Swelling of paw and/ or ankle 
extending from the toes along the 
length of the paw. 
4 
Loss of 
function 
 
Usually accompanied by even more 
swelling. Function of front paws was 
assessed by the ability to grip a cage 
lid and/or for the rear paws the ability 
to walk up a cage lid held at an 
inclination of ~45o. 
Table  7.1 Visualisation of murine arthritis. 
Development of arthritis was assessed by clinical observations in which a maximum score 
of 4 was assigned to each paw (maximum score per animal was 16).   
7.2.5 Histological assessment of arthritis 
For histological assessment rear paws were prepared by fixation for three weeks 
in 10% neutral buffered formalin (Sigma) and subsequent decalcification for 
three weeks in decalcification buffer, which was changed weekly, as described 
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(294). Paws were cut to 7 µM sections and stained with haemotoxylin and eosin 
(H&E, See below for details). The severity of arthritis was assessed by a blind 
observer and a histological score assigned. The severity of inflammatory 
infiltrate was scored as 0 = normal, 1 = minimal inflammatory infiltrate, 2 = 
synovial thickening and infiltration, 3 = moderate thickening  and 4 = severe 
thickening more than width of epiphysis. Articular destruction was separately 
graded as 0 = normal, 1 = erosion of < 25% of articular surface, 2 = 26-50%, 3 = 
51- 75% and 4 = > 75%. 
7.3 Ex vivo procedures 
7.3.1 Preparation of paws for histological analysis 
7.3.1.1 Tissue processing, embedding & sectioning 
Tissue processing 
Paws were removed from mice by cutting through the leg just above the ankle 
joint and the toes removed to aid the diffusion of buffers into the tissue. The 
paws were placed in approximately 5 ml of neutral buffered formalin (Sigma) for 
2 weeks at room temperature. After fixation the paws were then decalcified by 
incubating the paws in decalcification buffer (see buffers above) on a rotator for 
two weeks at room temperature. During this period the buffer was replaced 
approximately every three days to prevent re-deposition of calcium.  
The tissues were then dehydrated in an automated tissue processor (Thermo, 
Citodel 1000) which immersed the tissues into increasing concentrations of 
ethanol until they were completely dehyradated and then immersed in wax, to 
allow diffusion into the tissue; detailed below: 
1. Neutral buffered formalin  30 min 
2. 70% ethanol    1 hrs 
3. 90% ethanol    1 hrs 
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4. 95% ethanol    1 hrs 
5. 100% ethanol    2 hrs X 3 
6. Xylene    2 hrs X 3 
7. Paraffin wax    4 hrs X 2 
Tissue embedding 
Once the samples were processed they were embedded into wax blocks (Thermo 
histocentre 3) and allowed to cool. The blocks were then stored at 4oC until they 
were required for sectioning. 
Sectioning of tissue 
Firstly, the blocks were pared on the microtome set at 25 µm to allow quicker 
cutting through the wax. Once the tissue was reached the blocks were removed 
and placed on ice cold water to harden the paraffin wax. Once cooled the 
microtome was set to cut at a thickness of 7 µm and the required number of 
sections cut in ribbons. The ribbons of wax/ tissue were then placed in a floating 
water bath set at 40oC. Each section was then separated using a scalpel and then 
placed on a charged frosted microscope slide (Superfrost plus, VWR) and placed 
on a hotplate (Raymond A Lamb Hotplate) at 55oC at allowed to dry for 
approximately 30 min. The slides were then stored at 4oC until needed for 
staining. 
7.3.1.2 Haematoxylin and Eosin staining 
 
Paws were embedded and prepared in paraffin sections as described above. The 
sections were then stained with Haematoxylin and Eosin (H&E) as described 
below. All reagents were purchased from Sigma. The ethanol solutions were 
prepared by diluting 100% ethanol with dH2O to the required final percentage 
(v/v). 
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Firstly, the wax was softened by incubating the sections in an oven (GenLab) at 
60oC for approximately 35 min and then the wax removed from the sections by 
immersing them in xylene. The sections were then re-hydrated by incubating 
them in step wise decreasing concentrations of ethanol, to allow subsequent 
staining with H&E which are water soluble. 
These steps are summarised below: 
1. Incubate slides at 60oC   35 min 
2. Xylene    3 min X 2 
3. 100% Ethanol    3 min X 2 
4. 95% Ethanol    3 min X 2 
5. 90% Ethanol    3 min 
6. 70% Ethanol    3 min 
7. dH2O     3 min 
The sections were then stained with Harris Haematoxylin (Haematein), which 
binds to nucleic acids, and any excess stain removed by washing the sections 
gently by placing them in a sink with running water, detailed below: 
8. Harris Haematoxylin  2 min 
9. Running water   ~3 min 
After staining with Haematoxylin the sections were then counter stained with 
Eosin which binds to basic cellular and extracellular matrix proteins: 
10. 1% Eosin    2 min 
11. Running water   ~3 min 
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The sections were then dehydrated by incubating the sections in step wise 
increasing concentrations of ethanol. 
12. 70% Ethanol    30 s 
13. 90% Ethanol    30 s 
14. 100% Ethanol    30 s X 2 
15. Xylene*    1 min X 2 
* Clean xylene was used to prevent wax from the de-waxing process from 
sticking to the sections and thereby obscuring fields of view. 
One drop of DPX mount (VWR) was placed over the tissue section using a Pasteur 
pipette and a cover slip (VWR) gently lowered over tissue section. The DPX was 
allowed to dry before visualising slides.  
7.3.2 Anti-collagen antibody analysis 
Serum IgG2a and IgG1 anti-collagen antibodies titres were measured by Enzyme-
Linked Immunosorbent Assay (ELISA) following the general ELISA protocol as 
described in 7.5.1. Plates were coated with the indicated concentration of the 
type II collagen used for immunisation (MD Biosciences). Serum samples were 
serially diluted 1:2 with assay diluent and optical density measured at 450 nm. 
7.3.3 Lymph node intracellular cytokine analysis 
For intracellular cytokine staining inguinal and popliteal lymph nodes were 
removed and single-cell suspensions obtained by crushing the cells through a 
sterile monofilament filter cloth (100 µM- Cadisch). The number of viable cells 
(assessed by Trypan Blue staining) were counted and resuspended at 1 x 106/ml 
in complete media and stimulated overnight with phorbol myristate acetate 
(PMA - 50 ng/ml, Sigma) and Ionomycin (500 ng/ml, Sigma) in the presence of 
Golgi-Plug (1 mg/ml, BD Biosciences) which was added 1 hr after stimulation 
with PMA/ Ionomycin.  
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After incubation the cells were washed by addition of PBS and centrifugation at 
1200 RPM (300 g) and each sample split into three tubes containing 
approximately 3 X 105 cells/ tube. On the first sample an additional three tubes, 
were used for purposes of compensation (Table  7.2). The cells were then stained 
with 2 µl/ tube CD4 FITC or isotype control in 50 µl mouse Fc block (BD 
Biosciences), to inhibit non-specific interactions through the Fc portion of 
antibodies used for staining, and incubated at 4oC for 30 min in the dark. The 
cells were then washed with 2% FCS/ PBS and the supernatant discarded 
followed by incubation with 100 µl/ tube of cytofix/ cytoperm (kit supplied by 
BD Biosciences), to fix and permeabilize the cells, on ice for 20 min. The cells 
were washed in perm wash and then stained with anti-IL-17 PE, anti-IFNγ PE or 
isotype control (all BD Biosciences) and incubated at 4oC for 20 min. The cells 
were then washed and resuspended in 200 µl 2% FCS/ PBS. The cells were 
analysed on a FACS Calibre (BD Biosciences) using Cell Quest software TM. 
Intracellular cytokine staining 
1. Unstained 
2. IgG FITC, IgG PE 
3. CD4 FITC, IgG PE 
4. IgG FITC, IFNγ PE 
5. CD4 FITC, INFγ PE 
6. CD4 FITC, IL-17 PE 
Table  7.2 Stainig for intracellular cytokines 
The different combination of stains used for staining of intracellular cytokines on CD4+ T 
cells. Anti IL-17 PE and anti IFNγ PE share the same isotype. 
7.3.4 PCR Genotyping 
7.3.4.1 Preparation of tail tips for genotyping 
Mice were anaesthetised with isofluorane. Once deeply anaesthetised a 5 mm 
tail-tip was cut and the tail cauterised. 
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The tail-tip was placed in 100 µl tail-tip lysis buffer and incubated overnight at 
55oC. After the overnight incubation 500 µl of DNase free water (Ambion) was 
added to the tail-tip solution and incubated at 100oC for 10 minutes. The tubes 
were then placed on ice and once cooled the tail-tip solution was then 
centrifuged at 13000 RPM for 5 min. The supernatant was then placed in a fresh 
tube to be used for genotyping by polymerase chain reaction (PCR).  
7.3.4.2 PCR genotyping 
The following conditions and primer sequences (designed by Schering- Plough) 
were used for genotyping of the respective LXR null mice. The primers 
(synthesised by VH Bio) were reconstituted in Diethyl Pyrocarbonate (DEPC) 
treated water at a stock concentration of 100 µM and then diluted 1:5 with DEPC 
treated water for a working stock.  
LXRα knockout: 
The following primers were used for PCR genotyping of LXRα KO mice: 
ORG28-2 5’-TAGACACGGATGATTTGG 
ORG028-18 5’-GGAACTCACTATGTAGACC 
1µl of each primer  working stock (0.4 µM final) was added to a 45 µl PCR master 
mix (Thermo Scientific) 2.5 mM MgCl2 (final concentration ) and made up to 50 
µl with DEPC water (Ambion) and the PCR product amplified using on a thermal 
cycler (Eppendorf) using the setting below: 
1. 95oC, 10 min 
2. 95oC, 30 s 
3. 59oC, 30 s 
4. 72oC, 1 min – repeat steps 2 to 4 35 times 
5. 72oC, 10 min 
6. 4oC, 24 hr 
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The primers should amplify an 880 bp from the wild-type allele or a 470 bp PCR 
product from the Cre-excised allele. 
LXRβ knockout: 
The following primers were used for PCR genotyping of LXRβ KO mice: 
ORG029-98 5’-GTCACGAAGCAGCCTGCTGAAC 
ORG029-99 5’-GTTAGGATCTCCCATGATAAGAG 
ORG029-101 5’-TGAGGCCCAGGCTAGAGGTT 
1µl of each primer working stock (0.4 µM final) was added to a 45 µl PCR master 
mix (Thermo Scientific) 1.5 mM MgCl2 (final concentration) and made up to 50 µl 
with DEPC water (Ambion) and the PCR product amplified using on a thermal 
cycler (Eppendorf) using the setting below: 
1. 95oC, 10 min 
2. 95oC, 30 s 
3. 55oC, 30 s 
4. 72oC, 1 min – repeat steps 2 to 4 35 times 
5. 72oC, 10 min 
6. 4oC, 24 hr 
The primers should amplify a 437 bp product from the wild-type allele or a 640 
bp PCR product from the Cre-excised allele. 
7.3.4.3 Agarose gel electrophoresis 
All agarose gels used for PCR genotyping were 2% agarose weight/volume. 
Agarose gels were made by mixing 3 g agarose (Invitrogen) with approximately 
150 ml Tris-acetate-EDTA (TAE) buffer followed by heating in a microwave at full 
power for approximately three minutes until the agarose was dissolved. To 150 
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ml agarose/ TAE solution, approximately 5 µl ethidium bromide (Sigma) was 
added and mixed by gentle shaking. The solution was then poured into an 
agarose gel cast and allowed to set. The gel was then placed in an 
electrophoresis tank containing TAE buffer. Approximately 25 µl of the PCR 
product was then transferred into each well in the agarose gel alongside 5 µg of 
a 1Kbp DNA ladder (Invitrogen). The PCR products were electrophoresed at 100v 
for approximately 25 min followed by visualisation under UV light (Gel logic 200 
imaging system) and Kodak software. 
7.3.5 Preparation of bone marrow macrophages 
Mice were culled by a recognised schedule 1 method. The rear legs were 
removed by cutting through the connective tissue at the top of the tibia and 
placed on ice. All skin and muscle was then removed to give clean and intact 
tibia and femurs. In a tissue culture flow hood sterile scissors were used to cut 
through the top and bottom of each tibia and femur. The bone marrow was then 
flushed out with complete media using a 19G, 20G or 23G needle and syringe 
into a Petri dish. Using a 1ml pipette tip the bone marrow was then pipetted up 
and down several times to generate a single cell suspension and pelleted by 
centrifugation at 1200 RPM (~350 g) for 5min. The supernatant was then 
decanted and 500 µl of red blood cell lysis solution (Sigma) added to the cell 
pellet and incubated at room temperature. After two minutes 5ml of complete 
media was added and the cells pelleted by centrifugation. The number of viable 
cells (assessed by staining with Trypan Blue) were then counted using a 
haemocytometer and then resuspended at a concentration of 7X105 cells/ml in 
complete media supplemented with 10 ng/ml recombinant human MCSF 
(Peprotech). Human MCSF is crossreactive in mouse derived cells. 7x 106 cells 
were then incubated in a petri dish for 4 days at 37oC, 5% CO2. On the fourth day 
the media and non-adherent cells were removed and replaced with fresh media 
supplemented with 10 ng/ml MCSF and incubated for a further 3 days. On day 7 
the media was removed and the cells removed by cell scraping using ice cold 
PBS. The number of viable MCSF matured macrophages were then counted and 
plated out at the required concentration. 
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7.4 Human cell and tissue procedures 
7.4.1 Patients and clinical samples 
Leukocytes were purified from buffy coats or from blood of healthy controls or 
patients meeting ACR criteria for rheumatoid arthritis, CASPAR criteria for 
psoriatic arthritis or New York criteria for the diagnosis of ankylosing spondylitis 
after obtaining written informed consent. All RA patients were receiving DMARD 
therapy. This clinical component of our study was approved by the Glasgow East 
Ethics Committee. 
7.4.2 Separation of human leukocytes from peripheral blood 
If peripheral blood mononuclear cells (PBMCs) were being purified from buffy 
coats then the blood was first diluted 1:2 with PBS. Blood donated from patients 
or healthy controls was used neat. 
Approximately 10 ml of fresh or diluted blood was layered on top of 4 ml room 
temperature Histopaque 1077 and then centrifuged 2000 RPM (400 g) for 20 min 
at room temperature.  The mononuclear cell layer was then carefully removed 
using a pasteur pipette and transferred into a clean 15 ml tube, pooling two cell 
layers per sample. The cells were then washed by addition of 10 ml cold PEA 
followed by centrifugation for 5 min at 1200 RPM (200 g) at 4oC. This was 
continued until all the cells from the same sample were pooled into a single 
tube. The number of viable cells (assessed by Trypan Blue staining) were 
counted using a haemocytometer and then diluted to the required 
concentration. Cells were cultured at 37oC in 5% CO2 controlled environment and 
treated as described. 
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7.4.3 Purification of human CD14+ monocytes and CD3+ T cells 
Purification of CD14+ monocytes and CD3+ T cells was carried out following 
magnetic associated cells sorting (MACS) protocol described by Miltenyi Biotec 
Inc. 
PBMCs were prepared as previously described. The PBMCs were then incubated 
for 15 min at 4oC in 20 µl of CD14+ or CD3+ human micro beads (Miltenyi) and 180 
µl PEA per 1 X 107 cells on a MACSmix tube rotator (Miltenyi Biotec). 
Approximately 10 ml of PEA was then added to wash the cells and centrifuged at 
1200 RPM (200g). The supernatant was discarded. The cells were then 
resuspended in 1-2 ml PEA and the CD3+ or CD14+ cells purified by positive 
selection on an AutoMACS separator (Miltenyi Biotec) using the possel 
programme. The positive selection process was then repeated on the purified 
cells to increase cell purity; typically greater than 97% as assessed by FACS 
analysis staining for CD3+ or CD14+ cells (see results). The number of viable cells 
were then counted and diluted to the required concentration. Cells were 
cultured at 37oC in 5% CO2 controlled environment and treated as described 
below. 
7.4.4 Assessment of cell purity 
FACS analysis was used to that the recommended level of monocyte and T cell 
purity was being achieved as anticipated when using the Miltenyi MACS method 
of leukocyte purification. After purification cells were firstly washed by addition 
of PBS and centrifugation at 1200 RPM (300 g) and each sample split into two 
tubes per sample containing approximately 1 X 106 cells/ tube. Monocytes were 
stained with CD14-FITC or isotype control and the T cells were stained with CD3-
PE or isotype control (all BD Bioscience) and incubated for 15 min at room 
temperature. The cells were then washed and fixed by addition of 200 µl 
paraformaldehyde (sigma) and incubated for 10 min at room temperature.  The 
cells were then washed, resuspended in 200 µl PEA and stored at 4oC until 
analysis. The cells were analysed on a FACS Calibre (BD Biosciences) using cell 
quest software to determine the percentage of CD14+ or CD3+ cells. 
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7.4.5 Co-culture of human macrophages and T cells 
Co-culturing activated monocytes and T cells was first developed as an in vitro 
model of inflammation by Vey et al in 1992 in which they demonstrated the 
secretion of IL-1β was dependent upon interactions between THP-1 cells and 
phorbol myristate acetate/ phytohemagglutinin (PMA/PHA) stimulated fixed 
peripheral blood derived T cells (295). Since its first description this assay is now 
widely used and is accepted as an in vitro model of chronic inflammation which 
may lead to tissue destruction in diseases such as rheumatoid arthritis (reviewed 
in (296)). 
Human monocytes were purified as described above and resuspended at 5 X 105 
cells/ml in complete media supplemented with 50 ng/ml (final concentration) 
recombinant human Macrophage Colony Stimulating Factor (MCSF - PeproTech). 
The monocytes were cultured in a 96 well plate, 5 X 104 cells/ well, in a final 
volume of 200 µl media for six days. 
At the same time syngeneic T cells were purified as described above and 
resuspended at approximately 2.0 X 106 cells/ml in complete media 
supplemented with recombinant human IL-2 (25 ng/ml), IL-6 (100 ng/ml) and 
TNF-α (25 ng/ml) (all eBioscience) and cultured at 37oC, 5% CO2 in T 25 flasks. 
After six days the media was removed from the MCSF matured macrophages and 
discarded. The cytokine activated T (TcKs) cells were washed by addition of PEA 
and centrifugation at 1200 RPM (200 g) for 5 min. The TcKs were then 
resuspended at 2.0 X 106 cells/ml in complete media and 2.0 X 105 cells were 
transferred into each well containing MCSF matured macrophages; excluding 
three wells in which macrophages were cultured alone as a control. Similarly, 
three wells were reserved for culture of TcKs alone. The final volume of media 
was made up to 200 µl containing LXR agonists at the final concentration as 
indicated in the results. The TcKs were co-cultured for 24 hrs before 
supernatants were removed for cytokine analysis and cells were lysed in buffer 
RLT for TaqMan analysis. 
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7.4.6 Transwell assays 
Human CD14+ monocytes and CD3+ T cells were purified as described above. The 
macrophages were cultured in a HTS transwell 96 well plate (Corning) and 
differentiated with MCSF as described above. The CD3+ T cells were stimulated 
as described above. After six days the media was removed from the 
macrophages and replaced with 117.5 µl of fresh complete media supplemented 
with the LXR agonists at the final concentration as indicated in the results. A 
transwell insert (HTS transwell 96 well permeable support, Corning) was then 
placed into each well; a transwell with a pore size of 0.4 µm was selected to 
allow diffusion of molecules but not chemotaxis of cells. The TcKs were then 
washed, as described above, and resuspended in complete media at a 
concentration of 5.3 x 106 cells/ml.  37.5 µl of cells (2.0 x105 TcKs) was then 
transferred either into the upper or lower compartment so that the TcKS were 
separated or in co-culture with the macrophages respectively. In all conditions 
the final volume of media in the lower and upper compartments was made up to 
235 µl and 75 µl respectively. LXR agonist or vehicle was added to each 
compartment at a final concentration as indicated in the results. The cells were 
then cultured at 37oC, 5% CO2, for 24 hrs after which the supernatant from each 
compartment in each well was removed and pooled for cytokine analysis (see 
below).  
7.4.7 LPS stimulation of human CD14+ monocytes 
Human monocytes were purified as described above and resuspended at 1 x 106 
cells/ml in complete media and plated out at 1 x 105 cells/well in a 96 well 
plate. The monocytes were then treated with LXR agonists, see above for details 
of agonists, at a final concentration between 0.1 µM to 10 µM depending on the 
agonist as indicated in the results or vehicle (DMSO) and incubated for 24 hrs at 
37oC, 5% CO2. After 24 hrs the media was removed and replaced with fresh 
complete media supplemented with fresh agonist at the same final 
concentration and + 100 ng/ml LPS (Calbiochem). The monocytes were then 
cultured for a further 24 hrs after which the culture supernatants were removed 
for cytokine analysis (see below) and the cells lysed in buffer RLT (Qiagen) for 
RNA extraction and gene expression analysis (see below). 
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7.4.8 Dissection of synovial membrane 
Synovial membrane was obtained from patients with rheumatoid arthritis or 
osteoarthritis undergoing synovectomy or joint replacement surgery. Synovial 
membrane samples were obtained following informed written ethical consent 
approved by Glasgow East Ethics Committee. Synovial membrane (SM) was 
dissected out using sterile forceps and scissors and then cut into small pieces of 
tissue using sterile scalpels. The tissue was then digested with 0.2 mg/ml (final 
concentration) LPS free collagenase (Liberase LB3, Roche) and incubated at 37oC 
for 2 hrs in serum free media on a rotator. The digested tissue was then passed 
through a sterile monofilament filter cloth (100 µm- Cadisch) to make a single 
cell suspension. The cells were then washed in PEA by centrifugation at 1200 
RPM (~200 g) for 5 min and then resuspended in complete media. The number of 
viable cells were then counted using a haemocytometer and diluted to 2 x 106 
cells/ml. The cells were cultured at 37oC, 5% CO2 in a 96 well plate at a density 
of 2x 105 cells/ well and treated as described. 
7.5 Cytokine & chemokine analysis 
7.5.1 General ELISA protocol 
Enzyme Linked Immunosorbent assay (ELISA) was used to measure the 
concentration of human IL-6, TNFα and IL-23, murine IL-6 and murine anti-
collagen IgG1 or IgG2a in cell culture supernatants or serum. The concentrations 
of antibodies and buffers used for the analysis of each cytokine are shown in 
Table  7.3. 
Immunol microtiter (Thermo Labsystems) plates were coated with detection 
antibody in the appropriate buffer and incubated overnight at 4oC. The plates 
were then washed with 0.05% Tween/ PBS followed by addition of blocking 
buffer, to block non-specific binding, and incubated for 1 hr at 37oC. An eight 
point standard curve was made using recombinant mouse or human cytokine 
dissolved in complete media at a top standard concentration of 2,000 pg/ml and 
serially diluted 1:2. 100 µl of each concentration of standard was added in 
duplicate to the plate along with two wells containing only media. Samples were 
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then diluted 1:2-5 with complete media (assay and donor dependent) and 100 µl 
transferred to each well. The plates were covered and then incubated for 2 hrs 
at 37oC. The plates were washed with 0.05% Tween/ PBS followed by addition of 
secondary antibody and incubation at 37oC for 1 hr. The plates were washed and 
streptavidin HRP diluted 1:1000 with diluent was added to each well and the 
plates incubated for 1 hr at 37oC. After incubation the plates were washed 
before addition of 100 µl 3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase 
(Biosource). The reaction was stopped by addition of 100 µl Stop Solution 
(Biosource) and the mean intensity was read at 450nm on a microplate reader 
(Dynex Technology). 
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Cytokine Coating solution Blocking 
solution and 
diluent 
Concentration of 
primary antibody 
Concentration of 
secondary antibody 
Streptavidin HRP 
dilution 
Antibody 
supplier. 
Hs IL-6 PBS 0.5% BSA/ 
PBS 
2 µg/ml(100 µl/ 
well) (polyclonal) 
1.5 µg/ml (100 µl/ 
well) (polyclonal) 
1:1250 Invitrogen 
Hs TNFα PBS 0.5% BSA/ 
PBS 
2 µg/ml (100 µl/ 
well) (polyclonal) 
1.5 µg/ml (100 µl/ 
well) (polyclonal) 
1:1250 Invitrogen 
Hs IL-23 PBS 0.5% BSA/ 
PBS 
2 µg/ml (100 µl/ 
well) (polyclonal) 
1.5 µg/ml (100 µl/ 
well) (polyclonal) 
1:1250 Invitrogen 
Mm IL-6 0.1 M 
bicarbonate 
buffer 
10% FCS/ PBS 1 µg/ml: 50 µl/ well 
(MP5-32C11) 
1 µg/ml: 50 µl/ well 
(polyclonal) 
1:1000 (extravidin 
peroxidase) 
BD pharmingen/ 
Sigma 
Mm Anti-
collagen IgG1 
0.1 M 
bicarbonate 
buffer 
10% FCS/ PBS 0.4 µg/ml type II 
collagen (50 µl/ 
well) 
0.5 mg/ml: 50 µl/ 
well (A19-3) 
1:1000 (extravidin 
peroxidase) 
BD pharmingen/ 
Sigma 
Mm Anti-
collagen 
IgG2a 
0.1 M 
bicarbonate 
buffer 
10% FCS/ PBS 0.4 µg/ml type II 
collagen (50 µl/ 
well) 
0.5 mg/ml: 50 µl/ 
well (R19-15) 
1:1000 (extravidin 
peroxidase) 
BD pharmingen/ 
Sigma 
Table  7.3 Cytokine analysis by ELISA 
Human (Hs) and murine (Mm) cytokines were analysed using antibody pairs. The detection antibody was added to each well diluted in the appropriate 
coating buffer and the secondary antibody added in assay diluent. The final concentration of each antibody and the volume added to each well is shown. 
All antibodies are monoclonal unless indicated  and the clone number is shown in brackets.  
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7.5.2 Luminex assay 
Multiplex cytokine and chemokine analysis of cell culture supernatants or mouse 
serum concentrations was done by Luminex analysis (Biosource) on a Bio-Plex 
system (Bio-Rad). Standards were dissolved in 1 ml of assay diluent to 
reconstitute the each cytokine standard to the required concentration.  
Analysis of human cell culture supernatants 
For human cell culture supernatants the human cytokine twenty five-plex assay 
(Biosource) was able to be analyse the following cytokines and chemokines: 
Eotaxin, GM-CSF, IFNγ, IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6 IL-7, IL-8, IL-10, IL-
12p40/p70, IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES and 
TNFα.   
Mouse serum analysis 
Serum cytokines were analysed using the mouse cytokine twenty-plex 
(Biosource) which was able to measure the concentration of the following 
cytokines and chemokines: 
FGF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40/p70, IL-13, 
IL-17, IP-10, KC, MCP-1, MIG, MIP-1α, TNFα and VEGF.  
For both mouse and human all samples were diluted 1:2 with assay diluent and 
50 µl added to each well, samples were tested in duplicate following the 
manufacturer’s protocol.  
7.6 Gene expression analysis 
7.6.1 Purification of RNA 
DNase digestion was not performed when extracting RNA as all QRT-PCR primers 
and probes were selected on the basis that they crossed intron/ exon boundaries 
and would therefore not detect genomic DNA in a TaqMan assay.  
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7.6.1.1 RNA extraction from tissue 
Tissues were dissected from mice, snap frozen and stored at -80oC until required 
for RNA extraction to maintain RNA stability. 
The tissues were placed in a homogeniser tube (Precellys Kit CK28) and 1 ml of 
Trizol added to each sample. The tissue was then homogenised in a Precellys 
homogeniser set at 2 X 10 sec at 6500 RPM.  
After homogenisation 200 µl of chloroform was added to the sample, vortexed 
and the contents transferred to a fresh RNase free tube (eppendorf). The tubes 
were then centrifuged at 13,000 RPM for 20 min at 4oC to separate out the 
aqueous phase containing the RNA.  
The RNA was then precipitated from the aqueous layer by addition of 500 µl 
propan-2-ol and then pelleted by centrifugation at 13,000 RPM for 20 min at 4oC. 
The propan-2-ol was then removed and the RNA pellet then washed by addition 
of 300 µl 70% ethanol and centrifugation at 13,000 RPM for 5 minutes. The 
ethanol was then removed and the RNA pellet allowed to air dry for 
approximately 5 min before being dissolved in 300 µl Diethyl Pyrocarbonate 
(DEPC) treated water. 
The RNA was then quantified using a spectrophotometer (Amersham Biosciences) 
by diluting 1 µl of the RNA in 49 µl (1:50) of water. The stock RNA was then 
diluted to 0.2 µg/µl with DEPC treated water and stored at -80oC before cDNA 
synthesis. 
7.6.1.2 RNA extraction from cells 
RNA extraction from cells cultured in 96 well plates was done following the 
RNeasy 96 protocol by vacuum technology (Qiagen) as described by the 
manufacturers. The cells were lysed in 100 µl of buffer RLT, gently agitated to 
aid cell lysis and stored at -80oC until required for RNA extraction. The RNA was 
then precipitated by the addition of 100 µl 70% ethanol. The samples were then 
added to the RNeasy 96 plate to bind the RNA and a vacuum applied to remove 
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the supernatant. The columns were then washed to remove protein impurities 
and air dried before eluting the RNA in approximately 60 µl DEPC treated water. 
7.6.2 cDNA Synthesis 
The following pre-reactions were set up in a thin walled 96 well plate and then 
covered with a foil lid: 
1 µg RNA    5 µl* 
Random hexamers 50 ng/µl 1 µl 
10 mM dNTP mix    1 µl 
DEPC water    3 µl* 
Final volume    10 µl 
* RNA extracted from tissue or large volume cell cultures was previously 
quantified and diluted to 0.2 µg/µl using DEPC water. However, if RNA was 
extracted from cells cultured in 96 well plates then 8 µl of RNA was added and 0 
µl DEPC water to maintain a final reaction volume of 10 µl. 
The plate was then pulse centrifuged to mix the contents and the RNA denatured 
in a PCR machine on the following programme:  
1. 65oC 5 min 
2. 0oC 1 min 
3. 4oC  Forever 
A second master mix was then prepared: 
5X RT buffer    4 µl 
50 mM MgCl2    2 µl 
0.1 M DTT    2 µl 
RNase OUT    1 µl 
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Superscript II RT (200 u/ µl) 0.25 µl 
DEPC water    0.75 µl 
Final volume    10 µl 
The master mix was then added to the contents of each well and mixed by pulse 
centrifugation. The cDNA was then synthesised by incubating the plates in a PCR 
machine (eppendorf) on the following programme: 
1. 25oC 2 min 
2. 42oC 50 min 
3. 70oC  15 min 
4. 4oC Forever 
The cDNA was then diluted 1:3 with DEPC water before using for PCR for analysis 
of required target genes. 
7.6.3 TaqMan QRT-PCR 
The cDNA samples were prepared as previously described and assayed in 
quadruplicate in 10 µl final reaction volumes in a 384 well plate format. All 
reagents were purchased from Applied Biosystems. 
The following controls were required for TaqMan quantitative reverse 
transcriptase-polymerase chain reaction (QRT-PCR) when synthesising the cDNA: 
1. no RNA 
2. no template control (only water). 
Nb As all primers and TaqMan probes purchased were designed to span from 
exon to exon over intron gaps no control was required to check for 
contamination of genomic DNA. 
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A master mix of the following reagents for each primer and probe set was made; 
volumes are per QRT-PCR reaction: 
QPCR 2X master mix  5 µl 
Acid on Demand*  0.5 µl 
DEPC treated water  1.5 µl 
    7 µl 
* Acid on Demand (AoD) = Primer and TaqMan probe mix.  
The following AoDs were used for TaqMan analysis of human and mouse cDNA 
samples (Table  7.4). 
Gene name Species Catalogue 
number 
Nr1h3 (LXRα) Human Hs00172885_m1 
Nr1h2 (LXRβ) Human Hs00173195_m1 
TAF2 (TBP) Human Hs00162527_m1 
ABCA1 Human Hs00194045_m1 
TLR4 Human Hs01061963_m1 
TBP Human 4333769F 
TBP Mouse Mm00446973_m1 
Nr1H3 (LXRα) Mouse Mm00443454_m1 
Nr1H2 (LXRβ) Mouse Mm00437262_m1 
ABCA1 Mouse Mm00442646_m1 
Table  7.4 TaqMan AoDs: primers and probes. 
The details of primer and TaqMan probe mixtures purchased from Applied Biosystems used 
for TaqMan analysis of samples from humans or mice. 
The master mix was then added to a 384 well plate using a 16 channel pipette (7 
µl per well). 3 µl of each cDNA sample was then added in quadruplicate and 
covered with an optical cover. The plate was then centrifuged at 2000 RPM for 2 
min to mix the contents. The QRT-PCR reaction was then performed on an 
Applied Biosystems 17900HT machine for 40 cycles. 
The expression of target genes was then quantified relative to the house keeping 
gene using SDS2.2 software. 
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7.7 Statistical analysis 
All results are displayed + standard deviation and all statistical analysis was done 
by students T test or ANOVA test, as indicated in figure legends, using the Graph 
Pad Prism 4 software. A p value of < 0.05 was considered statistically significant. 
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8 Activation of the Liver X Receptors potentiates 
the severity of articular inflammation in vivo 
  106 
8.1 Aims & Introduction 
Activation of LXRs has been confirmed by several studies to exert beneficial 
effects in both the ApoE-/- and the LDLR-/- murine models of atherosclerosis (96, 
97, 102). This is mediated primarily by transcriptional upregulation of LXR target 
genes ABCA1/ G1, ApoE and LDLR which promote reverse cholesterol transport 
and excretion of cholesterol from the body (49). Many pharmaceutical 
companies are currently attempting to develop LXR specific agonists for the 
treatment of metabolic disorders. More recently LXR activation was shown to 
inhibit the release of the pro-inflammatory cytokine IL-6 from murine LPS 
stimulated macrophages in vitro (117). This study was the first to demonstrate 
an immuno-modulatory role for LXRs and although a role for LXR activation upon 
other inflammatory pathways in vivo remained unknown these data suggested an 
anti-inflammatory effect of LXR activation. We therefore hypothesised that 
whilst LXR agonists may be able to ameliorate atherosclerosis through the 
modulation of a cholesterol homeostasis they may also exert anti-inflammatory 
effects and therefore offer potential as a therapy in RA.  
The murine CIA model is a widely utilised model of human RA - it is initiated by 
activation of the immune response to an exogenous antigen that in turn 
promotes breach of tolerance to self antigen. It allows exploration of 
components of both the innate and adaptive arms of the immune response (219). 
The utility of this model has been further exemplified through the development 
of anti-TNFα therapy which was first suggested to offer therapeutic benefit for 
RA through studies in murine CIA (199). The CIA model therefore offers the 
potential to explore the role of LXRs and downstream molecular pathways upon 
inflammation in arthritis. I therefore sought to determine the effects of LXR 
activation upon inflammation generally and the development of arthritis 
specifically in the murine model of CIA. However, to ensure activation of LXRs it 
was first necessary to optimise the route, dose and frequency of agonist 
administration. 
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8.2 Optimisation of LXR agonist delivery 
8.2.1 Intraperitoneal injection is the optimal route for 
administration of LXR agonists 
Several synthetic LXR agonists, including T1317 and GW3965, have been used in 
the literature to explore the role of LXRs in vivo. However, these compounds 
were not commercially available and since patents initially prevented the use of 
GW3965 we were restricted at the outset of my studies to the use of T1317. 
Furthermore, both compounds had previously been administered by oral gavage 
as delivery of medications orally is favoured over injection. It was therefore first 
necessary to determine the optimal route of agonist administration to ensure 
maximum bioavailability of LXR agonists and subsequent activation of LXRs. Male 
7 week old C57BL/6 mice were treated daily with vehicle (5% mulgofen/ PBS) or 
10 mg/kg T1317, a dose which had previously been shown to induce LXR 
activation, by oral gavage, sub-cutaneous injection or intraperitoneal (IP) 
injection daily for seven days. Mice were culled six hours post final drug 
administration. The liver and bone marrow were removed to determine the level 
of LXR transcriptional activation by analysis of ABCA1 expression using Taqman 
QRT-PCR (Figure  8.1). Administration of T1317 caused an approximate two to 
three fold increase in the expression of ABCA1 in the liver relative to the vehicle 
controls by all routes of administration. Similarly, the expression of ABCA1 was 
upregulated by approximately six and eight fold within the bone marrow by IP or 
sub-cutaneous injection respectively. However, the expression of ABCA1 in the 
bone marrow was not altered from basal levels of expression by oral gavage of 
T1317. This suggests that oral administration does not provide sufficient 
bioavailability of LXR agonists to all tissues. Since, IP administration of T1317 
robustly activated LXRs in both tissues with the least degree of variability IP 
injection was selected as the method of LXR agonist administration for future in 
vivo studies. 
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Figure  8.1 Intraperitoneal injection is the optimal route of T1317 administration. 
Male mice were treated daily with 10 mg/kg T1317 or vehicle (5% mulgofen/ PBS) by oral 
gavage, sub-cutaneous injection (sub-cut) or intraperitoneal injection (IP) for 7 days. Mice 
were culled approximately 6 hrs after final agonist administration and the liver and bone 
marrow were removed for analysis of ABCA1 expression by Taqman QRT-PCR relative to 
TBP. Results are displayed as fold increase of ABCA1 expression relative to the respective 
vehicle group. n = 5/ group. 
8.2.2 Optimisation of drug dose 
In order to determine the concentrations of T1317 that would induce the 
activation of LXRs male C57BL/6 mice at 7 weeks of age were treated with 
vehicle or T1317 at the indicated concentrations by daily IP injection for seven 
days. Six hours post final drug administration the livers were removed for 
Taqman QRT-PCR analysis of the expression of ABCA1 expression (Figure  8.2). 
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The expression of ABCA1 was upregulated by all concentrations of T1317 in a 
dose dependent manner relative to the vehicle control with the highest level of 
LXR activation being achieved with a dose of 30 mg/kg T1317. Similarly, the 
expression of ABCA1 was up-regulated by 3 fold upon treatment with 10 mg/kg 
T1317 consistent with the previous experiment (Figure  8.1).  
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Figure  8.2 T1317 induces the activation of LXRs in a dose responsive manner. 
Male mice were treated daily with T1317 or vehicle (5% mulgofen/ PBS) at the indicated 
concentration by IP injection for 7 days. Mice were culled approximately 6 hrs after final 
agonist administration and the livers were removed for analysis of ABCA1 expression by 
Taqman QRT-PCR relative to TBP. Results are displayed as fold increase of ABCA1 
expression relative to the vehicle group. n = 5/ group. 
LXRs also regulate the expression of FAS which, similar to ABCA1, can also be 
used to confirm activation of LXR mediated transcription. The expression of FAS 
was also significantly upregulated in the liver of mice treated with 20 mg/kg and 
30 mg/kg T1317 but not at lower agonist concentrations (Figure  8.3). FAS is the 
rate limiting enzyme in the synthesis of fatty acids and triglycerides and has 
been shown to be responsible in part for the development of hepatic steatosis in 
mice treated with LXR agonists (81). This is characterised by the presence of 
white lipid droplets which can be visualised at the macroscopic level in the liver. 
In accordance with previous publications the livers of all mice treated with 
T1317 exhibited signs of hepatic steatosis; this was most prominent in the liver 
of mice treated with the highest concentrations of T1317 (Figure  8.4).  
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Figure  8.3 LXR activation induces the expression of FAS. 
Male mice were treated daily with T1317 or vehicle (5% mulgofen/ PBS) at the indicated 
concentration by IP for 7 days. Mice were culled approximately 6 hrs after final agonist 
administration and the livers were removed for analysis of FAS expression by Taqman QRT-
PCR relative to TBP. Results are displayed as fold increase of FAS expression relative to the 
vehicle group. n = 5/ group. 
 
Figure  8.4 Activation of LXRs induces hepatic steatosis. 
Livers were removed from mice treated with the indicated concentration of T1317 or vehicle 
(V- 5%mulgofen/ PBS). The livers of all mice treated with T1317 exhibited hepatic steatosis 
visualised by the accumulation of white lipid droplets. Representative livers of n = 5/ group.  
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8.2.3 T1317 is required to be given daily to sustain LXR activation  
Early studies shared with us by Schering Plough had indicated that T1317 was 
undetectable in the circulation of mice within 24 hrs post delivery (data not 
shown). Therefore, it was important to determine the frequency at which LXR 
agonist should be administered in order to sustain activation of LXRs in vivo. 
Mice were injected IP with 10 mg/kg T1317 or vehicle and were culled at 6 hrs, 
24 hrs and 48 hrs post drug administration. The expression of ABCA1 was 
determined by Taqman QRT-PCR (Figure  8.5). Similar to previous experiments 
LXR activation by T1317 induced an approximately 3 fold increase in the 
expression of ABCA1 6 hrs post agonist delivery. However, at 24 hrs and 48 hrs 
post administration of drug the expression of ABCA1 had returned to basal 
levels. This data suggests that daily IP administration of LXR agonist is the 
minimum frequency required, but also the maximum permitted by the Home 
Office, to ensure sustained activation of LXRs. Therefore, daily IP injection was 
selected as the chosen route and frequency of LXR agonist administration for all 
future experiments. 
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Figure  8.5 T1317 is required to be given daily to sustain activation of LXRs. 
Male mice were treated with 10 mg/kg T1317 or vehicle (5% mulgofen/ PBS) by IP. Mice were 
culled 6 hrs, 24 hrs or 48 hrs after agonist administration and the livers were removed for 
analysis of ABCA1 expression by Taqman QRT-PCR relative to TBP. Results are displayed 
as fold increase of ABCA1 expression relative to the vehicle group. n = 5/ group. 
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8.2.4 Mulgofen does not impact the severity of CIA 
T1317 is usually dissolved in the vehicle 5% mulgofen/PBS for in vivo delivery. 
Mulgofen is a detergent which improves drug solubility. To ensure that the 
mulgofen did not effect the severity of CIA, arthritis was induced in DBA/1 mice 
treated with PBS or vehicle (5% mulgofen/PBS) by daily IP from day -1 to day 42. 
Daily administration of vehicle did not significantly alter the clinical score (P = 
0.6546) or paw swelling (P = 0.2089) relative to mice treated with PBS (Figure 
 8.6). Furthermore, there was no significant difference in the concentration of 
several pro-inflammatory cytokines assayed in serum (Figure  8.7).  
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Figure  8.6 Mulgofen does not affect the severity of CIA. 
Arthritis was induced in mice which were treated daily IP with vehicle (5% mulgofen/ PBS) 
or PBS. There was no significant difference in the clinical score (A) or paw thickness (B) 
between the two treatment groups. Two Way ANOVA; P = 0.2089. n = 12/group. 
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Figure  8.7 Vehicle does not induce the secretion of pro-inflammatory cytokines in vivo. 
Administration of vehicle (5% mulgofen/PBS) to CIA mice does not alter the concentration 
of serum pro-inflammatory cytokines or chemokines compared to PBS measured by 
Luminex analysis. n =12/group. 
Together these data suggest that activation of LXRs could be achieved in vivo 
using concentrations of T1317 between 1 mg/kg and 30 mg/kg when 
administered by daily IP injection; this ensured sufficient bioavailability of 
agonist and maintained satisfactory activation of LXR transcriptional activity. 
Furthermore, these data show that the vehicle had no obvious effect upon 
inflammation and did not affect the severity of murine CIA. Therefore, mulgofen 
is a suitable vehicle in which to dissolve LXR agonists and explore the role of 
LXRs in inflammation in vivo. 
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8.3 Identification of a novel pro-inflammatory role for 
LXRs in vivo 
8.3.1 LXR activation by T1317 increases the severity of murine 
collagen-induced arthritis 
8.3.1.1 The clinical severity of arthritis is increased by T1317 
Since the delivery of LXR agonists in vivo had been optimised it was now possible 
to investigate whether activation of LXRs by T1317 could modulate inflammation 
in murine CIA. Arthritis was induced in male DBA/1 mice at approximately 8 
weeks of age. Power calculations determined that twelve mice per group was 
sufficient to detect a 50% change between active and placebo groups with 
p=0.01. Mice were treated daily IP with 2 mg/kg and 20 mg/kg T1317 or vehicle 
(5% mulgofen/PBS). In order to investigate the ability of T1317 to affect the 
development of pre-clinical or established arthritis T1317 was delivered over 
two time courses; one day prior to the induction of arthritis to day 42 (early 
treatment regime), or from day 24 post induction of arthritis to 42 (late 
treatment regime). The experimental design is summarized in (Figure  8.8). 
 
Figure  8.8 CIA experimental design. 
Mice were inoculated with 100 µg type II bovine collagen in complete freunds adjuvant (CFA) 
by an intradermal injection on day 0. At day 21 mice were injected IP with 100 µg type II 
collagen in PBS. Mice were treated with 2 mg/Kg and 20 mg/Kg T1317 over the two different 
time courses by daily IP injection. Vehicle (5% mulgofen/ PBS) was administered by daily IP 
injection over the early time course. n =12/ group. 
Administration of T1317 via the early treatment regime induced an earlier onset 
of disease compared to vehicle recipients (Figure  8.9). From day 21 onwards 
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mice were monitored daily and assessed for the development of arthritis by the 
use of a clinical score and measurement of paw swelling. The severity of disease 
was significantly increased in all the groups receiving T1317 compared to vehicle 
in a dose dependent manner (Figure  8.10). Furthermore, the groups treated with 
both 2 mg/kg and 20 mg/kg T1317 on the longer “early” treatment regime 
exhibited an increased severity of arthritis compared to the respective groups on 
the shorter “late” treatment regime.  
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Figure  8.9 Activation of LXRs increases the incidence of arthritis. 
Arthritis was induced in male DBA/1 mice and were treated daily with vehicle (5% 
mulgofen/PBS) or the indicated concentrations of T1317 by IP injection. T1317 was 
administered over two time course; early: day -1 to day 42 and late: day 24 to day 42. 
Vehicle was administered by the early treatment regime. n = 12/ group.   
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Figure  8.10 The clinical severity of arthritis is increased in mice receiving T1317. 
Arthritis was induced in male DBA/1 mice and were treated daily with vehicle (5% 
mulgofen/PBS) or the indicated concentrations of T1317 by IP injection. T1317 was 
administered over two time course; early: day -1 to day 42 and late: day 24 to day 42. 
Vehicle was administered by the early treatment regime. Mice were monitored daily and 
assigned a clinical score as a measure of arthritis severity. Two way ANOVA, *** P < 0.001 
relative to vehicle; n = 12/ group.   
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Over the same time period paw swelling was measured as an independent 
measure of arthritis disease severity ( 
Figure  8.11). In accordance with the clinical score, paw swelling was 
significantly increased in all the groups receiving T1317 and did so in a dose 
dependent manner. Similarly, paw swelling was higher in the groups on the early 
treatment regime compared with the late treatment regime.  
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Figure  8.11 Paw swelling is increased in mice receiving T1317. 
Arthritis was induced in male DBA/1 mice and were treated daily with vehicle (5% 
mulgofen/PBS) or the indicated concentrations of T1317 by IP injection. T1317 was 
administered over two time course; early: day -1 to day 42 and late: day 24 to day 42. Paw 
swelling was measured as a independent indicator of arthritis severity. Vehicle was 
administered by the early treatment regime. Two way ANOVA; ** P < 0.01, *** P < 0.001 
relative to vehicle; n = 12/ group.   
In accordance with the Animals (Scientific Procedures) Act 1986 mice were 
required to be euthanised if disease severity was too high (maximum score of 12 
per animal) or if animals were displaying other signs of general ill health, e.g. 
weight loss, scruffy coat or sedentary behaviour, as outlined in the appropriate 
home office project licence. This therefore provided a threshold outcome 
measure for disease severity with which to compare severe disease in the 
groups. More mice in the groups receiving T1317, relative to vehicle, were 
required to be euthanised prior to the planned end of the experiment time 
course due to the greatly increased level of disease severity (Figure  8.12). 
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Figure  8.12 The number of mice required to be euthanised is increased with T1317. 
More mice in the groups receiving T1317 had to be euthanised due to the greatly increased 
level of disease severity in accordance with the Home Office project licence under the 
Animals (Scientific Procedures) Act 1986. n = 12/group. 
8.3.1.2 T1317 induced the expression of ABCA1 in vivo 
To confirm that administration of T1317 induced the activation of LXRs the liver 
was removed from all mice approximately six hours post drug administration and 
the expression of ABCA1 measured by Taqman QRT-PCR (Figure  8.13). Treatment 
with 2 mg/Kg or 20 mg/Kg T1317 by both treatment regimes up-regulated the 
expression of ABCA1 by approximately 2 and 3 fold respectively in comparison to 
the vehicle control consistent with preliminary experiments (compare to Figure 
 8.2). 
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Figure  8.13 T1317 induces LXR activation and the expression of ABCA1 in vivo. 
To confirm LXR activation in the groups treated with T1317 liver was removed and the 
expression of the LXR target gene ABCA1 measured by Taqman QRT-PCR normalised to 
TBP. All groups treated with T1317 exhibited a dose responsive fold increase in the 
expression of ABCA1 compared to vehicle. n = 12/ group. Students T test; *** P< 0.001. 
8.3.2 T1317 but not low dose GW3965 increases the severity of 
murine CIA 
Other studies in the literature have previously demonstrated clear anti-
inflammatory effects of LXR agonism (117). Therefore, the pro-inflammatory 
effects of LXR activation in CIA were unexpected and needed to be confirmed. 
Furthermore, patents that previously prohibited the use of GW3965 had since 
been withdrawn. GW3965, which is a more specific LXR agonist, could therefore 
be used alongside T1317 to explore and confirm the effect of LXR agonism upon 
inflammation in CIA.  
8.3.2.1 T1317 but not low dose GW3965 increased the clinical severity of 
collagen-induced arthritis  
To confirm the previous results demonstrating a pro-inflammatory effect of LXR 
agonism in vivo arthritis was induced in male DBA/1 mice at approximately 8 
weeks of age, twelve mice per group. Mice were treated daily IP with vehicle 
(5% mulgofen/PBS), 10 mg/kg and 20 mg/kg T1317 or 10 mg/kg GW3965. T1317 
and GW3965 have been shown to induce the expression of ABCA1 at similar Ec50 
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therefore a concentration of 10 mg/Kg GW3965, similar to T1317 was selected 
(33, 34). In addition another positive control group was treated with 200 µg/kg 
dexamethasone to demonstrate that an anti-inflammatory effect could be 
achieved thereby controlling for operator variability and any adverse effects of 
multiple IP injections. Since the greatest effect of T1317 was previously seen 
over the longer treatment period all drugs were administered one day prior to 
the induction of arthritis to day 41. The experimental design is summarised in 
(Figure  8.14). 
 
Figure  8.14 CIA experimental design utilising T1317 & GW3965. 
Mice were inoculated with 100 µg type II bovine collagen in complete freunds adjuvant (CFA) 
by an intradermal injection on day 0 and challenged on day 21 IP with 100 µg type II collagen 
in PBS. Mice were treated daily with vehicle (5% mulgofen/ PBS), 200 µg/Kg dexamethasone, 
10 mg/Kg and 20 mg/Kg T1317 or 10 mg/Kg GW3965 from day -1 to day 41 by IP injection. n 
=12/ group. 
Similar to previous results, administration of T1317 and GW3965 resulted in 
increased incidence of disease compared to vehicle recipients (Figure  8.15). 
Furthermore, as expected, the group treated with dexamethasone did not 
develop any clinical signs of disease. 
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Figure  8.15 Both T1317 and GW3965 increase the incidence of arthritis 
Arthritis was induced in male DBA/1 mice which were treated daily with vehicle (5% 
mulgofen/PBS), 200 µg/kg dexamethasone, T1317 or GW3965 by IP injection from day -1 to 
day 41. n = 12/ group.   
As before, mice were monitored from day 21 onwards for the development of 
arthritis (Figure  8.16). The development and severity of disease was significantly 
increased in all the groups receiving T1317 compared to vehicle in a dose 
responsive manner. The clinical score upon treatment with 20 mg/kg T1317 was 
comparable with that obtained in prior experiments (compare to Figure  8.10). 
However, treatment with 10 mg/kg GW3965 did not significantly alter the 
severity of disease. The clinical scores were also confirmed by two blinded 
observers at several time points throughout the experiment.  
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Figure  8.16 T1317 but not low dose GW3965 increases the severity of arthritis 
Arthritis was induced in male DBA/1 mice which were treated daily with vehicle (5% 
mulgofen/PBS), 200 µg/kg dexamethasone, T1317 or GW3965 by IP injection from day -1 to 
day 41. Mice were monitored daily and assigned a clinical score for the severity of arthritis. 
Two way ANOVA; *** P < 0.001 relative to vehicle; n = 12/ group.   
Similarly, paw swelling was significantly increased in both groups receiving 
T1317 compared to vehicle (Figure  8.17). Although, paw swelling was greater in 
the group receiving GW3965 this was not statistically significant (P = 0.06). In 
accordance with the clinical score there was no increase in the paw thickness in 
the mice receiving dexamethasone. Moreover, more mice were euthanised in the 
groups treated with T1317, but not GW3965, compared to vehicle control (Figure 
 8.18). Together these data indicate that disease severity was only increased in 
the groups receiving T1317. 
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Figure  8.17 Paw swelling is increased by LXR agonism 
Arthritis was induced in male DBA/1 mice which were treated daily with vehicle (5% 
mulgofen/PBS), 200 µg/kg dexamethasone, T1317 or GW3965 by IP injection from day -1 to 
day 41. Paw swelling was measured as an independent indicator of arthritis severity. Two 
way ANOVA; ** P < 0.01; n = 12/ group.   
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Figure  8.18 Mortality is increased in mice receiving T1317. 
Arthritis was induced in male DBA/1 mice which were treated daily with vehicle (5% 
mulgofen/PBS), 200 µg/kg dexamethasone, T1317 or GW3965 by IP injection from day -1 to 
day 41. Mice were euthanised if the severity of disease was too severe or displayed general 
signs of ill health in accordance with the Home Office project licence. Mortality was not 
altered in mice receiving GW3965 in comparison to vehicle. n = 12/ group.   
8.3.2.2 Ex vivo assessment of inflammatory cytokines and antibody titres 
Upon termination of the experiment blood samples were taken by cardiac 
puncture for analysis of serum cytokine and chemokine concentrations measured 
by Luminex analysis (Figure  8.19). The concentration of several serum 
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proinflammatory cytokines, IL-1, IL-17, IL-12 and GM-CSF, were increased in the 
groups treated with T1317 in a dose responsive manner. None of these pro-
inflammatory cytokines were significantly elevated in response to 10 mg/kg 
GW3965. However, the anti-inflammatory cytokine IL-10 was elevated in 
response to treatment with both T1317 and GW3965. Furthermore, treatment 
with T1317 increased the serum concentration of the chemokine MIP-1α, whilst 
the concentration of MIG was higher in both the T1317 and GW3965 groups. The 
concentration of IL-12 was significantly decreased and was the only cytokine 
affected by dexamethasone. IL-12 supports the polarisation of naïve T cell 
towards a Th1 phenotype. Lower concentrations of serum IL-12 are indicative of 
and consistent with findings that steroids ameliorate articular inflammation 
primarily through the inhibition of T cell proliferation. The cytokines and 
chemokines IL-2, IL-4, IL-5, IL-6, IL-13, IFNγ, TNFα, FGF, VEGF, IP-10, KC and 
MCP-1 were not detectable at this time point. 
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Figure  8.19 T1317 increases the concentrations of serum inflammatory cytokines and 
chemokines. 
Serum cytokine and chemokine concentration from mice at day 41 of the CIA model were 
measured by Luminex analysis. Mice had been treated daily IP with vehicle ( 5% mulgofen/ 
PBS), 200 µg/kg dexamethasone (Dex), T1317 or GW3965. Other cytokines or chemokines 
were not detectable at this time point. Unpaired Students T test; * P < 0.05, ** P < 0.01 and *** 
P < 0.001. n =12/group. 
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To determine the effect of LXR activation by T1317 or GW3965 upon T cell 
activation the popliteal and inguinal lymph nodes were removed and crushed 
through a cell strainer to generate a single cell suspension. Very few cells were 
obtained from the group treated with dexamethasone which precluded analysis 
of T cell function by this method (Figure  8.20). The cells were stimulated 
overnight with PMA and Ionomycin and the percentage of CD4+ cells that were 
IFNγ+ (Th1) or IL-17+ (Th17) was analysed by flow cytometry (Figure  8.21). In the 
groups treated with T1317, despite a dose dependent trend, no significant 
increase in the percentage of IFNγ+ cells was observed (20 mg/Kg T1317; P = 
0.535). However, there was a significant increase in the percentage of CD4- IL-
17+ cells.  
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Figure  8.20 The number of lymph node cells is increased by LXR agonism. 
The popliteal and inguinal lymph nodes were removed from mice treated with vehicle (V), 
200 µg/Kg Dexamethasone (Dex), T1317 or GW3965 (mg/Kg) and crushed through a cell 
strainer to make a single cell suspension and the total number of viable cells assessed by 
staining with Trypan blue were counted. The number of cells from the group treated with 
200 µg dexamethasone was significantly reduced relative to vehicle control. Unpaired 
students T test; *** P < 0.001, * P < 0.05. n = 12/group. 
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Figure  8.21 Intracellular cytokine analysis of lymph node T cells. 
The cells from popliteal and inguinal lymph nodes of mice treated with vehicle, T1317 or 
GW3965 at the indicated concentration (mg/Kg) were stimulated overnight with PMA and 
Ionomycin. The percentage of CD4+IL-17+ or CD4+IFNγ+ T cells was determined by flow 
cytometric analysis. (A) Representative images of flow cytometric analysis from each group. 
(B) Graphical representation of mean percentage IFNγ or IL-17 positive cells from each 
group. Unpaired Students T test; * p < 0.05. n = 12/ group. 
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Murine CIA is associated with anti-collagen antibodies of which IgG2a is the 
predominant isotype. Since 20 mg/kg T1317 had the largest effect upon the 
concentration of serum cytokines and chemokines and lymphocytes activation 
the concentration of serum anti-collagen IgG2a specific antibodies in this group 
was measured by ELISA (Figure  8.22). However, there was no significant 
difference in the concentration of anti-collagen antibodies in the group treated 
with 20 mg/Kg T1317 relative to vehicle at this time point. 
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Figure  8.22 T1317 does not alter serum anti-collagen IgG2a antibody titres. 
Serum from mice treated with vehicle of 20 mg/Kg T1317 was serially diluted and the 
concentration of anti-collagen IgG2a antibodies was measured by ELISA. n = 12/group. 
8.3.2.3 T1317 and GW3965 induce activation of LXRs 
Since treatment of mice with 10 mg/Kg T1317 or 10 mg/Kg GW3965 had 
different effects upon the development of arthritis disease severity it was 
essential to ensure that both compounds had induced the transcriptional 
activation of LXRs (Figure  8.23). In previous experiments the expression of 
ABCA1 had previously been measured in the liver. However, data from Schering 
Plough indicated that GW3965 does not readily induce the expression of ABCA1 
in the liver whereas both T1317 and GW3965 are able to up-regulate ABCA1 
expression in the jejunum (data not shown). The expression of ABCA1 at six 
hours post drug administration was upregulated approximately 10 fold in the 
groups treated with T1317 and GW3965 as measured by Taqman QRT-PCR 
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relative to vehicle control. Treatment with dexamethasone did not alter LXR 
mediated expression of ABCA1. 
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Figure  8.23 Induction of LXR activation by T1317 and GW3965. 
The expression of the LXR reporter gene ABCA1 was measured by Taqman QRT-PCR in the 
jejunum of mice treated with 200 µg/kg dexamethasone (dex), T1317 or GW3965 at the 
indicated concentration (mg/Kg). Results are displayed as mean fold increase of ABCA1 
expression relative to vehicle. n = 12/ group. Students T test; *** P < 0.001. 
8.3.3 LXR agonism by high dose GW3965 promotes articular 
inflammation 
8.3.3.1 LXR activation by GW3965 increases the incidence and severity of 
arthritis 
The results of the previous two independent experiments have demonstrated 
that LXR activation by T1317 increases the severity of murine CIA in a dose 
responsive manner but not by a lower concentration of GW3965. To address the 
effects of GW3965 administration at a higher concentration, arthritis was 
induced in male DBA/1 mice at approximately 8 weeks of age. Mice were treated 
daily IP with vehicle (5% mulgofen/PBS) or 30 mg/kg GW3965. Drugs were 
administered from one day prior to the induction of arthritis to the expected 
peak of disease at day 31. The experimental design is summarised in (Figure 
 8.24). Treatment with 30 mg/Kg GW3965 dramatically increased the incidence 
of disease compared to vehicle recipients (Figure  8.25). 
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Figure  8.24 CIA experimental design utilising 30 mg/Kg GW3965. 
Mice were inoculated with 100 µg type II bovine collagen in complete freunds adjuvant (CFA) 
by an intradermal injection on day 0 and challenged on day 21 IP with 100 µg type II collagen 
in PBS. Mice were treated daily with vehicle (5% mulgofen/ PBS or 30 mg/Kg GW3965 from 
day -1 to day 31 by IP injection. n =12/ group. 
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Figure  8.25 GW3965 increases the incidence of arthritis. 
Arthritis was induced in male DBA/1 mice and treated daily by IP injection with vehicle (5% 
mulgofen/ PBS) or 30 mg/kg GW3965 from day -1 to day 31. n =12/group. 
Similar to previous experiments, mice were monitored for clinical signs of 
disease. Treatment with 30 mg/Kg GW3965 significantly increased the clinical 
severity of arthritis (Figure  8.26). In agreement with the clinical score the 
extent of paw swelling was also greater in the group receiving 30 mg/Kg GW3965 
(Figure  8.27). Due to the short period of time in which disease was allowed to 
develop and the lack of time points the difference in paw swelling was not 
significant by Two Way ANOVA. However, the individual time points were 
significantly different by Students unpaired T test (not shown). 
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Figure  8.26 GW3965 increases the clinical severity of arthritis. 
Arthritis was induced in male DBA/1 mice and treated daily by IP injection with Vehicle (5% 
mulgofen/ PBS) or 30 mg/kg GW3965 from day -1 to day 31. Mice were monitored and 
assigned a clinical score as a measure of disease severity. Two Way ANOVA; ** P < 0.01. n 
=12/ group. 
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Figure  8.27 Paw swelling is increased by treatment with GW3965. 
Arthritis was induced in male DBA/1 mice and treated daily by IP injection with Vehicle (5% 
mulgofen/ PBS) or 30 mg/kg GW3965 from day -1 to day 31. Mice were monitored and the 
extent of paw swelling measured as an independent indicator of disease severity. The 
increase in paw swelling was not significant by Two Way ANOVA but the individual time 
points were significantly different by unpaired T test (not shown). n =12/ group. 
Upon termination of the experiment paws were fixed, decalcified and stained 
for histological analysis of articular inflammation and erosion (Figure  8.28). In 
the group receiving 30 mg/Kg GW3965 histological analysis revealed a marked 
inflammatory infiltrate, cartilage erosion and hyperplasia of the synovial 
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membrane. The overall extent of inflammation and erosion was significantly 
increased in the groups treated with GW3965. 
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Figure  8.28 Histological severity of arthritis is increased by GW3965. 
(A) Representative H & E staining of joints from mice receiving vehicle ( 5% mulgofen/ PBS) 
or 30 mg/kg GW3965. Photos at 10X magnification. Abbreviations; B = bone, C = cartilage, J 
= joint space and M = synovial membrane. Bone erosion is indicated by the arrow (B) 
Administration of 30mg/kg GW3965 (black bar) increases the amount of inflammatory 
infiltrate and the severity of erosion relative to vehicle (open bar). Mann Whitney-test; ** P < 
0.01. n = 12/ group. 
8.3.3.2 Ex vivo cytokine and anti-collagen antibody analysis 
Previously it was necessary to euthanize mice prior to completion of the full 
experimental time course which introduced a degree of variability in the results 
of ex vivo cytokine analysis. Therefore the shorter experimental time course was 
chosen to allow analysis of cytokines at the peak of disease and remove 
variability caused by individuals being culled at multiple time points. Multiple 
pro-inflammatory cytokines, IL-1, IL-6, IL-13, IL-17, GM-CSF, and inflammatory 
chemokines, MIP-1α, MCP-1, MIG, IP-10 and KC, were higher in the group treated 
with 30 mg/Kg GW3965 compared to vehicle controls (Figure  8.29 and Figure 
 8.30). In addition, there was no significant difference in the concentration of 
serum IL-10, IL-12 and FGF between the two groups. IL-2, IL-4, IL-5, TNFα and 
VEGF were not detected at this time point. 
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Figure  8.29 GW3965 increases the concentration of serum proinflammatory cytokines. 
Blood samples were removed from mice at day 31 of the CIA model by cardiac puncture and 
the concentration of serum cytokines was measured by Luminex. Student T test; * P < 0.05, 
*** P < 0.001. n =12/ group. 
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Figure  8.30 GW3965 increases the concentration of serum chemokines. 
The concentrations of multiple pro-inflammatory chemokines are increased in mice 
receiving 30 mg/kg GW3965 relative to vehicle as measured by Luminex analysis. Other 
inflammatory chemokines were below the level of detection. Unpaired Students T test; * P < 
0.05, *** P < 0.001. n = 12/group. 
To determine the effect of GW3965 upon T cell activation the popliteal and 
inguinal lymph nodes were removed and crushed through a cell strainer to 
generate a single cell suspension. The cells were stimulated overnight with PMA 
and Ionomycin and the percentage of CD4+ cells that were IFNγ+ (Th1) or IL-17+ 
(Th17) was analysed by flow cytometry (Figure  8.31). The percentage of Th1 
(CD4+, IFNγ+) and Th17 (CD4+, IL-17+) cells is higher in mice treated with GW3965 
relative to vehicle. However, the most striking difference was in the CD4- 
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population as there was a significant increase in the percentage of IL-17+ or 
IFNγ+ cells; the identity of which are unknown. 
 
Vehicle GW3965
0
1
2
3
4
5
6
7
8
9 *
%
 
CD
4+
IF
N
g+
Vehicle GW3965
0
10
20
30
***
%
 
CD
4-
 
IF
N
g+
Vehicle GW3965
0
10
20
30
40
***
To
ta
l %
 
IF
N
g+
Vehicle GW3965
0
1
2
3
*
%
 
CD
4+
IL
-
17
+
Vehicle GW3965
0
1
2
3
4
5
6
7
8
***
%
 
CD
4-
 
IL
-
17
+
Vehicle GW3965
0
1
2
3
4
5
6
7
8
9
10 ***
To
ta
l %
 
IL
-
17
+
 
Figure  8.31 Increased activation of lymph node cells by GW3965. 
The percentage of Th1 (CD4+, IFNγ+) and Th17 (CD4+, IL-17+) cells is higher in mice treated 
with GW3965 relative to vehicle (5% mulgofen/ PBS). There is also a significant increase in 
the percentage of CD4-, IL-17+ or IFNγ+. The identity of these cells is unknown. Unpaired 
Students T test; * P < 0.05, ** P < 0.001. n = 12/group. 
The concentration of serum anti-collagen antibodies was measured by ELISA. The 
titers of IgG2a and IgG1 anti-collagen antibodies were higher in the group 
receiving 30 mg/kg GW3965 relative to vehicle providing clear evidence of 
enhanced antigen specific adaptive responses in GW3965 treated mice (Figure 
 8.32).  
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Figure  8.32 Anti-collagen antibody titres are increased by GW3965. 
Serially diluted serum analysis of IgG2a and IgG1 anti-collagen antibodies in mice receiving 
30 mg/kg GW3965 relative to vehicle (5% mulgofen/ PBS).  Unpaired students T test * P < 
0.05, ** P < 0.01. n =12/ group. 
8.3.3.3 GW3965 induced activation of LXRs 
To confirm LXR activation by GW3965 the jejunum was removed six hours post 
drug administration and the expression of ABCA1 was measured by Taqman QRT-
PCR. The expression of ABCA1 was upregulated approximately twenty fold in the 
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GW3965 group relative to the vehicle control indicating robust transcriptional 
activation of LXRs (Figure  8.33). 
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Figure  8.33 Induction of LXR transcriptional activation by GW3965. 
The expression of the LXR reporter gene ABCA1 was measured by Taqman QRT-PCR in the 
jejunum of mice treated with 30 mg/Kg GW3965 or vehicle at the indicated concentration. 
Results are displayed as mean fold increase of ABCA1 expression relative to vehicle. n = 12/ 
group. Students T test; *** P < 0.001. 
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8.4 Discussion & conclusion  
Previous studies have suggested a regulatory role for LXRs upon inflammation. 
Therefore, this study was initiated to determine if LXR agonists could offer 
beneficial effects upon inflammation in the joint. However, contrary to my 
expectations, the incidence and severity of arthritis was markedly increased thus 
suggesting a novel pro-inflammatory role for LXRs.  
Preliminary experiments were set up to determine the optimal route of agonist 
administration. These studies demonstrated that IP injection was a suitable 
route for delivery of LXR agonists in vivo and was optimal for bioavailability LXR 
agonists in the tested tissues; liver and bone marrow. Early studies also 
addressed the use of 5% mulgofen/ PBS as a vehicle in which to deliver agonists. 
These were initiated under the premise that mulgofen may contribute towards 
the inflammatory aspect of arthritis and could be further amplified by LXR 
agonism and thereby potentially explaining the unexpected pro-inflammatory 
effect of LXR agonism. However, comparison of vehicle with PBS showed that 
there was no effect upon inflammation and the subsequent severity of arthritis. 
This suggests that any effect upon inflammation and the severity of disease are 
mediated specifically by drug administration. 
Initial experiments analysing the role of LXRs upon inflammation in arthritis 
were limited by the use of T1317 which increased the severity of disease in a 
dose responsive manner. However, in addition to LXR, T1317 has also been 
shown to agonise Pregnane X receptor (PXR) and Farnesoid X receptor (FXR) 
which primarily regulate carbohydrate, lipid and bile acid metabolism but their 
role in inflammation is as yet unknown (297, 298). Therefore, any observed 
effects could be at least in part attributed to non-specific activation of PXR and/ 
or FXR by T1317. In comparison GW3965 is highly specific and does not exert any 
known off target effects on any other nuclear receptors. Therefore, results 
obtained using GW3965 probably more accurately reflect the role of LXRs in 
inflammation. However, administration of 10 mg/Kg GW3965 did not 
significantly increase the severity of disease. It is possible that the concentration 
of 10 mg/kg GW3965 used was too low. Indeed, although the results were 
significant, 10 mg/kg T1317 had only a small effect upon serum cytokine and 
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chemokine concentrations (Figure  8.19). This is consistent with in vitro findings 
where the effect of GW3965 upon cytokine secretion is generally lower than that 
mediated by T1317(Figure  10.18). Furthermore, treatment of mice at a higher 
concentration, with 30 mg/Kg GW3965, significantly increased the severity of 
CIA. Although the use of these highly selective agonists suggest a specific pro-
inflammatory effect off target effects of LXR agonism can not be precluded and 
will be dealt with in subsequent studies in LXR deficient mice. 
The severity of disease was also increased by a longer time course of T1317 
administration (Figure  8.10). It is unlikely that this reflects accumulation of 
T1317 over a prolonged time course as the expression of ABCA1 was comparable 
between the early and late time courses of agonist administration; suggesting 
that the level of LXR activation, and therefore the tissue specific concentration 
of agonist, was similar between the two treatment groups. These results are 
therefore more likely to reflect the prolonged action of LXRs upon inflammatory 
pathways.  
We hypothesised that LXR agonism would be therapeutic in CIA. Mice were 
therefore treated with drugs up to day 42 as it was unknown in which phase of 
disease LXR agonists would have an effect i.e. the priming or resolution phase of 
disease. However, LXR agonists dramatically increased the severity of disease 
and as such individuals had to be euthanised at multiple time points to comply 
with Home Office regulations. This therefore introduced a large degree of 
variability making it difficult to draw firm conclusions from my first ex vivo 
analysis. This is exemplified in the groups treated with 20 mg/Kg T1317 in which 
although clinical signs of disease were markedly increased, i.e. clinical score and 
paw thickness, there was little or no effect upon serum cytokine/chemokine 
concentrations, lymphocyte activation and anti-collagen antibody titres. CIA in 
the DBA/1 mouse has been well characterised - the severity of disease peaks at 
approximately day 34 after which the anti-inflammatory cytokines IL-10 and 
TGF-β are upregulated leading to inhibition of inflammation and resolution of 
disease. It was therefore necessary to terminate the experiment at an earlier 
time point in subsequent studies in order to accurately analyse the effect of LXR 
agonism upon pro-inflammatory mediators at the peak of disease. As such in 
later experiments, C57BL/6 mice were treated with 30 mg/Kg of GW3965 up to 
day 31 post induction of arthritis in which the level of proinflammatory 
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cytokines/ chemokines, lymphocyte activation and anti-collagen antibody titres 
were clearly elevated compared to controls.  
Together these data support a pro-inflammatory role for LXRs however the 
mechanism whereby LXR agonists promote articular inflammation in vivo is not 
clear. The numbers of activated lymphocytes were increased by LXR agonism 
characterised by an increased number of IL-17 and IFNγ secreting cells 
suggesting amplification of effector T cell subsets, namely Th1 and Th17 cells. 
Interestingly, there was also a substantial increase in the proportion of CD4- IFNγ 
and IL-17 positive cells which likely comprise multiple cell types including NK 
cells, γδ T cells, CD8+ T cells and macrophages (174, 175). Since the effect of 
LXR agonism is not limited to a specific cell type it is possible that the 
amplification of a pro-inflammatory cytokine milieu in vivo is capable of 
supporting T cell differentiation, characterized by increased serum 
concentrations of IL-6, IL-12 and IL-23. Additionally, the increased concentration 
of anti-collagen specific antibodies further suggests that LXR agonism was able 
to exert a general, but context specific, pro-inflammatory effect and thereby 
enhance both the innate and adaptive immune responses. Further, studies will 
therefore be required to identify the affects of LXR agonism on the activation 
and differentiation of specific inflammatory cell types. 
Both T1317 and GW3965 are dual LXR agonists and therefore induce the 
activation of both LXRα and LXRβ. The individual role of LXRα and LXRβ is 
currently being studied in the context of atherosclerosis in which it is evident 
that agonists specifically targeting LXRβ may be more favourable for 
ameliorating atherosclerotic lesions (37, 101, 102, 299). LXR agonism has been 
shown to result in hepatic steatosis in the ApoE-/- model of atherosclerosis. It is 
therefore possible that hepatic steatosis could operate as a potential driver of 
acute phase responses and hence inflammation and thereby enhance disease 
severity. Indeed, in preliminary experiments in which mice were treated for 
seven days with T1317 the expression of FAS, the rate limiting enzyme involved 
in lipogenesis, was significantly upregulated which has been shown to lead to the 
accumulation of triglycerides within the liver (Figure  8.3). The effect of 
prolonged agonist treatment in the CIA model upon hepatic FAS expression and 
lipid accumulation was not tested; this will be addressed in ongoing studies using 
LXR knockout animals. The effect of LXR agonism upon driving hepatic steatosis 
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is lost in ApoE-/-, LXRα-/- double knockout mice. It is now well accepted that 
hepatic steatosis by LXR agonism is primarily driven by LXRα. Therefore, as 
discrete functions are emerging in metabolism, it is also possible that LXRα or 
LXRβ may have different, and potentially opposing, roles in inflammation. 
Further studies are required to identify the individual role of LXRα and LXRβ on 
immune pathways.  
The data obtained from these experiments contradict the work by 
Chintalacharuvu et al, who reported that treatment of established CIA with 
T1317 yielded beneficial effects; i.e. reduced disease severity (125). However, 
there are differences between the two studies. Firstly, Chintalacharuvu et al 
used oral gavage for administration of T1317 whereas we administered all drugs 
IP. Interestingly my preliminary experiments demonstrated that, in comparison 
to IP, oral gavage of T1317 did not induce the expression of ABCA1 in the bone 
marrow suggesting restricted bioavailability of agonist when administered by 
oral gavage. Furthermore, administration of dexamethasone was suppressive 
showing that there were no unexpected adverse effects of multiple IP injections. 
Secondly, the treatment protocols and drug dose are not identical. In other 
studies, T1317 was used at 50 mg/Kg over a much shorter time course, day 27 to 
day 33 post induction of arthritis, with no evidence of dose dependent effects at 
lower agonist concentrations. It is therefore possible that T1317 when used at 
such high concentrations may exert non-specific effects promoting anti-
inflammatory pathways. In addition, these data were not reproduced using the 
highly specific LXR agonist GW3965 or supported by data from LXR deficient 
animals. The precise effects of T1317 upon LXR activation at such high 
concentrations has not previously been reported in the literature. 
Chintalacharuvu et al did not document LXR activation in their model and it is 
therefore possible that increasing concentrations of T1317 may exert 
unrecognised bi-phasic effects upon the activation of LXRs. 
In conclusion, the precise mechanism in which LXRs are able to augment 
articular inflammation is not clear. However, my data suggest that the 
mechanism in vivo is in part through the ability to exacerbate the secretion of 
proinflammatory chemokines and cytokines and thereby enhance the 
recruitment and activation of inflammatory cells to the site of inflammation. In 
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subsequent chapters I shall describe experiments designed to further explore 
these possibilities. 
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9 Exacerbation of articular Inflammation is 
specific to the activation of Liver X Receptors  
  143 
9.1 Introduction & Aim  
Several studies have suggested a novel role for LXRs in inflammation in which 
pharmacological activation of LXRs was generally ascribed an anti-inflammatory 
effect (19, 104, 117, 121). These initial studies demonstrated that activation of 
LXRs would be beneficial for the treatment of human inflammatory disorders. I 
therefore previously sought to determine the effect of LXR activation upon 
inflammation in RA by utilising the murine model of CIA. However, contrary to 
my expectations and other observations in the literature (125), LXR agonism 
exerted potent pro-inflammatory effects and markedly accelerated the time of 
onset and severity of arthritis. In an attempt to prove that the pro-inflammatory 
effect was mediated specifically through the activation of LXRs two 
pharmacologically distinct LXR agonists were used; GW3965 and T1317. Both 
compounds are widely used LXRs agonists; however, whilst both agonists 
demonstrate similar efficacy in murine models of atherosclerosis it is well 
recognised that T1317 activates the nuclear receptors FXR and PXR non-
specifically (297, 298). Moreover, whereas GW3965 is considered to be highly 
specific and does not induce the activation of other nuclear receptors, off target 
effects of GW3965 cannot be discounted as a potential explanation for the 
unexpected pro-inflammatory effects observed in vivo. 
CIA has been widely used as a murine model of arthritis in which susceptibility is 
restricted to strains, such as DBA/1 mice, with the MHC Class II I-Aq haplotype 
(222). Most transgenic mice, including currently available LXRα-/- and LXRβ-/-
mice, are on the C57BL/6 background which is generally considered resistant to 
CIA. However, with the recent development of a refined protocol it is now 
possible to induce CIA in C57BL/6 mice and therefore study the effect of LXR 
agonist administration in LXR deficient mice (225). I therefore sought to 
determine if the pro-inflammatory effects of LXR agonists in the murine 
collagen-induced arthritis model was mediated specifically by the activation of 
LXRs. 
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9.2 Induction of CIA in C57BL/6 mice 
It was first necessary to ensure that CIA could be induced in the C57BL/6 strain. 
Following the protocol by Inglis et al, arthritis was induced in male wild-type 
C57BL/6 mice at 10 weeks of age by inoculation with 200 µg of type II chicken 
collagen/ CFA injected intradermally at the base of the tail (225). Three weeks 
later (day 21) mice were challenged with 200 µg type II collagen/ PBS injected IP 
and monitored for clinical signs of disease. Arthritis was evident from day 21 
onwards and consistent with the findings of Inglis et al 50% of the animals had 
developed clinical signs of arthritis by day 40 (Figure  9.1). The severity of 
disease was also monitored and increased from day 21 onwards. However, unlike 
arthritis in the DBA/1 mice that is self remitting the severity of disease in the 
C57BL/6 mice was maintained for up to ten weeks post induction of arthritis 
(Figure  9.2). These experiments provided evidence that arthritis could 
successfully be induced in the C57BL/6 strain of mice by this protocol. 
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Figure  9.1 Incidence of arthritis in wild-type C57BL/6 mice. 
Arthritis was induced in male C57BL/6 mice at 10 weeks of age following the published 
protocol by Inglis et al (225). Mice were monitored from day 21 onwards for clinical signs of 
disease. n = 10. 
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Figure  9.2 Chronic arthritis in C57BL/6 mice. 
The severity of arthritis in C57BL/6 mice was monitored from day 21 onwards. Mice were 
assigned a clinical score (A) whilst paw swelling was measured as an independent measure 
of disease severity (B). The severity of disease was maintained for up to 10 weeks at which 
point the experiment was terminated. n = 10.  
9.3 Generation of LXR double KO mice 
LXRα-/- and LXRβ-/- (single knockouts) have been generated to study the role of 
LXRs in atherosclerosis however, the effect of LXR deficiency and the role of the 
individual LXR isoforms in the context of inflammation is unknown (101, 102). 
Deletion of LXRα or LXRβ is associated with increased susceptibility to 
atherosclerotic plaque formation and enhanced autoimmunity, this is in part 
mediated through the inability to clear apoptotic thymocytes and B cells (300).  
Both LXRα and LXRβ share some of the same target genes; e.g. ABCA1/ G1, LDLR 
A 
B 
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and NPC-1 (49, 83-85), which suggests that deficiency of one isoform may be 
potentially compensated by the other. Additionally, T1317 and GW3965 are dual 
LXRα/ LXRβ agonists therefore the pro-inflammatory effect of LXR agonism may 
be mediated by either LXRα or LXRβ. Therefore, to further investigate the 
individual role for LXRα and LXRβ and demonstrate an LXR specific pro-
inflammatory effect of GW3965 administration in arthritis it was necessary to 
generate LXRα/β double KO mice (LXRα/β KO). A schematic of the breeding 
programme is illustrated in Figure  9.3. LXRα-/- and LXRβ-/- mice, supplied by 
Schering Plough, were crossed to generate LXRα/β heterozygotes (LXRα+/-, 
LXRβ+/-) (F1 generation); this was confirmed by PCR screening of the LXRβ 
genotype of genomic DNA (Figure  9.4). Seven breeding pairs from the F1 were 
set up and self-crossed to generate the F2 offspring which were all screened by 
PCR for the LXRα and LXRβ genotype. All the potential genotypes are illustrated 
in Figure  9.3 and the chance of generating an LXRα/β KO mouse, of either sex, is 
1:16. Three LXRα/β KO mice were generated; two females #15 and #24 and one 
male #22 (Figure  9.5). From these three mice female #15 and male #24 were 
selected for further breeding to generate more breeding pairs (F3 generation) to 
setup an LXRα/β KO breeding colony. The genotype of the F3 was confirmed by 
PCR screening to be LXRα/β KO before further breeding was allowed (Figure 
 9.6).  
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Genotype α+,β+ α+,β- α-,β+ α-,β- 
α+,β+ α+/+,β+/+ α+/+,β+/- α+/-,β+/+ α+/-,β+/- 
α+,β- α+/+,β-/- α+/+,β-/- α+/-,β+/- α+/-,β-/- 
α-,β+ α+/-,β+/+ α+/-,β+/- α-/-,β+/+ α-/-,β+/- 
α-,β- α+/-,β+/- α+/-,β-/- α-/-,β+/- α-/-,β-/- 
Figure  9.3 Generation of the LXR alpha/beta double knockout mice 
A schematic showing generation of the LXRα/β KO mice. LXRα-/- mice were crossed with 
LXRβ-/- mice to generate LXR α/β heterozygotes (F1). The F1 generation was then self 
crossed (F1 X F1) to generate the LXR double KO mice (F2). The table demonstrates all the 
potential genotypes that can arise from the F1 cross and giving a 1:16 chance of generating 
an LXRα/β double knockout mouse of either sex. 
 
 
F2: 
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Figure  9.4 Generation of LXR heterozygotes: F1 generation. 
Tail tips from potential LXRα/β heterozygotes were digested and the genomic DNA extracted 
(see materials & methods). A PCR of genomic DNA for LXRβ was used to confirm the 
genotype which was visualised on a 2% agarose gel; LXRβ KO ~640 bp and LXRβ WT ~ 
437bp. Molecular weight ladder (MW) and samples 1 to 14. 
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Figure  9.5 Generation of LXRα/β double KO mice: F2 generation. 
Tail tips from potential LXRα/β double KO were digested and the genomic DNA extracted 
(see materials & methods). A PCR of genomic DNA for LXRβ (A, C) and LXRα (B, D) was 
used to confirm the genotype which was visualised on a 2% agarose gel against a molecular 
weight ladder (MW). LXRβ KO ~640 bp and LXRβ WT ~437bp, LXRα KO ~470 bp and LXRα 
WT ~880 bp. Number 15, 24 and 22 were LXRα/β KO; the later was the only male.  
C 
B 
D 
A 
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Figure  9.6 Confirmation of LXRα/β double knockout genotype in F3 offspring. 
(A) Schematic showing that LXRα/β KO mice (F2) were self crossed to generate breeding 
pairs for an LXRα/β KO breeding colony (F3). PCR screening of genomic DNA for LXRβ (B) 
LXRα (C) was visualised on a 2% agarose gel against a molecular weight ladder (MW). LXRβ 
KO ~640 bp and LXRβ WT ~437 bp, LXRα KO ~470 bp and LXRα WT ~880 bp. 
B 
C 
A 
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9.4 Induction of CIA in LXR deficient mice 
9.4.1 The effect of GW3965 in arthritis is mediated specifically by 
activation of LXRs 
With the successful generation of the LXRα/β KO mice and confirmation that it is 
possible to induce CIA in the C57BL/6 strain of mice it was possible to proceed 
and determine if the pro-inflammatory effects of GW3965 in arthritis were 
mediated specifically by agonism of LXRs. Arthritis was induced in male wild-
type, LXRα-/-, LXRβ-/- or LXRα/β KO mice at approximately 8-11 weeks of age 
following the protocol described by Inglis et al (225). GW3965 is a highly specific 
LXR agonist and as a dose of 30 mg/Kg was previously used with the greatest 
pro-inflammatory effect in arthritis this dosing regime was taken forward for 
future studies. Mice were therefore treated with 30 mg/Kg GW3965 or vehicle 
(5% mulgofen/ PBS) from day -1 to day 37. A schematic of the experimental 
design is described in Figure  9.7 and the number of mice in each group is shown 
in Table  9.1. The results of the study are pooled from three independent 
experiments in which each genotype had equal numbers of mice treated with 
GW3965 as with vehicle in the same experiment. The mice were monitored daily 
from the start of the experiment for the development of clinical arthritis. The 
incidence of arthritis was comparable between all the genotypes and did not 
differ between the groups treated with vehicle or GW3965 (Figure  9.8); these 
data are also tabulated in Table  9.1. 
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Figure  9.7 Experimental design for the induction of arthritis in LXR deficient mice. 
 
Treatment Group Vehicle 30 mg/Kg GW3965 
Genotype Subjects Incident (%) Subjects Incident (%) 
WT 19 10 (52) 18 9 (50) 
LXRα-/- 27 13 (48) 26 12 (46) 
LXRβ-/- 18 9 (50) 24 10 (42) 
LXRα/β KO 9 5 (55) 10 5 (50) 
Table  9.1 The incidence of arthritis in wild-type and LXR deficient mice. 
Arthritis was induced in male mice at approximately 8-11 weeks of age on the C57BL/6 
background; either wild-type (WT), LXRα-/-, LXRβ-/- or LXRα/β KO. Mice were treated daily 
with vehicle (5% mulgofen/PBS) or 30 mg/Kg GW3965 by IP injection. Mice were monitored 
daily for the first signs of clinical arthritis. The number of mice that were entered into the 
study (subjects) and the number (and percentage) of incident mice are described for each 
treatment group of each genotype. Results are pooled from three independent experiments.  
The development of arthritis was monitored from day 21 onwards and mice were 
assigned a clinical score based upon the severity of arthritis as before and 
described in materials & methods (Figure  9.9). In support of a pro-inflammatory 
effect of LXR agonism the severity of disease was significantly increased in wild-
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type mice treated with GW3965 relative to vehicle. This was specific to wild-
type mice as there was no significant difference in the severity of disease in 
LXRα-/- (P = 0.09), LXRβ-/- (P = 0.73) or LXRα/β KO (P = 0.62) treated with 30 
mg/Kg GW3965 compared to vehicle. Similarly, the extent of paw swelling was 
measured as an independent measure of disease severity which was significantly 
increased in wild-type mice receiving GW3965 compared to vehicle (Figure 
 9.10). Consistent with the clinical score there was no significant difference in 
the paw swelling of LXRα-/- (P = 0.3017), LXRβ-/- (P = 0.671) or LXRα/β KO (P = 
0.063) mice treated with GW3965 relative to vehicle controls.  
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Figure  9.8 The incidence of arthritis in LXR deficient mice. 
Arthritis was induced in male mice at approximately 8-11 weeks of age on the C57BL/6 
background; either wild-type (WT), LXRα-/-, LXRβ-/- or LXRα/β KO. Mice were treated daily 
with vehicle (5% mulgofen/PBS) or 30 mg/Kg GW3965 by IP injection. Mice were monitored 
daily from day 21 onwards for the first signs of clinical arthritis. Results are pooled from 
three independent experiments and are also tabulated in Table  9.1. 
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Figure  9.9 Increased severity of clinical arthritis is mediated specifically by LXRs. 
Arthritis was induced in male mice at approximately 8-11 weeks of age on the C57BL/6 
background; either wild-type (WT), LXRα-/-, LXRβ-/- or LXRα/β KO. Mice were treated daily 
with vehicle (5% mulgofen/PBS) (dotted lines) or 30 mg/Kg GW3965 (solid lines) by IP 
injection. Mice were monitored daily and assigned a clinical score as a measure of arthritis 
severity. Results are pooled from three independent experiments. The number of 
contributing animals is shown in Table  9.1. Two way ANOVA; * P < 0.05, not significant (n/s), 
with respect to GW3965 vs. vehicle within the same genotype. 
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Figure  9.10 Increased paw swelling is mediated specifically by LXRs. 
Arthritis was induced in male mice at approximately 8-11 weeks of age on the C57BL/6 
background; either wild-type (WT), LXRα-/-, LXRβ-/- or LXRα/β KO. Mice were treated daily 
with vehicle (5% mulgofen/PBS) (dotted lines) or 30 mg/Kg GW3965 (solid lines) by IP 
injection. Mice were monitored daily and paw thickness was measured as an independent 
measure of arthritis severity. Results are pooled from three independent experiments. The 
number of contributing animals is shown in Table  9.1. Two way ANOVA; ** P < 0.01, not 
significant (n/s), with respect to GW3965 vs. vehicle within the same genotype. 
 
 
 
 
  156 
9.4.2 The induction ABCA1 expression is diminished in LXR 
deficient mice 
To confirm LXR activation, and loss of LXR induced transcription in LXR deficient 
mice, the jejunum was removed from mice at day 37 and snap frozen for RNA 
extraction. Nine samples were chosen at random representative of each group 
and the expression of ABCA1 was measured by Taqman QRT-PCR (Figure  9.11). 
Similar to previous results treatment of wild-type mice with 30 mg/Kg GW3965 
induced an approximate 15 fold increase in the expression of ABCA1 (compare to 
Figure  9.11 to Figure  8.33) . As expected the expression of ABCA1 was also 
significantly increased in LXRα-/- mice treated with GW3965 and to a lesser 
extent in LXRβ-/- by approximately eight and four fold respectively (37, 101, 
102). The expression of ABCA1 in LXRα/β KO mice was not significantly different 
between the vehicle and GW3965 treated group (P = 0.235); however, the basal 
level of ABCA1 expression was approximately three fold higher compared to 
wild-type mice also treated with vehicle. 
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Figure  9.11 Induction of ABCA1 expression is diminished in LXR null mice. 
Arthritis was induced in wild-type (WT), LXRα-/-, LXRβ-/- or LXRα/β KO. Mice were treated 
daily with vehicle (5% mulgofen/PBS) (white bars) or 30 mg/Kg GW3965 (black bars) by IP 
injection. At cull jejunum was removed and the RNA extracted for gene expression analysis 
of ABCA1 by Taqman QRT-PCR. n = 9 per group, chosen at random which are 
representative of each genotype and treatment group. Students T test; *** P < 0.001, not 
significant (n/s) (relative to vehicle group within the same genotype). 
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9.5 Discussion & conclusion 
My previous studies suggested a novel pro-inflammatory effect of LXR agonism in 
the context of arthritis. However, these results were controversial to another 
study in the literature (125) and off target effects attributable to T1317 or 
GW3965 could not be discounted as potential drivers of inflammation and 
increased disease severity in CIA. Therefore, this study was initiated to 
determine if the pro-inflammatory effect observed upon administration of LXR 
agonists was mediated specifically by LXRs. Administration of GW3965 markedly 
increased the severity of arthritis in wild-type mice but not in LXRα-/-, LXRβ-/- or 
LXRα/β KO suggesting a specific pro-inflammatory effect of dual LXRα/ LXRβ 
activation. 
LXRα-/- and LXRβ-/- mice are on the C57BL/6 background which is generally 
considered resistant to CIA. However, Inglis et al recently published a study 
describing a detailed protocol for the induction of arthritis in C57BL/6 mice 
(225). Indeed, my preliminary experiments demonstrated that arthritis could be 
induced successfully in C57BL/6 following this protocol. However, it remains 
evident that C57BL/6 mice are generally more resistant to the development of 
arthritis than other strains of mice as disease is only observed in 50% of mice 
(Figure  9.1 and Figure  9.8), similar to previous reports (225, 301), in comparison 
to 80 to 100% incidence in DBA/1. Furthermore, the severity of disease is 
generally lower but more chronic in the C57BL/6, in comparison with DBA/1 
mice, and is characterised with a sustained T cell response and anti-type II 
collagen antibodies (301). Consistent with these findings, DBA/1 mice treated 
with 30 mg/Kg GW3965 exhibited a mean arthritis score of 12 compared to 7 in 
C57BL/6 mice (compare Figure  8.26 to Figure  9.9). Although the ability to induce 
CIA in C57BL/6 mice is an extremely useful model the direct comparison of CIA, 
and the effect of LXR agonism, to DBA/1 is precluded.  
To date the mechanism by which LXRs modulate inflammation is not fully 
understood and the individual role of LXRα or LXRβ in an inflammatory context is 
unknown. GW3965 and T1317 induce the activation of both LXR isoforms 
simultaneously and as isoform specific agonists have not been developed LXR KO 
mice are required to study the individual role of LXRα or LXRβ. Several studies 
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have also demonstrated that in mice deficient of either LXRα or LXRβ the 
expression of some LXR target genes is maintained by the intact LXR isoform; for 
example the induction of ABCA1 expression is maintained in LXRα-/- mice (37, 
101, 102). Therefore, to demonstrate that the pro-inflammatory effect observed 
with GW3965 administration was mediated specifically by LXRs it was necessary 
to generate LXRα/β KO mice. Secondly, by inducing arthritis in LXRα-/- and LXRβ-
/- mice this will aid elucidation of the individual roles of the LXRs in 
inflammation. LXR deficient mice have been generated previously and whilst 
they are more susceptible to atherosclerosis i.e. increased LDL but reduced HDL 
cholesterol and accumulation of foam cells in arterial vessel walls, no other 
severe adverse phenotypes have been reported (299, 302). Indeed, this is the 
first study in which the individual role of LXRα and LXRβ has been assessed in 
inflammation in vivo. Administration of 30 mg/Kg GW3965 significantly increased 
the severity of disease in wild-type but not LXR deficient mice. However, there 
was a large, but non-significant, increase in the paw swelling and clinical score 
in the LXRα/β KO mice treated with GW3965 relative to vehicle. This is primarily 
caused by a high degree of variability and a lack of mice entered into these 
groups. Throughout these studies I have found that LXRα/β KO mice, but not 
LXRα-/- or LXRβ-/-, are poor breeders and produce small litters generally between 
one to four pups. These observations have also been confirmed through personal 
communication with Prof David Mangelsdorf (Southwestern Medical Center, 
University of Texas). Due to the lack of mice the LXRα/β KO group is under 
powered. However, disease severity is not altered in the LXRα-/- or LXRβ-/- 
groups by treatment with GW3965. This suggests that the pro-inflammatory 
effect of GW3965 administration was mediated specifically by LXRs and not off 
target effects. Furthermore, these data suggest that cooperation between the 
two LXR isoforms or downstream effects is required to drive inflammatory 
pathways; at least in the context of arthritis.  
LXRs have been primarily studied in the context of metabolism in which LXRα 
has been shown to primarily regulate the expression of genes involved 
lipogenesis (synthesis of fatty acids and triglycerides) whilst LXRβ regulates the 
expression of genes involved in lipid transport and adipocyte gene expression 
(75, 112, 303). In particular LXRα regulates the expression of FAS and SREBP-1c 
in the liver and prolonged treatment of LXRβ-/- mice with GW3965 or T1317 has 
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been shown to cause the development of hepatic steatosis; a potential driver of 
inflammation in arthritis (33, 81, 92). However, the severity of disease is not 
increased in LXRβ-/- mice that express LXRα. Although I have not measured lipid 
fatty acids and triglyceride concentrations these data suggest that hepatic 
steatosis is not the driver of inflammation and disease severity in arthritis. 
However, of interest the severity of arthritis in the vehicle treated groups is 
elevated in all the LXR deficient genotypes compared to wild-type mice (Figure 
 9.9 and Figure  9.10). The reason for this is unknown; however, as LXR null mice 
develop atherosclerosis it is clear that lipid pathways mediated by LXRs are 
impaired in LXR deficient mice. This may exert functional consequences upon 
inflammation in arthritis as several reports have demonstrated that deletion of 
the cholesterol transporter ABCA1, which is primarily regulated by LXRs, 
enhances the inflammatory response. Deletion of ABCA1 promotes macrophage 
polarisation to an M1 phenotype; increased STAT6 signalling, NF-κB activation 
and pro-inflammatory cytokine secretion, and neutrophil activation in vivo (304-
307). Further in detail analysis of the innate and adaptive immune response 
including analysis of T cell phenotype, serum cytokines and antibodies is 
therefore required to determine the effect of LXR deletion upon inflammation in 
arthritis.  
The expression of ABCA1 is regulated by both LXRα and LXRβ and is increased by 
approximately 13 fold in the jejunum of wild-type mice treated with GW3965 
confirming activation of LXRs (96). Consistent with previous reports induction of 
ABCA1 expression was diminished in LXRα-/- mice but to a greater extent in LXRβ-
/- (302). However, in LXRα/β KO mice although the expression of ABCA1 was not 
altered by GW3965 the basal level of ABCA1 expression was approximately three 
fold higher in LXRα/β KO mice compared to wild-type vehicle treated mice. The 
reason for this is unknown. However, inflammation inhibits reverse cholesterol 
transport in vivo in part mediated by the decreased expression of ABCA1 (308). 
Indeed my own data demonstrates that the expression of ABCA1 is decreased in 
murine LPS stimulated macrophages (Figure  10.7); similar results have also been 
demonstrated in murine kidney cells (41). Inhibition of ABCA1 expression has 
been suggested to be mediated in part through decreased LXRα expression and 
activation. Indeed, the recruitment of co-repressor complexes, e.g. NCoR, is a 
mechanism by which LXRs have been shown to repress the transcription of 
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several target genes including ABCA1, FAS and SREBP-1c  (53). Therefore, 
inflammation may exert inhibitory effects mediated by LXRs upon the expression 
of LXR target genes which will be lost in LXRα/β KO mice potentially leading to 
elevated levels ABCA1 expression. However, further studies are required to 
confirm this hypothesis by examination of NCoR, and other co-repressors, 
recruitment to LXR heterodimers under an inflammatory context. 
These data suggest that the increased severity of arthritis is mediated 
specifically through the activation of LXRα and LXRβ. However, the mechanism 
by which LXR agonism potentiates inflammation in the context of arthritis is 
unknown. Further studies are therefore required to elucidate the function of 
LXRα and LXRβ and the separate pathways they induce in an inflammatory 
context. 
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10 Analysis of Liver X Receptor activation in 
human & murine leukocytes 
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10.1 Aim & introduction 
Whilst it is evident from other studies that activation of LXRs may exert anti-
inflammatory effects my prior data clearly demonstrated that specific 
pharmacological activation of LXRs can promote inflammation in vivo in murine 
CIA. However, the potential role for LXRs in RA disease derived cells or tissues 
remains unknown. 
The primary site of inflammation in RA is the synovium which contains high 
numbers of activated immune cells; macrophages, T cells, B cells and stromal 
derived fibroblasts in close proximity. Although the etiology of RA is unknown 
several mechanisms have been suggested by which inflammation in RA may be 
initiated and/or persist. Several studies have demonstrated increased expression 
of TLR3, TLR4 and TLR7/8 on RA derived synovial tissue leading to the 
hypothesis that viral and/or bacterial infection may promote synovitis (150, 
152). Whilst various potential bacterial derived TLR ligands have been detected 
within the synovium more recently the presence of endogenous self ligands such 
as RNA and heat shock proteins released from necrotic synoviocytes have been 
shown to stimulate TLRs (149, 153). This observation not only provides support 
for a role for TLRs in mediating synovial inflammation but also suggests that the 
local environment within the synovium may potentiate the inflammatory 
response. Leukocyte activation may also occur through cellular interactions by a 
mechanism which is distinct from TLR ligation. For example, co-culture of 
synovial membrane derived T cells with syngeneic macrophages induces the 
secretion of macrophage derived TNFα in a cell contact dependent manner (162, 
198). This can be recapitulated in an in vitro ‘contact assay’ by co-culture of 
cytokine-activated T cells (TcKs) with MCSF matured macrophages as an in vitro 
model of synovitis.  
Although several studies have analysed the role of LXRs in inflammation these 
have been generally restricted to murine cells or rodent models of human 
disease. Both LXRα and LXRβ have been shown to be expressed in a wide number 
of human immune cells including monocytes/ macrophages, T cells, dendritic 
cells, neutrophils and B cells (16-19, 118). However, how activation of LXRs 
affects inflammatory pathways in human cells, specifically in RA, and the 
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downstream impact upon human RA disease pathology remains unknown. I 
therefore sought to determine how LXR agonism may impact upon inflammatory 
pathways in human cells that are relevant to RA disease pathology. 
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10.2 LXR activation exerts differential species specific 
effects upon TLR4 stimulation  
10.2.1 Optimisation of in vitro LXR agonist concentrations 
The LXR agonists T1317 and GW3965 have been widely used as a tool to study 
the role of LXRs in physiology and disease. However, they have been utilised 
over a wide range of concentrations, especially in vitro, from as low as 0.01 µM 
up to 100 µM (33). To determine an optimal concentration range of T1317 which 
sufficiently induces the expression of LXR target genes, monocytes were purified 
from the peripheral blood of healthy volunteers and treated with vehicle (DMSO) 
or T1317 for twenty four hours. A range of 2 µM to 20 µM T1317 was selected 
from initial pharmacological studies which identified T1317 as an LXR agonist in 
mice (33). The RNA was extracted and analysed by Taqman QRT-PCR from which 
the fold increase of ABCA1 expression was used as a reporter of LXR activation 
(Figure  10.1). T1317 induced the expression of ABCA1 at all concentrations by 
approximately 8 fold at 2 µM T1317 to 12 fold with 20 µM T1317 relative to 
media alone. However, there was no difference in the expression of ABCA1 
above 6 µM T1317 suggesting maximal stimulation had been achieved. Therefore, 
to identify a sub-optimal concentration range of T1317 which induced the 
expression of ABCA1 in a dose-responsive manner, primary human monocytes 
were treated with vehicle or 0.01 µM to 4 µM T1317. The expression of ABCA1 
was measured by Taqman QRT-PCR to determine the level of LXR transcriptional 
activation (Figure  10.2). T1317 induced the expression of ABCA1 in a dose 
responsive manner by approximately 10 to 40 fold with 0.01 µM and 4 µM T1317 
respectively. T1317 has been shown to non-specifically activate PXR and FXR and 
as the expression of the LXR specific reporter gene ABCA1 was not different with 
concentrations of T1317 above 4 µM, concentrations of T1317 between 0.01 µM 
and 4 µM were selected for future human in vitro analysis (297, 298). 
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Figure  10.1 Induction of LXR activation by T1317 in primary human monocytes. 
Primary human monocytes were cultured with media alone, vehicle (V - DMSO) or T1317 at 
the indicated concentrations for 24 hours. The fold increase of ABCA1 expression relative 
to cells treated with media alone was measured by Taqman QRT-PCR and normalised to 
TATA binding protein (TBP). Each condition was tested in triplicate. 
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Figure  10.2 The expression of ABCA1 is induced with by T1317 with concentrations between 
0.01 to 4 µM. 
Primary human monocytes were cultured with media alone, vehicle (V - DMSO) or T1317 at 
the indicated concentrations for 24 hours. The fold increase of ABCA1 expression relative 
to cells treated with media alone was measured by Taqman QRT-PCR normalised to TAT 
binding protein (TBP). Each condition was tested in triplicate. 
10.2.2 LXR activation inhibits IL-6 secretion from TLR 
stimulated murine macrophages. 
A regulatory role for LXR activation upon pro-inflammatory cytokine secretion 
was first demonstrated by Joseph et al in which LXR agonism suppressed the 
expression of iNOS in murine macrophages stimulated with LPS or infected with 
E.coli (117). To confirm this anti-inflammatory effect of LXR agonism, bone 
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marrow derived macrophages (BMDM) from male wild-type C57BL/6 mice were 
treated with 1 µM to 4 µM GW3965, concentrations similar to that used by 
Joseph et al, for 24 hours and then stimulated with 100 ng/ml LPS. After twenty 
four hours, the concentration of the secreted pro-inflammatory cytokine IL-6 
was measured by ELISA (Figure  10.3). Treatment of LPS stimulated macrophages 
with GW3965 significantly inhibited the secretion of the pro-inflammatory 
cytokine IL-6. These data were consistent with prior observations and confirmed 
that my methodological approach was sufficiently sound to address the relative 
contribution of LXRs towards cytokine secretion. 
More recent reports in human monocytes suggested that LXR agonists could exert 
differential effects upon the secretion of pro-inflammatory cytokines dependent 
upon the length of time that cells were pre-incubated with LXR agonists (61). 
Therefore, to determine if different pre-incubation times might effect the 
secretion of IL-6 murine BMDMs were pre-incubated with 4 µM GW3965 for 6 hrs, 
9 hrs, 24 hrs and 48 hrs; time points which are comparable to the previous 
report, prior to stimulation with 100 ng/ml LPS (Figure  10.4). The concentration 
of IL-6 secreted into the cell culture supernatants was significantly decreased at 
all time points but to a greater extent with longer periods of GW3965 pre-
incubation.  
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Figure  10.3 LXR agonism inhibits the secretion of IL-6 from LPS stimulated murine 
macrophages. 
Bone marrow derived macrophages were treated with media alone (0), vehicle (V – DMSO) 
or GW3965 at the indicated concentrations for 24 hours after which they were stimulated 
with 100 ng/ml LPS. The concentration of IL-6 was measured by ELISA. Each condition was 
tested in triplicate with macrophages derived from 5 individual mice. Students T test; ** P < 
0.01, *** P < 0.001. 
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Figure  10.4 Prolonged pre-incubation with GW3965 further inhibits the secretion of IL-6. 
Bone marrow derived macrophages were treated with 4 µM GW3965 for the indicated 
number of hours or vehicle (V –DMSO) for 48 hours prior to stimulation with 100 ng/ml LPS. 
The concentration of IL-6 was measured by ELISA. Each condition was tested in triplicate 
with macrophages derived from 5 individual mice. Students T test; * P < 0.05, ** P < 0.01, *** 
P < 0.001. 
My results are consistent with the studies of Joseph et al (117) which suggested 
an anti-inflammatory effect of LXR activation in the context of bacterial 
infection and TLR4 ligation in murine macrophages. However, the effect of LXR 
agonism upon pro-inflammatory cytokine secretion mediated by the ligation of 
other TLRs was unknown. BMDMs were pre-incubated for 48 hrs with 4 µM 
GW3965 prior to stimulation with various TLR ligands; 100 ng/ml LPS (TLR4), 1 
µg/ml PAM3Cys (TLR2), 1 µg/ml Lipoteichoic acid (LTA - TLR2), 10 µg/ml Poly IC 
(TLR3), 1 µg/ ml CL97 (TLR7/8) and 1 µM CpG (TLR9). After stimulation for 24 
hours, the concentration of IL-6 in cell culture supernatants was measured by 
ELISA (Figure  10.5). GW3965 significantly decreased the secretion of IL-6 in cells 
stimulated with LPS, LTA and PAM relative to vehicle. PiC, CpG and CL97 failed 
to induce the secretion of IL-6. This study demonstrates that LXR agonism is able 
to suppress cytokine secretion mediated by other TLR ligands in murine 
macrophages. 
To demonstrate that inhibition of IL-6 secretion induced by PAM and LTA as well 
as LPS was mediated specifically by LXRs, BMDMs were differentiated from male 
wild-type, LXRα-/- and LXRβ-/- mice on the C57BL/6 background. The cells were 
pre-incubated for 48 hrs with 4 µM GW3965 prior to stimulation with TLR ligands 
at the indicated concentrations (Figure  10.6). Consistent with my previous 
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results treatment of LPS, PAM or LTA stimulated BMDMs from wild-type mice 
with 4 µM GW3965 significantly inhibited the secretion of IL-6. Supporting an 
anti-inflammatory effect of LXRs, deletion of LXRα or LXRβ was associated with 
an increased concentration of IL-6 upon ligation of TLR4. Furthermore, the 
inhibitory effect of GW3965 upon the secretion of IL-6 in response to TLR 4 
ligation was diminished in BMDMs from LXRα-/- and LXRβ-/-mice. These data 
suggest that the anti-inflammatory effect observed after treatment of BMDMs 
with GW3965 is mediated specifically through the activation of LXRs. 
Interestingly, inhibition of IL-6 secretion by treatment with GW3965 in response 
to stimulation with PAM or LTA appears to be mediated specifically through the 
actions of LXRβ. This is evident as deletion of LXRβ, but not LXRα, is associated 
with increased concentrations of IL-6 and GW3965 was not effective at reducing 
the concentrations of IL-6 in the LXRβ-/- macrophages. 
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Figure  10.5 LXR activation inhibits IL-6 secretion from TLR activated murine macrophages. 
Bone marrow derived macrophages were pre-incubated for 48 hrs with vehicle (V – DMSO) 
or 4 µM GW3965 prior to stimulation with the following TLR ligands; 100 ng/ml LPS (TLR4), 1 
µg/ml PAM3Cys (TLR2), 1 µg/ml Lipoteichoic acid (LTA - TLR2), 10 µg /ml Poly IC (PiC - 
TLR3), 1 µg/ ml CL97 (TLR7/8) and 1 µM CpG (TLR9). The concentration of IL-6 was 
measured by ELISA. Students T test; * P < 0.05. n = 4 per group. 
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Figure  10.6 Inhibition of TLR induced IL-6 secretion is mediated specifically by LXRs. 
Bone marrow derived macrophages were differentiated from male wild-type, LXRα-/- and 
LXRβ-/- mice and pre-incubated for 48 hrs with vehicle (V – DMSO) or 4 µM GW3965 (GW) 
prior to stimulation with the following TLR ligands; 100 ng/ml LPS (TLR4), 1 µg/ml PAM3Cys 
(PAM -TLR2), 1 µg/ml Lipoteichoic acid (LTA - TLR2). The mean concentration of IL-6 was 
measured by ELISA. Students T test; *** P < 0.001, ** P < 0.01 relative to vehicle control. n = 
4/ group. 
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10.2.3 LXR activation synergises with TLR4 ligation to 
promote pro-inflammatory cytokine secretion  
The role of LXRs, especially in an inflammatory context, has been predominantly 
studied in mice or murine cells in which it is evident that LXR agonism can exert 
an anti-inflammatory effect upon TLR ligation in murine macrophages. The 
effect of LXR agonism upon TLR ligation in human macrophages was unknown. To 
evaluate the effect of LXR activation upon cytokine secretion in humans CD14+ 
monocytes were purified from the peripheral blood of healthy volunteers. The 
monocytes were pre-incubated for twenty four hours with vehicle (DMSO) or 
T1317 prior to stimulation with 100 ng/ml LPS. Taqman QRT-PCR for the 
increased expression of ABCA1 confirmed activation of LXRs by T1317 that was 
significantly inhibited by the addition of LPS (Figure  10.7). In contrast to the 
effect of LXR activation in murine macrophages, treatment of LPS stimulated 
human monocytes with T1317 increased the secretion of the pro-inflammatory 
cytokine IL-6 in a dose responsive manner (Figure  10.8). Treatment of monocytes 
with T1317 alone did not induce IL-6 secretion thus indicating that there was no 
contamination with any TLR ligands that could potentiate the inflammatory 
response.  
To determine if the pro-inflammatory effect of LXR agonism was specific to IL-6 
the concentration of TNFα in the same cell culture supernatants was measured 
by ELISA (Figure  10.9). In accordance with the increased concentrations of IL-6, 
LXR agonism by T1317 also increased the concentration of TNFα from LPS 
stimulated monocytes. These data suggest that LXR agonism exerts a general 
pro-inflammatory effect. Therefore, to determine the cytokine profile induced 
by LXR activation and TLR4 ligation, Luminex analysis was used to measure the 
concentration of multiple pro-inflammatory cytokines and chemokines (Figure 
 10.10 and Figure  10.11). In support of a pro-inflammatory effect of LXR agonism 
the concentration of several pro-inflammatory cytokines, namely IL-1β, IL-6, IL-
7, IL-12 and IL-17, and the inflammatory chemokines, MIP-1α, MIP-1β and 
RANTES, were increased in cell culture supernatants whilst the concentration of 
the anti-inflammatory cytokine IL-10 was significantly reduced. IL-2, IL-4, IL-5 
and IFNγ were not detectable and IL-8 was above the limits of assay detection. 
In agreement with my results, other studies have since demonstrated a pro-
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inflammatory effect of LXR agonists in LPS stimulated human macrophages in 
which they demonstrated that the elevated levels of MCP-1 in the presence of 
LXR agonists was mediated through the increased expression of TLR4 (61). I have 
since confirmed the findings of this study and have also demonstrated that the 
expression of TLR4 in human monocytes was increased by LXR activation (Figure 
 10.12). 
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Figure  10.7 TLR4 ligation inhibits LXR induced transcription in primary human monocytes. 
Human CD14+ monocytes were pre-incubated for 24 hrs with media alone (0), vehicle (V – 
DMSO) or T1317 prior to stimulation with 100 ng/ml LPS (black bars) or media (white bars). 
The fold increase of ABCA1 expression relative to media alone was measured by Taqman 
QRT-PCR and normalised to TATA binding protein (TBP). Each condition was tested in 
triplicate. Students T test; * < 0.05. 
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Figure  10.8 LXR activation increases the secretion of IL-6 from human LPS stimulated 
monocytes. 
Human CD14+ primary monocytes were pre-incubated for 24 hrs with media alone (0), 
vehicle (V – DMSO) or T1317 at the indicated concentrations prior to stimulation with 100 
ng/ml LPS. The concentration of IL-6 in cell culture supernatants was measured by ELISA. 
Each condition was tested in triplicate. These data are representative of results from 6 
individual donors. Students T test; * P < 0.05, ** P < 0.01, *** P < 0.001. 
0 V
0.0
1 0.1 0.5 4 0 V 0.0
1 0.1 0.5 4
0
500
1000
1500
2000
2500
3000
**
**
***
0 ng/ml LPS 100 ng/ml LPS
T1317 (µM)
TN
F-
αα αα
 
(p
g/
m
l)
 
Figure  10.9 LXR agonism increases the secretion of TNFα from LPS stimulated human 
monocytes. 
Human CD14+ monocytes were pre-incubated for 24 hrs with media alone (0), vehicle (V – 
DMSO) or T1317 at the indicated concentrations prior to stimulation with 100 ng/ml LPS. The 
concentration of TNFα in cell culture supernatants was measured by ELISA. Each condition 
was tested in triplicate. Students T test; ** P < 0.01, *** P < 0.001. 
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Figure  10.10 LXR agonism increases the secretion of multiple pro-inflammatory cytokines 
from LPS stimulated human monocytes. 
Human CD14+ monocytes were pre-incubated for 24 hrs with media alone (0), vehicle (V – 
DMSO) or 4 µMT1317 prior to stimulation with media alone (white bars) or 100 ng/ml LPS 
(black bars). The concentration of cytokines in cell culture supernatants was measured by 
Luminex. Each condition was tested in triplicate. Students T test; * < 0.05, ** < 0.01 *** < 
0.001. 
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Figure  10.11 The secretion of inflammatory chemokines is increased by LXR activation. 
Human CD14+ monocytes were pre-incubated for 24 hrs with media alone (0), vehicle (V – 
DMSO) or 4 µMT1317 prior to stimulation with 100 ng/ml LPS. The concentration of 
inflammatory chemokines in cell culture supernatants was measured by Luminex. Each 
condition was tested in triplicate. Students T test; * < 0.05, ** < 0.01. 
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Figure  10.12 LXR activation increased the expression of TLR4. 
Human CD14+ monocytes were pre-incubated for 24 hrs with media alone (0), vehicle (V – 
DMSO) or T1317 prior to stimulation with 100 ng/ml LPS (black bars) or media (white bars). 
The expression of TLR4 normalised to TATA binding protein (TBP) was measured by 
Taqman QRT-PCR. Each condition was tested in triplicate. Students T test; * < 0.05 (relative 
to vehicle), ** P < 0.01. 
The importance of an LXR driven pathway in the pathology of RA is unknown. 
Therefore, to determine if the pro-inflammatory effect of LXR activation upon 
TLR4 ligation is conserved in patients with RA, CD14+ monocytes were purified 
from RA peripheral blood. As previously described, the cells were pre-treated 
with media, vehicle, T1317 or GW3965 for 24 hours prior to stimulation with 100 
ng/ml LPS. LXR agonism significantly increased the concentration of LPS induced 
secretion of IL-6 and TNFα in cell culture supernatants as measured by ELISA in a 
dose responsive manner (Figure  10.13). Of interest, in the absence of LPS 
although both TNFα and IL-6 were secreted at low concentrations, reflecting the 
systemic pro-inflammatory environment in RA; LXR agonism did not alter the 
level of cytokine secretion. These results demonstrate that LXR agonism is able 
to induce pro-inflammatory effects in LPS stimulated monocytes in samples from 
both healthy controls and patients with RA. 
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Figure  10.13 LXR agonism promotes cytokine secretion from LPS stimulated RA 
monocytes. 
(A – B) Monocytes were purified from the peripheral blood of patients with RA and 
incubated for 24 hrs with media alone (0), vehicle (V – DMSO), T1317 and GW3965 at the 
indicated concentrations prior to stimulation with 100 ng/ml LPS. The concentration of TNFα 
(A) and IL-6 (B) was measured by ELISA. Each condition was tested in triplicate and the 
results are representative of 3 independent donors. Students T test; * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
10.2.4 LXR activation has no effect upon pro-inflammatory 
cytokine secretion from inflamed synovial membrane 
The effect of LXR activation at the primary site of inflammation within the RA 
synovium has not previously been defined. Both LXRα and LXRβ are expressed 
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within cells derived from collagenase digested RA synovial membrane 
(synoviocytes) and synovial derived fibroblasts from patients with RA (Figure 
 10.14). Therefore, to determine if LXR activation could potentially increase the 
basal level of cytokine secretion within the synovium freshly isolated RA derived 
synoviocytes were treated with vehicle or T1317 (Figure  10.15). In the absence 
of any exogenous inflammatory stimuli, the RA derived synoviocytes 
spontaneously secreted high concentrations of TNFα. However, addition of T1317 
or GW3965 did not affect the secretion of TNFα. Fibroblasts are the major cell 
type of the synovial membrane. Therefore, fibroblasts derived from inflamed RA 
synovial membrane were treated with T1317 and stimulated with 100 ng/ml LPS 
(Figure  10.16). However, despite induction of the TLR4 pathway, evident by the 
increased secretion of IL-6, LXR agonism did not further increase the 
concentration of IL-6 secreted from RA fibroblasts. Similar results were also 
obtained in RA synoviocytes (Figure  10.17).  
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Figure  10.14 LXRs are expressed in synoviocytes and synovial fibroblasts. 
(A – B)The expression of LXRα and LXRβ was assessed by RT-PCR. (A) RNA was extracted 
from synovial membrane from RA patients following collagenase digestion; n =3 (A) and RA 
synovial derived fibroblast explant cultures at passage 5; n = 4 (B). Molecular weight ladder 
(MW), blank (B – no RNA) positive control (+, human monocytes), negative control (- , 
without reverse transcriptase). 
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Figure  10.15 LXR agonism does not promote cytokine secretion from synoviocytes. 
Synoviocytes derived from rheumatoid arthritis synovial membrane following collagenase 
digestion were treated with media alone (0), vehicle (V – DMSO), T1317 or GW3965 at the 
indicated concentration for 24 hrs. The concentration of TNFα was measured by ELISA. 
Each condition was tested in triplicate. The results are representative 3 separate donors. 
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Figure  10.16 LXR activation does not increase secretion of IL-6 from LPS stimulated 
rheumatoid synovial fibroblasts. 
RA synovial fibroblast explant cultures at passage 5 were pre-incubated for 24 hrs with 
media alone (0), vehicle (V – DMSO) or T1317 at the indicated concentrations prior to 
stimulation with 100 ng/ml LPS. The concentration of IL-6 was measured by ELISA. Each 
condition was tested in triplicate. The results are representative 5 separate donors. 
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Figure  10.17 LXR agonism does not promote TNFα secretion from LPS stimulated 
synoviocytes. 
Synoviocytes derived from RA synovial membrane following collagenase digestion were 
treated with media alone (0), vehicle (V – DMSO), T1317 (T) or GW3965 (GW) at the indicated 
concentration for 24 hrs prior to stimulation with 100 ng/ml LPS. The concentration of TNFα 
was measured by ELISA. Each condition was tested in triplicate. The results are 
representative of 3 separate donors. 
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10.2.5 LXRs exacerbate cytokine secretion in an in vitro 
model of synovitis 
LXR agonism supports the secretion of inflammatory cytokines and chemokines 
from human LPS stimulated monocytes but not RA synovial tissue derived 
synoviocytes or fibroblasts. The effect of LXR agonism upon other inflammatory 
pathways relevant to RA remains unknown. Whilst RA is considered a Th1 disease 
synovial T cells have a phenotype more similar to cytokine activated T cells 
(TcKs) which are able to induce macrophage activation and consequently the 
secretion of macrophage derived pro-inflammatory cytokines including TNFα 
(162). To determine if LXR activation has the potential to drive an inflammatory 
response through the interaction of macrophages and TcKs, monocytes were 
purified from the peripheral blood of healthy controls and matured to a 
macrophage phenotype with MCSF in the presence of vehicle, GW3965 or T1317. 
Syngeneic CD3+ T cells were simultaneously purified and activated with IL-2, IL-6 
and TNFα. After seven days, macrophages and TcKs were co-cultured for 24 
hours and the concentration of macrophage derived TNFα was measured by ELISA 
(Figure  10.18). Co-culture of macrophages and TcKs induced the secretion of 
TNFα which was significantly increased by treatment with T1317 or GW3965 in a 
dose responsive manner. Luminex analysis was used to assess the effect of LXR 
agonism upon the secretion of other inflammatory cytokines and chemokines 
(Figure  10.19 and Figure  10.20). Indeed, the concentration of multiple pro-
inflammatory cytokines IL-1β, IL-2, IL-5, IL-6, IL-12, IL-13, IL-15, IL-17, GM-CSF, 
IFNγ and TNFα, were significantly increased in cell culture supernatants by 
T1317 and GW3965. Similarly, both T1317 and GW3965 significantly increased 
the concentration of the inflammatory chemokines MIP-1α and MIP-1β. The 
concentration of IL-1Ra, IFNα, IL-4, IL-7, RANTES, IP-10, MIG and MCP-1 were not 
changed, whilst IL-8 and eotaxin were outwith the limits of assay detection. 
These data suggest that LXR agonism may be able to promote an inflammatory 
response mediated through the interaction of cytokine activated T cells and 
macrophages within an inflamed RA synovium. 
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Figure  10.18 LXR agonism increases the secretion of TNFα in an in vitro model of synovitis. 
Primary human monocytes were purified and matured to a macrophages (MФ) phenotype 
with MCSF. Simultaneously, unfixed syngeneic CD3+ T cells were activated with IL-2, IL-6 
and TNFα (cytokine activated T cells- TcKs). After seven days the cells were co-cultured and 
incubated overnight in the presence of media alone (0), vehicle (V – DMSO), T1317 or 
GW3965 at the indicated concentration. The concentration of TNFα was measured by ELISA. 
Each condition was tested in triplicate and the results are representative of 6 different 
donors. Students T test; * P < 0.05, ** P < 0.01, *** P < 0.001.  
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LXR agonism promotes inflammatory cytokine secretion from T cell activated macrophages, 
(continued over). 
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Figure  10.19 LXR agonism promotes inflammatory cytokine secretion from T cell activated 
macrophages. 
Primary human monocytes were purified and matured to a macrophages (MФ) phenotype 
with MCSF. Simultaneously, syngeneic CD3+ T cells were activated with IL-2, IL-6 and TNFα 
(cytokine activated T cells- TcKs). After seven days the cells were co-cultured and 
incubated overnight in the presence of media alone (0), vehicle (V – DMSO), 4 µM T1317 (T) 
or 4 µM GW3965 (GW). The concentration of cytokines was measured by Luminex. Each 
condition was tested in triplicate. Students T test; * P < 0.05, ** P < 0.01, *** P < 0.001.  
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Figure  10.20 LXR agonism promotes inflammatory chemokine secretion from T cell 
activated macrophages. 
Primary human monocytes were purified and matured to a macrophages (MФ) phenotype 
with MCSF. Simultaneously, syngeneic CD3+ T cells were activated with IL-2, IL-6 and TNFα 
(cytokine activated T cells- TcKs). After seven days the cells were co-culture and incubated 
overnight in the presence of media alone (0), vehicle (V – DMSO), 4 µM T1317 (T) or 4 µM 
GW3965 (GW). The concentration of chemokines was measured by Luminex. Each condition 
was tested in triplicate. Students T test; * P < 0.05, ** P < 0.01, *** P < 0.001.  
10.2.6 The effects of LXR activation are contact mediated 
The precise mechanism(s) by which TcKs can induce macrophage activation is 
(are) not fully understood although several ligand pairs have been implicated 
e.g. CD40/ CD40L, ICAM1 / LFA-1 and CD45/CD45R (309, 310). Furthermore, how 
LXRs interact with such inflammatory pathways to promote macrophage cytokine 
and chemokine secretion is unknown. To determine whether the effect of LXRs 
was mediated through soluble mediators or via mechanisms that support cell 
surface interactions human macrophages and TcKs were generated as previously 
described. The TcKs were then placed either in co-culture with the macrophages 
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or in the same well but on a transwell insert, to keep the T cells and 
macrophages spatially separated. Cells were treated with media alone, vehicle 
or T1317 (Figure  10.21). Transwell inserts with a pore size of 0.4 µM were 
selected so as to allow the diffusion of soluble proteins but not intact cells. As 
expected, co-culture of MCSF matured macrophages with TcKs induced the 
secretion of TNFα which was increased by approximately two fold by treatment 
with T1317; supporting previous findings suggesting a pro-inflammatory effect of 
LXR agonism. However, when the TcKs were separate from the macrophages 
TNFα was not detectable and addition of T1317 mediated no effect. Similarly, 
pre-treatment of only the TcKs, but not the macrophages, with LXR agonist 
during the cytokine activation stage had no effect upon subsequent TNFα 
secretion (Figure  10.22). These data suggest that the mechanism by which LXR 
agonism potentiates TcK induced macrophage derived inflammatory cytokine 
secretion is mediated through enhancement of cell-cell surface interactions 
rather than via elaboration of soluble mediators and that LXR activation in both 
the TcKS and macrophages is required to increase the secretion of TNFα. 
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Figure  10.21 LXR agonism potentiates T cell induced macrophage derived pro-inflammatory 
cytokine secretion through cell surface interactions. 
Human macrophages and cytokine activated T cells were co-cultured (C) or were physically 
separated by transwell inserts (T) and treated with media, vehicle (DMSO) or 4 µM T1317. 
The mean concentration of TNFα was measured by ELISA; not detectable (n/d). Each 
condition was tested in triplicate. Representative results from three individual donors. 
Students T test; ** P < 0.01. 
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Figure  10.22 LXR agonism in both TcKs and macrophages is required to potentiate the 
secretion of TNFα. 
Human CD14+ monocytes were matured to a macrophage (MФ) phenotype with MCSF whilst 
syngeneic T cells were cytokine activated (TcKs). The T cells, but not the macrophages, 
were pre- treated with media alone (0), vehicle (V- DMSO) 4 µM  T1317 (T) or 4 µM GW3965 
(GW) prior to being co-cultured with macrophages. The concentration of TNFα was 
measured by ELISA. 
10.2.7 TNFα regulates the expression of LXRs 
10.2.7.1 TNFα induces the expression of LXRα expression in murine 
macrophages 
Several reports suggest a cell type / subset specific capacity for TNFα to 
modulate expression of LXRα and the LXR target gene ABCA1. Specifically, the 
expression of LXRα is increased  by TNFα in rabbit adipocytes whereas in mouse 
and human kidney and liver cells the expression of LXRα is reduced (40, 41, 44). 
However, the effect of TNFα upon LXRα expression in macrophages is unknown.  
Therefore, to determine if TNFα could modulate the expression of LXRα in 
macrophages, BMDM were treated with 5 ng/ml TNFα; a concentration which 
was previously shown to modulate LXRα expression in murine adipocytes (Figure 
 10.23) (44). The macrophages were incubated with TNFα for 4 hrs, 8 hrs, 12 hrs 
or 24 hrs to determine whether any effect of TNFα upon LXRα expression was a 
primary or secondary transcriptional event. Treatment of murine macrophages 
with TNFα significantly increased the expression of LXRα by approximately two 
fold at all time points indicating that the effect of TNFα upon LXRα expression 
was likely a primary transcriptional event. Previous reports have demonstrated 
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that TNFα can alter the expression of LXRα but not LXRβ. BMDM were therefore 
treated with 2.5 ng/ml to 20 ng/ml TNFα for 24 hrs to firstly determine the 
effect of TNFα upon the expression of LXRβ and LXR target genes and to 
secondly determine the optimal concentration of TNFα (Figure  10.24). The 
expression of LXRα was significantly increased by all concentrations of TNFα-
similar to the previous experiment treatment, 5 ng/ml TNFα increased the 
expression of LXRα by approximately two fold. Similarly, the expression of 
ABCA1 was significantly increased by distinct concentrations of TNFα. However, 
although the expression of LXRβ was significantly increased by treatment with 
2.5 ng/ml and 10 ng/ml TNFα these effects were modest. 
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Figure  10.23 TNFα up-regulates the expression of LXRα in murine macrophages. 
Murine bone marrow derived macrophages were treated with 5 ng/ml TNFα for the indicated 
period of time. RNA was extracted for the analysis of LXRα expression by Taqman QRT-PCR 
and normalised to TATA binding protein (TBP). n = 4/ group. Students T test; * P < 0.05, *** P 
< 0.001. 
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Figure  10.24 TNFα induces the expression of LXRα and downstream LXR target genes. 
Murine bone marrow derived macrophages were treated with TNFα at the indicated 
concentrations for 24 hrs. RNA was extracted for mean gene expression analysis of LXRα, 
LXRβ and ABCA1 by Taqman QRT-PCR normalised to TATA binding protein (TBP).  Each 
condition was tested in triplicate; n = 5/ group. Students T test; * P < 0.05, ** P < 0.01, *** P < 
0.001. 
10.2.7.2 TNFα but not IL-6 induces the expression of LXRα in human 
macrophages 
TNFα can induce the expression of LXRα and subsequently ABCA1 in murine 
macrophages. Similar effects upon LXRα expression have also been shown by the 
administration of IL-1 and LPS to human liver cell lines and primary monocytes 
respectively (40, 311). The effect of TNFα and other inflammatory cytokines 
upon the expression and activation of LXRs in primary human monocyte derived 
macrophages was unknown. Therefore, MCSF matured human macrophages were 
treated with increasing concentrations of TNFα or IL-6 for twenty four hours 
after which the expression of LXRα, LXRβ and ABCA1 was measured by Taqman 
QRT-PCR (Figure  10.25). The concentration range of TNFα was derived from 
previous work in the literature and comparable to concentrations used in murine 
macrophages in previous experiments (Figure  10.24) (40, 41). The effect of IL-6 
upon LXR expression has not previously been assessed. IL-6 is effective in vitro 
at 100 ng/ml – for example at this concentration it efficiently promotes T cell 
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activation. Treatment with TNFα significantly increased the expression of LXRα 
but not LXRβ or ABCA1; P = 0.2556 and P = 0.6827 both at concentrations of 12.5 
ng/ml respectively. Treatment with IL-6 did not affect the expression of LXRα, 
LXRβ or ABCA1. These results suggest that TNFα but not IL-6 mediated signalling 
pathways are capable of modulating LXRα expression in human macrophages. 
I next wished to analyse the down stream signal pathways that might explain 
these observations. TNFα binding to the TNF receptor (TNFR1) induces the 
recruitment of the adaptor molecule TRADD which subsequently recruits the 
signalling molecules TRAF2 and TRAF5 leading to activation of NF-κB (reviewed 
in (42)). Similarly, IL-1 and LPS have also been shown to exert modulatory 
effects upon the expression of LXRα both of which ultimately induce the 
activation of NF-κB (40, 311, 312). Both human and murine LXRα contain NF-κB 
response elements within their promoter region proximal to the transcriptional 
start site (Figure  10.26). To determine if the effects of TNFα upon LXRα 
expression were mediated through NF-κB activation murine BMDM were treated 
with 5 ng/ml TNFα and a pharmacological inhibitor of NF-κB, Bay11-7082 
(Bay11), at concentrations between 2.5 µM and 20 µM or vehicle (DMSO) (Figure 
 10.27). Concentrations of Bay11 were selected from previous work in the 
literature which was shown to inhibit NF-κB induced expression of E-selectin at 
an Ec50 of 10 µM (313). Similar to previous experiments TNFα significantly 
increased the expression of LXRα in human macrophages by approximately four 
fold. Addition of Bay11 significantly reduced the expression of LXRα below basal 
levels of LXRα expression.  
Further control experiments were essential to interpret this observation. NF-κB 
activation promotes cell survival and suppresses apoptosis therefore inhibition of 
NF-κB may potentially promote macrophage apoptosis. Therefore, to ensure that 
the macrophages were viable after treatment with Bay 11 BMDM were treated 
with vehicle (DMSO) or 2.5 µM Bay11 for 4 hours and analysed by flow cytometry. 
To assess cell viability after treatment with BAY11 the cells were stained with 
Propidium Iodide (PI) (Figure  10.28). PI stains DNA but can only cross the plasma 
membrane of non-viable cells; therefore PI positive cells are considered 
apoptotic or necrotic. Treatment of BMDM with BAY11 significantly increased the 
percentage of PI positive cells compared to vehicle suggesting that inhibition of 
NF-κB by BAY11 induced macrophage apoptosis. Therefore, although the 
  190 
expression of LXRα was reduced in macrophages treated with BAY11 it is not 
clear if this is due to the induction of apoptotic or necrotic pathways or specific 
inhibition of NF-κB mediated induction of LXRα expression. Further studies 
utilising LXRα luciferase reporters are therefore required to confirm that the 
effect of TNFα upon LXRα expression is mediated through NF-κB. Time 
availability in my thesis studies precluded my performing these experiments.  
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Figure  10.25 TNFα induces the expression of LXRα in human macrophages. 
MCSF matured human macrophages were treated with TNFα or IL-6 at the indicated 
concentrations for 24 hrs. RNA was then extracted for gene expression analysis of LXRα, 
LXRβ and ABCA1 measured by Taqman QRT-PCR and normalised to TATA binding protein 
(TBP). Each condition was tested in triplicate and the results are representative of four 
individual donors. Students T test; * P < 0.05. 
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Figure  10.26 The human and mouse LXRα promoters contain NF-κB response elements.  
A schematic demonstrating the location of the NF-κB binding sites within the human and 
mouse LXRα promoters. The sequence of the NF-κB binding element is shown in bold (5’ to 
3’) and the position relative to the transcriptional start site in base pairs is shown below. 
The transcriptional start site is indicated by the arrow.  
 
      GAGGGGATGACCT                                   AAGTGGATGCCCT  
Mouse 
5’ 3’ 
NF-κB NF-κB 
-3358                -3346    +297                 +309    
Human 
5’ 3’ 
NF-κB 
-1011                       -1019        
CGGGGAATGTCCTAAG 
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Figure  10.27 Inhibition of NF-κB activation reduces the expression of LXRα. 
Murine bone marrow derived macrophages were treated with 5 ng/ml TNFα and the 
pharmacological NF-κB inhibitor Bay11-7082 (Bay11) or vehicle (V- DMSO) for 24 hrs. RNA 
was extracted for gene expression analysis of LXRα, normalised to TATA binding protein 
(TBP) by Taqman QRT-PCR. Each condition was tested in triplicate; n = 4/ group. Students T 
test; *** P < 0.001. 
 
Figure  10.28 Inhibition of NF-κB by BAY11 induced macrophage apoptosis. 
Murine bone marrow derived macrophages were treated with vehicle (DMSO) or 2.5 µM 
BAY11 for 4 hrs. The cells were then stained with Propidium Iodide (PI) to assess cell 
viability. Representative results of n = 3 mice. 
Vehicle 
2.5 µM Bay11 
PI 
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10.2.8 Characterisation of LXR expression in human 
inflammatory arthropathies 
10.2.8.1 Expression of LXRs is increased in PBMCs from AS patients 
In addition to the maintenance of a cholesterol homeostasis it is now well 
established that LXRs play an immuno-modulatory role - my data discussed thus 
far suggest a predominantly pro-inflammatory effect upon LXR activation. 
Although the role for LXRs in arthritis is unknown recent reports in the literature 
support a role for LXRs in human disease pathology in which the expression of 
LXRα and LXRβ is altered in the PBMCs of patients with multiple sclerosis (MS) 
but not other neurological conditions (123, 124). Therefore, to determine if the 
expression of LXRs is altered in RA, PBMCs were purified from patients with RA 
and healthy controls (HC). For comparison with other inflammatory 
arthropathies, PBMCs were obtained from patients with ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) to determine whether any biology around LXR 
expression was specific to RA or common to other autoimmune inflammatory 
conditions. The number of subjects and patient characteristics is shown in Table 
 10.1; all patients had established disease, met ACR diagnostic criteria and were 
receiving DMARD therapy as prescribed by their physician. RNA was extracted 
from the PBMCs and the level of expression of LXRα, LXRβ and ABCA1 was 
measured by Taqman QRT-PCR (Figure  10.29). There was no correlation of LXRα, 
LXRβ or ABCA1 expression with age in any of the subject groups (Table  10.2). 
Therefore, differences in subject age could not account for any changes in the 
level of LXR expression.  
The expression of LXRα was not altered in the patients with RA or PsA relative to 
HC. Unexpectedly, LXRα mRNA expression was significantly higher in AS patients 
by approximately twenty two fold. Similarly, the expression of LXRβ was 
significantly higher in AS compared to HC by approximately seventeen fold. 
There was also a significant, but modest, increase in the expression of LXRβ 
expression in PsA whilst in RA the expression of LXRβ was significantly lower 
than HC. The expression of ABCA1 was measured to determine if increased LXR 
transcriptional activation was associated with increased LXR expression. 
However, the expression of ABCA1 was constant between all subject groups 
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tested. These data demonstrate that the expression of LXRs is increased and 
suggest dysregulation of pathways which mediate the expression of LXRs 
specifically in AS. 
 HC RA PsA AS 
Samples 36 48 22 19 
Sex: Male (%) 
       Female (%) 
20 (56) 
16 (44) 
11 (23) 
37 (77) 
10 (45) 
12 (55) 
16(84) 
3(16) 
Age: Mean (range) 39 (22-64) 60 (35-84) 54 (35-67) 58 (39-73) 
ESR: Mean (range) N/A 14 (1-48) 12 (2-30) 12.7 (4-29) 
CRP: Mean (range) N/A 9.3 (0.5-109) 9.6 (1-35) 10.1 (0.8-44) 
Table  10.1 Characterisitics of patients and healthy control subjects. 
Healthy controls (HC), Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing 
spondylitis (AS). Data not available (N/A). 
 
R2 (P) HC RA PsA AS 
LXRα 0.012 (0.52) 0.009 (0.47) 0.002 (0.82) 0.009 (0.76) 
LXRβ 0.06 (0.64) 0.013 (0.39) 0.015 (0.59) 0.103 (0.08) 
ABCA1 0.008 (0.6) 0.001 (0.86) 0.005 (0.75) 0.001 (0.93) 
Table  10.2 The expression of LXRs does not correlate with age. 
The expression of LXRα, LXRβ and ABCA1 was measured by Taqman QRT-PCR. Healthy 
controls (HC), Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis 
(AS). Values shown are linear regression (r2) and P value of significance in brackets.  
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Figure  10.29 The expression of LXRs is higher in ankylosing spondylitis. 
The expression of LXRα, LXRβ and ABCA1, normalised to TATA binding protein (TBP) was 
measured by Taqman QRT-PCR in peripheral blood mononuclear cells purified from healthy 
controls (HC) or patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 
ankylosing spondylitis (AS). Students T test; * P < 0.05, *** P < 0.001.  
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CRP/ ESR RA 
 
  
PsA AS 
LXRα 0.004 (0.67)/  
0.034 (0.24) 
0.003 ( 0.82)/ 
0.051 (0.31) 
0.04 (0.43)/  
0.188 (0.07) 
LXRβ 0.062 ( 0.09)/ 
0.141 (0.09) 
0.004 (0.78)/ 
0.141 (0.09) 
0.025 (0.53)/ 
0.012 (0.67) 
ABCA1 0.238 (0.007)/ 0.002 (0.84)/ 0.139 (0.13)/ 
 0.212 (0.002) 0.075 (0.22) 0.003 (0.83) 
Table  10.3 The expression of LXRs or ABCA1 does not correlate with disease severity. 
Linear regression analysis (r2) of disease severity as measured by CRP and ESR in 
Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS); patient 
characteristics and numbers are shown in Table  10.1. The expression of LXRα, LXRβ and 
ABCA1 was measured by Taqman QRT-PCR. Values shown are linear regression of CRP/ 
ESR vs LXR or ABCA1 expression and P values are shown in brackets. 
10.2.8.2 LXR mediated cytokine secretion is increased in patients with 
ankylosing spondylitis 
I next wished to determine whether this elevated basal level of LXR expression is 
in PBMCs of AS patients had any functional significance. The increased 
expression of LXRs suggests that PBMCs from AS patients may potentially have an 
increased capacity to respond to LXR agonists and subsequently promote 
inflammation. I have previously shown that LXR agonism can increase LPS 
mediated secretion of pro-inflammatory cytokines/ chemokines from human 
primary monocytes (Figure  10.8) an observation which has since been confirmed 
by other studies in the literature (61). Therefore, to determine how increased 
expression of LXRs may impact the secretion of IL-6 in response to TLR4 ligation 
with LPS and LXR agonism PBMCs were purified from subjects with AS, PsA, RA 
and HC. The subject characteristics and numbers are described in Table  10.4. 
PBMCs were pre-incubated with media alone, vehicle (DMSO) or 0.25 µM to 4 µM 
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GW3965 for 36 hours prior to addition of 100 ng/ml LPS. After twenty four hours 
the concentration of IL-6 in the cell culture supernatants was measured by ELISA 
(Figure  10.30). Consistent with previous findings LXR activation significantly 
increased the secretion of IL-6 in response to LPS from PBMCs of HC in a dose 
responsive manner. Similarly, the concentration of IL-6 was also significantly 
increased from LPS stimulated PBMCs of PsA, RA and AS patients in response to 
LXR activation. However, the concentration of IL-6 secreted from AS PBMCs was 
significantly higher than that secreted from HC in response to TLR4 ligation at 
several concentrations of GW3965. Similarly, the concentration of IL-6 secreted 
from PsA PBMCs was significantly higher than HC but only at the highest 
concentration of 4 µM GW3965. There was no significant difference in the 
concentration of IL-6 secreted from RA PBMCs compared to HC (P = 0.6423). 
These data indicate that AS PBMCs have an increased capacity to respond to LXR 
agonists and subsequently promote an inflammatory response mediated by TLR4 
stimulation with LPS. 
 HC RA PsA AS 
Samples 12 11 10 16 
Sex: Male (%) 
       Female (%) 
8 (66) 
4 (33) 
5 (45) 
6 (55) 
3 (30) 
7 (70) 
11 (68) 
5 (32) 
Age: Mean (range) 43 (25 – 59) 60 (57-77) 46.6 (32-64) 48 (24-75) 
ESR: Mean (range) N/A 14.8 (2-56) 15.6 (1.5-57) 8.7 (1.8-25) 
CRP: Mean (range) N/A 15.6 (0.8-33) 13.4 (0.7-29) 9.9 (0.7-9.9) 
Table  10.4 Subject characteristics. 
Healthy controls (HC), Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing 
spondylitis (AS). Data not available (N/A). 
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Figure  10.30 LXR mediated cytokine secretion is increased in patients with ankylosing 
spondylitis.  
PBMCs were purified from healthy controls (HC), Rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and ankylosing spondylitis (AS) and pre-incubated with media alone (0), 
vehicle (V- DMSO) or GW3965 at the indicated concentrations for approximately 36 hrs. The 
PBMCs were then stimulated with 100 ng/ml LPS for 24 hrs and the concentration of IL-6 in 
the cell culture supernatants was measured by ELISA. The subject characteristics and 
numbers are shown in Table  10.4. Each condition was tested in triplicate. Students T test; * 
P < 0.05 between disease groups and healthy controls at the same concentration of GW3965 
or # P < 0.05, ## P < 0.01 at concentrations of GW3965 within the same subject group 
relative to vehicle control. 
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10.3 Discussion & conclusion 
There is now a large body of evidence supporting a role for LXRs in inflammation 
in which LXR activation is generally ascribed an anti-inflammatory effect. This 
was first demonstrated by the treatment of LPS stimulated murine macrophages 
with LXR agonists which inhibited the expression of iNOS (117). Similarly, my 
own and other studies in the literature have since confirmed these findings and 
have demonstrated similar inhibitory effects of LXR agonism upon LPS 
stimulation in vivo (19, 118, 314, 315). Together these studies suggest a general 
anti-inflammatory effect of LXR agonism in murine systems. In support of this, I 
found that the anti-inflammatory effect of LXR activation is not unique to TLR4 
ligation but is also common to TLR2 induced inflammatory pathways as GW3965 
reduced the secretion of IL-6 from murine macrophages stimulated with the 
TLR2 ligands PAM3Cys or LTA. However, it is unclear what effect activation of 
LXRs has upon other TLR signalling pathways as I was unable to detect IL-6 by 
ELISA in cell culture supernatants from TLR3, TLR7/8 or TLR9 stimulated murine 
macrophages. TLR3, TLR7, TLR8 and TLR9 predominantly sense viral infection 
through the binding of dsRNA and DNA to promote the secretion of IFNα or IFNβ. 
Therefore, measurement of IFNα and IFNβ concentrations in cell culture 
supernatants by ELISA are required to determine if LXR agonism can affect IFN 
secretion and thereby infer a potential role for LXRs in defence against viral 
infection.  
Joseph et al previously demonstrated that the inhibitory effect of LXR agonism 
upon TLR4 induced iNOS expression was mediated by antagonism of NF-κB 
signalling (117). Similar to TLR4 ligation TLR2 also induces the activation of NF-
κB. It is therefore likely that inhibition of TLR2 induced IL-6 secretion by LXR 
agonism is mediated through the inhibition of NF-κB signalling pathways. This 
remains to be formally tested - the use of an NF-κB luciferase reporter would 
inform any inhibitory effect of LXRs upon NF-κB activation. These results suggest 
that LXR activation would be detrimental towards the clearance of a bacterial 
infection. However, contradictory to this hypothesis mice lacking LXRs are highly 
susceptible to Listeria monocytogenes infection and exhibit defective bacterial 
clearance in vivo (316). This was mediated by accelerated macrophage apoptosis 
due to aberrant regulation of the anti-apoptotic factor SPalpha; I conclude at 
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this stage only that the role of LXRs in innate immunity is complex and requires 
further investigation. I am also struck by the distinctions between murine and 
human studies thus far and interpolate cautious interpretation of my own in vivo 
experiments that constituted part of my own volume of work herein.  
The role of LXRs in inflammation has been predominantly studied in rodents or 
rodent derived tissues. Therefore, how LXRs modulate an inflammatory response 
in human cells was until recently unknown. I therefore first sought to determine 
if the anti-inflammatory effect of LXR agonism upon TLR4 induced inflammatory 
pathways in murine macrophages was conserved in humans. Paradoxically, 
treatment of human LPS stimulated monocytes with LXR agonists markedly 
increased the secretion of multiple pro-inflammatory cytokines and chemokines. 
These results demonstrate a novel pro-inflammatory effect of LXR activation in 
humans and are in direct contrast to the effect of LXR agonism in mice. Fontaine 
et al have since confirmed these results and demonstrated that the pro-
inflammatory effect of LXR agonism upon TLR4 activation is through the 
increased expression of TLR4 mediated by LXRα (61). Stimulation of TLR4 with 
LPS induces the phosphorylation of the MAPKs Jnk, Erk and p38 and accordingly 
LXR agonism increases MAPK phosphorylation downstream of TLR4. These data 
suggest that LXR activation potentiates the inflammatory response through 
increased TLR4 expression and downstream signalling pathways leading to 
enhanced pro-inflammatory cytokine secretion. Notably, the LXRE is not present 
within the murine TLR4 promoter hence LXR activation in murine macrophages 
does not alter TLR4 expression. Additionally, Fontaine et al also demonstrated a 
biphasic effect of LXR activation in human macrophages. Pre-treatment of 
human LPS stimulated macrophages with LXR agonists for 12 hrs or less 
decreased the secretion of MCP-1 and TNFα whereas MCP-1 and TNFα secretion 
was increased from macrophages pre-incubated with LXR agonists for 24hrs or 
longer. These observations are in agreement with my results where monocytes 
were pre-incubated with T1317 or GW3965 for 24 hrs or longer.  
The induction of human TLR4 expression by LXRα is a primary transcriptional 
event, evidenced by the direct binding of LXRs to the TLR4 promoter. However, 
the expression of human TLR4 is only increased in macrophages pre-incubated 
with LXR agonists for longer than 24 hrs, hence cytokine secretion is only 
increased in monocyte/ macrophages pre-incubated with LXR agonist for longer 
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than 24 hrs. Although no change in TLR4 expression is observed with shorter 
periods of macrophage/ LXR agonist pre-incubation, it is evident that there is an 
inhibitory effect of LXR agonism upon inflammatory cytokine/ chemokine 
secretion. It is not clear how LXRs mediate the switch between the biphasic 
effects upon the regulation of TLR4 mediated signalling pathways. However, 
LXRs have been shown to promote the expression of the nuclear receptor Rev-
erbα which inhibits TLR4 expression (5). Furthermore, whether LXR agonism in 
human monocytes/ macrophages inhibits NF-κB activation similar to that 
demonstrated in murine macrophages at the earlier time points of agonist 
incubation is unknown. This is summarised in Figure  10.31. The effect of LXR 
agonism upon other TLR mediated pathways in human macrophages has not been 
tested however these studies so far have demonstrated a novel pro-inflammatory 
effect of LXR agonism upon TLR4 mediated inflammation in human monocytes/ 
macrophages. 
 
Figure  10.31 Regulation of TLR4 expression and signalling pathways by LXRs. 
Activation of LXRs is able to upregulate the expression of TLR4 in human macrophages 
leading to increased downstream signalling and secretion of inflammatory cytokines and 
chemokines. However, LXRα can also induce the expression of Rev-erbα which can inhibit 
LXR mediated induction of TLR4; thereby negative feedback upon TLR4 expression. In 
murine macrophages LXR can also inhibit the activation of NF-κB and the expression of 
downstream target genes it is not clear if there is any interaction between LXR and NF-κB 
signalling pathways in human macrophages. 
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The pro-inflammatory effect of LXR agonism upon TLR4 induced cytokine 
secretion from human peripheral blood derived monocytes is conserved in 
patients with RA. LXR agonism may therefore support the development of an 
inflammatory environment through the secretion of cytokines and chemokines 
induced via the activation of TLR4 by either endogenous or bacterial derived 
ligands. Unlike monocytes/ macrophages treatment of fibroblasts or 
synoviocytes with T1317 or GW3965 did not change the basal or likewise the 
concentration of LPS induced secretion of TNFα or IL-6. This demonstrates that 
fibroblasts and synoviocytes are not already maximally activated as addition of 
LPS increased the secretion of IL-6. Secondly these results suggest that the pro-
inflammatory effect of LXR may potentially be exclusive to the periphery. 
In support of a role for LXRs in driving inflammation in the synovium LXR 
activation increased the secretion of multiple macrophage derived pro-
inflammatory cytokines and chemokines in the TcK/ macrophage contact assay. 
By using a transwell assay system I was able to confirm previous findings 
demonstrating that the secretion of TNFα was mediated through macrophage/ 
TcK cell-cell contact (162). As addition of T1317 did not affect the secretion of 
TNFα from macrophages cultured separately from TcKS this would suggest that 
LXRs were not able to induce the secretion of soluble mediators that were able 
to initiate the inflammatory response. Therefore, how LXR agonism drives 
macrophage derived pro-inflammatory cytokine secretion in this context is 
unknown but may be in part through positive feedback of IL-2, IL-6 and TNFα or 
IL-15 upon TcK activation. 
To explore the role of potential feedback loops upon LXR biology, macrophages 
were treated with TNFα or IL-6. Interestingly, TNFα increased the expression of 
LXRα in both human and murine macrophages. Although the expression of LXRα 
was consistently increased it was not clear what effect TNFα exerted upon LXR 
transcriptional activation as ABCA1 was increased in murine but not human 
macrophages; the effect on other LXR target genes was not tested. These results 
have important implications for the role of LXRs in inflammation especially in RA 
where TNFα is central to disease pathology. My results have demonstrated a 
predominantly pro-inflammatory effect of LXR activation. This may be positively 
regulated by TNFα through the increased expression of LXRα thereby further 
enhancing the inflammatory response mediated by agonism of LXRs. It would 
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therefore be interesting to test the combined effect of TNFα with LXR agonists 
upon the secretion of inflammatory cytokines. Furthermore, if TNFα is able to 
increase the basal level of LXR transcriptional activation; as suggested by the 
increased expression of ABCA1, this would infer that TNFα is able to increase 
signalling pathways which support oxysterol synthesis or cellular uptake. Gas 
chromatography could be used to measure changes in endogenous oxysterol 
concentrations in response to treatment with TNFα to determine if TNFα 
mediates oxysterol synthesis and cholesterol metabolism. Similarly, the 
concentration of intra-cellular vs extra cellular LDL can be measured in 
macrophages treated with acetylated LDL to inform whether TNFα affects 
cholesterol uptake. These findings are summarised in Figure  10.32. 
 
 
Figure  10.32 TNFα positively regulates LXRα expression. 
LXR agonism increases the secretion of TNFα in response to TLR4 ligation or TcK induced 
activation of macrophages (MФ) by an unknown mechanism. Increased concentrations of 
TNFα may positively regulate LXRα expression by signaling through the TNF receptor 
(TNFR). TNFα may also positively regulate the transcriptional activation of LXRs as 
suggested by the increased expression of ABCA1 in murine macrophages. The increased 
secretion of TNFα by LXR agonism may support TcK activation and thereby increase TcK 
induced activation of macrophages within the synovium. 
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Together with the pro-inflammatory effects of LXR agonism in vivo and in vitro 
and the potential positive feedback loops of TNFα upon LXRα expression, and 
potentially LXR activation, these results suggest that LXRs may play a role in RA 
disease pathology. Gene expression analysis of LXRα, LXRβ and ABCA1 showed 
that the expression of LXRs in RA PBMCs was similar to that of healthy controls. 
However, these results do not exclude a role for LXRs in RA pathology as LXRs 
are constitutively expressed and are activated by the binding of cholesterol 
derived oxysterol ligands therefore, basal levels of LXR expression, but increased 
LXR activation, may drive inflammation in RA. It is also likely that the 
mechanisms which lead to pathology in RA or PsA compared to AS are different 
and may exert distinct effects upon LXRs.  
The expression of LXRs in RA PBMCs, as well as healthy controls, was also 
compared to that of patients with the spectrum of spondyloarthritis, namely 
psoriatic arthritis (PsA) and ankylosing spondylitis (AS). The expression of LXRα 
and LXRβ was dramatically increased in AS and moderately so in PsA. Both AS 
and PsA are autoimmune inflammatory conditions collectively affecting 
approximately 4% of the population. AS is manifest as inflammation of the 
sacroiliac joints and other enthesis organs, leading to fusion of vertebrae and 
curvature of the spinal column. Whereas PsA can have spinal involvement it is 
associated primarily with synovial and enthesial inflammation in peripheral 
joints and then with articular destruction. It is normally also associated with 
psoriatic skin lesions. Both conditions are distinct from RA by being seronegative 
for RF and ACPA. Although the pathogenesis of AS and PsA is unknown both 
conditions share some common genetic risk factors. SNPs in the IL-23 receptor 
and ERAP1 (ARTS-1) have been identified and are both associated with AS and 
PsA disease (317-321). HLA-B27 is also predictive of erosive arthritis in PsA and is 
present in approximately >90% of AS patients (322). The role of HLA-B27 in PsA 
and AS disease pathology is not full understood however several reports have 
suggested that HLA-B27 misfolding may trigger the unfolded protein response 
(UPR) causing endoplasmic reticulum (ER) stress (323, 324). Indeed, all the AS 
patients were HLA-B27 positive but the HLA-haplotype of the PsA patients was 
unknown.  
A role for LXRs in ER stress has not yet been identified although, activation of 
PPARγ, which can induce the expression of LXRs, has been shown to induce ER 
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stress and attenuate subsequent IL-1 and IFNγ signalling (49, 325). Additionally, 
the transcription factor SREBP-1c, an LXR target gene, is present within the ER 
lumen. ER stress induces the cleavage of SREBP-1c and stabilises its binding to 
the promoters of target genes (326, 327). These observations implicate the LXR 
signalling pathway in ER stress but how ER stress may potentially effect LXR 
expression/ activation is unknown. It would therefore be of interest to further 
explore the association of HLA-B27 with LXR expression and determine how LXRs 
may effect inflammatory cytokine secretion in a context of ER stress. In addition 
to the genetic risk AS and PsA are associated with inflammatory bowel disease 
(IBD); ulcerative colitis and Crohn’s disease. However, as IBD is only present in 
approximately 60% of AS and PsA patients it is unlikely that IBD is the reason for 
the increased expression of LXRs in all the PsA and AS samples tested; although 
the IBD status of these individuals was unknown. Whether the expression of LXRs 
may serve as a suitable biomarker for the development of AS is currently 
unknown but further studies are required to identify the mechanisms leading to 
the increased expression of LXRs specifically in AS. 
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11 Discussion & conclusion 
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At the outset of my studies, some reports suggested an immuno-modulatory role 
of LXR activation. I therefore sought to determine how activation of LXRs could 
impact upon inflammatory signalling pathways with potential consequences for 
RA disease pathology. Unexpectedly, I have demonstrated a profound and novel 
pro-inflammatory effect of LXR agonism. This is exemplified by the dramatic 
increase in articular inflammation and destruction observed with administration 
of T1317 or GW3965 in vivo in a murine model of CIA. Enhanced disease severity 
was associated with elevated numbers of Th1 and Th17 cells and increased 
serum concentrations of multiple pro-inflammatory cytokines and inflammatory 
chemokines. Consistent with these observations the secretion of inflammatory 
cytokines was increased by LXR agonism regardless of mode of activation, 
namely via TLR4 (LPS) or cell-cell interactions; TcK stimulated human 
macrophages. Overall, my results have demonstrated a previously unrecognised 
pro-inflammatory effect of LXR activation that may drive pathology and disease 
severity in arthritis. 
My results contradict previous findings in the literature in which LXR activation 
has been described to exert a general anti-inflammatory effect. Many such 
studies have used murine models of disease or rodent derived tissue ex vivo in 
which an inflammatory response has been initiated by the use of LPS (19, 117, 
118, 120, 314, 315, 328-331). In this context LXR agonism does indeed reduce 
the secretion of pro-inflammatory cytokines and ameliorates disease pathology 
induced by LPS. However, paradoxically LXR agonism in human LPS stimulated 
monocytes/ macrophages supports the secretion of pro-inflammatory cytokines 
(61). Therefore, studies in which inflammation is induced with LPS in rodents or 
rodent derived tissue are unlikely to accurately reflect the action of LXRs in 
human cells; neither do they inform the action of LXRs upon other inflammatory 
pathways. This is best exemplified where LXR agonism was shown to inhibit LPS 
induced airways inflammation in mice whereas administration of GW3965 in an 
LPS free model of asthma is clearly detrimental – thus LXR agonism in such a 
context in mice is pro-inflammatory (19, 119, 315). Likewise LXR activation has 
also been shown to induce the expression of inflammatory markers; ICAM-1, 
VCAM-1 and E-selectin, on human endothelial cells (105).  
LXRs are best known and investigated for their role in lipid regulation and 
transport and therefore separating out whether the effects LXR agonism upon 
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inflammation is mediated directly or is a result of altered lipid metabolism may 
prove problematic. It is evident that LXRs can exert direct effects upon 
inflammatory signalling pathways as mediated by the increased expression of 
human TLR4 induced by LXRα (61). In support of a direct effect and as a 
potential explanation for the pro-inflammatory effects of LXR agonism in the 
murine CIA model, LXRs have been shown to regulate the expression of genes 
involved in glucocorticoid biology. GCs are synthesised and secreted in an inert 
form from the adrenal glands under the control of the hypothalamic-pituitary-
adrenal (HPA) axis. Activation of GCs is mediated by the enzyme 11β-
hydroxysteroid-dehydrogenase-type-1 (11βHSD-1) that catalyses the conversion 
of inert cortisone to active cortisol in humans permitting GC signalling through 
the glucocorticoid receptor (GR). Steroid signalling, as in the case of RA patients 
treated with for example prednisolone or triamcinolone hexanoate, exerts a 
profound anti-inflammatory effect which is mediated by increased T cell 
apoptosis and macrophage phagocytosis of apoptotic leukocytes (265, 266). LXR 
activation has been shown to inhibit the expression of 11βHSD-1 and GR thereby 
reducing GC signalling and potentially the beneficial anti-inflammatory effects 
attributable GC (7, 8, 93). In accordance with an inhibitory effect upon GC 
enhanced disease severity was associated with increased lymph node T cell 
numbers and neutrophil accumulation; potentially mediated through decreased 
macrophage phagocytosis. Further studies are therefore required to elucidate 
how the action of LXRs may impact upon GC/ GR signalling to drive disease 
pathology in RA. 
Part of my original interest in LXR biology came from the well recognised 
association of RA with enhanced vascular risk –indeed I considered at outset the 
possibility that LXR agonism might mediate beneficial effects in both tissue 
compartments namely primary articular disease and comorbid vascular 
atheroma. It is interesting to note that RA patients have accelerated CVD 
characterised by an atherosclerotic lipid profile and the presence of 
atherosclerotic lesions up to fifteen years prior to the clinical onset of RA (250, 
251, 253, 257). It is now widely accepted that pathology associated with 
atherosclerosis and RA may cooperate to promote a state of generally enhanced 
inflammation. As well as understanding a role of LXRs in inflammation this study 
was also initiated in an attempt to understand how altered lipid metabolism may 
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drive RA pathology. I hypothesise that cholesterol degradation within the 
periphery to form oxysterols could drive the development of synovial pathology 
by activation of LXRs. Indeed, my results which suggest a pro-inflammatory 
effect of LXR activation support this hypothesis. However, although my studies, 
as with other reports in the literature using T1317 or GW3965, are informative of 
LXR activation they may not faithfully represent the action of specific 
endogenous oxysterol species upon the activation of LXRs. Synthetic LXR agonists 
induce activation of LXRs systemically whereas endogenous agonists are 
restricted to particular anatomical locations and indeed different oxysterols are 
recognised to differentially activate or inhibit LXRs (29). Further studies are 
therefore required to demonstrate that specific oxysterols do exert pro-
inflammatory effects. Identifying which species of oxysterols are present in the 
serum and synovium of RA patients and if concentrations of these are altered 
relative to healthy controls is also important for understanding whether LXRs 
have a pathological role in RA. It would also be of interest to analyse the 
oxysterol content in patients both prior and post development of clinical 
arthritis. Nevertheless, my results do suggest that elevated levels of cholesterol, 
or altered cholesterol metabolism, may exert detrimental effects upon the 
progression of RA by activation of LXRs. This is in agreement with clinical trials 
performed by the host laboratory in which the use of atorvastatin modified 
markers of cardiovascular risk surrogates and exerted anti-inflammatory effects 
in RA (290). Notably in vivo studies have suggested that some of the anti-
inflammatory effects of statins may be independent of altered cholesterol 
concentrations (332).  
Understanding the individual roles of LXRα and LXRβ is central to understanding 
how lipid metabolism may impact upon inflammation and for the design of 
future therapeutics; for example it is already recognised that agonists designed 
specifically towards the activation of LXRβ are more favourable than dual LXRα/ 
LXRβ agonists for the treatment of atherosclerosis (101, 102). Furthermore, 
deletion of LXRα or LXRβ is protective against the pro-inflammatory effects 
mediated by administration of GW3965 or T1317 in murine CIA and suggests that 
cooperation between the LXR isoforms is necessary to drive inflammation. The 
separate role(s) of LXRα and LXRβ in inflammation is (are) unknown. It would be 
of interest to determine whether cooperation between LXRα and LXRβ is also 
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required to drive inflammation in human cells e.g. in the T cell / macrophage 
contact assay of synovitis. Importantly these findings have considerable 
implications for the development of LXR agonists as future therapeutics in which 
LXR agonists are already in pre-clinical trials for the treatment of atherosclerosis 
(36, 126). My results suggest that dual LXRα/LXRB agonism especially in patients 
with an underlying autoimmune condition or bacterial infection may cause an 
adverse pro-inflammatory effect. The current strategy of pharmaceutical 
companies is to develop agonists specifically targeted towards LXRβ. The use of 
LXRβ specific agonists may avoid the pro-inflammatory effects attributable to 
dual LXRα/ LXRβ agonism whilst preserving the beneficial effects upon the 
regression of atherosclerosis disease progression. However, endogenous 
oxysterol LXR ligands activate both LXRα and LXRβ and together with synthetic 
LXRβ agonists may exacerbate an inflammatory response over a prolonged period 
of time. Therefore, future LXRβ specific agonists should be thoroughly tested 
and used with caution. 
While the new evidence on the potential involvement of LXRs in RA is intriguing, 
major issues remain to be explored. Future studies must identify which 
mediators are responsible for the pro-inflammatory effects of LXRs and should 
elucidate why LXR agonism may exert either a pro or anti-inflammatory response 
in different contexts and indeed species. Finally, understanding what the 
consequences of elevated levels of LXR expression in AS is now a matter of 
paramount importance, representing an entirely novel and unexpected outcome 
from the present studies.
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